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Abstract 
Magnetic resonance imaging (MRI) has significantly enhanced clinical diagnosis of disease due to a 
number of advantages, such as high resolution, rich information content that can be derived from a 
single scan, its non-invasive nature, no limitation on tissue penetration depth and the lack of 
radiation burden that is often encountered when other imaging modalities are utilised. In recent 
years 
19
F MRI has gained renewed attention as an increasingly important MRI technique, mainly 
due to the commercial availability of high field scanners (up to 16.4 T in the preclinical setting). 
19
F 
has comparable nuclear magnetic resonance (NMR) properties as 
1
H, including large gyromagnetic 
ratio (40.03 MHz T
-1
, 94% relative to 
1
H), high sensitivity (83% relative to 
1
H) and 100% natural 
abundance. An essentially attractive feature of 
19
F MRI is the absence of confounding background 
signal because there is no endogenous 
19
F NMR-detectable fluorine in the body. Hence 
19
F MRI is a 
highly quantitative technique and naturally relies on the presence of 
19
F–containing imaging agents 
to generate an image. However, 
19
F MRI is not routinely used in clinical mainly because of the lack 
of suitable contrast agents.  
  In the past few years, partly-fluorinated polymers have been considered as excellent candidates for 
19
F MRI contrast agents due to the diverse architecture and functionality of polymers. However, 
understanding the relationship between molecular structure, NMR properties and imaging 
performance remains a challenging task. In addition, it is still a minimally explored field for the 
development of multifunctional agents, such as biologically-responsive 
19F agents (“smart” agents) 
and 
19
F MRI-incorporating multimodal imaging agents. To tackle these challenges, this thesis aims 
to study the design of next-generation polymeric 
19
F MRI agents by developing a fundamental 
understanding of multifunctional polymers with different molecular architectures and components 
for selective 
19
F MRI, multimodal molecular imaging, improved 
19
F MRI, and theranostics.  
  The first approach adopted for achieving high 
19
F mobility was by distributing and separating the 
19
F segments in a hyperbranched structure. In Chapter 2, star-like polymers with a hyperbranched 
core and hydrophilic arms were synthesised using the arm-first approach by reversible 
addition─fragmentation chain transfer (RAFT) polymerisation. The core was composed of units of 
2,2,2-trifluoroethyl acrylate (TFEA), 2-(dimethylamino)ethyl methacrylate (DMAMEA) and 
ethylene glycol dimethacrylate (EGDMA), while the arms consisted of brush-like homopolymers of 
poly(ethylene glycol) methyl ether methacrylate (PEGMA). The chemical structure and 
composition of the polymers were characterised to obtain detailed information about the molecular 
structure. The pH-responsiveness of particle size was also investigated by dynamic light scattering 
(DLS) and cryo-transmission electron microscopy (cryo-TEM). The 
19
F NMR properties, such as 
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19
F signal intensity, spin-lattice (T1) relaxation time and spin-spin (T2) relaxation time were 
examined in solutions of different pH. Finally the imaging performance of the polymers at different 
pH was evaluated by in vitro 
19
F MRI. 
As the T2 relaxation time is sensitive to the chemical environment of 
19
F nuclei, the influence of 
polymer architecture on imaging performance was then studied. Chapter 3 describes the 
development of core crosslinked star (CCS) polymers and these materials were compared to the 
star-like hyperbranched polymers described in Chapter 2. The CCS polymers were constructed of a 
biodegradable core and block copolymers as arms. In contrast to the polymers described in Chapter 
2, the 
19
F units were positioned within the block copolymer arms by the RAFT copolymerisation of 
2,2,2-trifluoroethyl methacrylate (TFEMA) and DMAEMA using PPEGMA as a macroCTA. The 
pH-responsiveness of 
19
F NMR properties was characterised, and the biodegradability were 
evaluated. The capability of the CCS polymers for selective 
19
F MRI was assessed in solutions of 
different pH. The change in imaging properties of different polymer architectures were also 
compared and discussed.  
  In order to expand the possible application of polymeric imaging agents, multifunctional 
hyperbranched polymers were synthesised for computed tomography (CT)/
19
F MRI bimodal 
molecular imaging. In Chapter 4, hyperbranched polymers containing units of 2-(2',3',5'-
triiodobenzoyl)ethyl methacrylate (TIBMA) and PEGMA were synthesised by RAFT 
polymerisation and were chain extended with TFEA and PEGMA. The biodegradability was 
studied in the presence of reducing agents. Nanoparticles were formed and characterised by DLS 
and TEM techniques. The radio-opacity of these polymers was assessed by in vitro CT experiments, 
and the MRI performance was evaluated by 
19
F MRI. The material showed good imaging potential 
in both modalities pointing towards a new class of multimodal imaging agents. 
  In order to systematically study the relationship between molecular structure and imaging 
performance, segmented highly-branched polymers (SHBPs) were synthesised by self-condensing 
vinyl polymerisation via the RAFT process (RAFT SCVP). Chapter 5 describes the synthesis of a 
polymerisable chain transfer agent (CTA) that was used for the copolymerisation of fluoro 
monomers and PEG-based monomers. A series of SHBPs with different compositions and degrees 
of branching (DBs) were synthesised and thoroughly characterised. The 
19
F NMR properties were 
strongly affected by the sequence distribution of fluorinated units, type of polymer backbone and 
degree of branching. As a result, SHBPs consisting of statistical copolymer segments with acrylate 
backbones were excellent candidates for imaging due to a single 
19
F signal, long T2 relaxation times 
and high 
19
F contents. The SHBPs could be all imaged or selectively imaged by 
19
F MRI using 
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different pulse sequences by taking advantage of the differences in relaxation times, demonstrating 
the tuneable and selective imaging performance through tailoring the structure and composition of 
the SHBPs. 
  Finally, Chapter 6 describes the synthesis of star polymers with a polyhedral oligomeric 
silsesquioxanes (POSS) core and eight partly-fluorinated arms. Here the aim was to investigate how 
to combine 
19
F MRI with drug delivery by designing a platform possessing 
19
F-containing polymers 
and POSS cages. A macroCTA having eight CTA molecules attached to a POSS core was 
synthesised and used for the synthesis of star polymers by the R-group approach. The arms were 
composed of statistical copolymers consisting of TFEA and PEGA. Star polymers having different 
arm lengths were prepared and characterised. The particle size and 
19
F NMR properties were 
studied by DLS and 
19
F NMR, respectively. Finally the imaging performance was preliminarily 
evaluated by calculating the theoretical 
19
F MRI intensities and comparing with the previous 
imaging results.  
  In summary, this thesis studies the development of multifunctional nanostructured polymers as 
contrast agents for 
19
F MRI-related molecular imaging and theranostics using the RAFT technique. 
The molecular level understanding gained in this work provides useful guidance for the future 
design of highly-efficient 
19
F MRI contrast agents. 
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CHAPTER 1  
INTRODUCTION 
Modern medical science has benefitted enormously from the rapid development of diagnostic 
techniques, such as optical imaging, magnetic resonance imaging (MRI), X-ray imaging, computed 
tomography (CT), positron emission tomography (PET), single photon emission computed 
tomography (SPECT) and ultrasonography. With the help of these techniques, a vast range of 
diseases can be detected accurately and treated effectively. 
  Despite these advances, cancer related diseases, which have become increasingly problematic 
worldwide, still present large challenges today. It has been well-recognised that early and accurate 
diagnosis of cancer is crucial for successful treatment. As a key imaging modality, MRI has been 
widely implemented in the clinic for the diagnosis of cancerous tissues because it can produce high 
quality images of internal organs and tissue without providing a radiation burden.
1, 2
 
1.1 Magnetic Resonance Imaging  
As an indispensable medical diagnostic technique, MRI generates images by collecting and 
analysing the signals from certain types of isotopes in magnetic fields. This technique features 
images with high spatial resolution, especially for soft tissues, as well as not being hindered by 
tissue penetration limitations. Unlike other imaging modalities such as X-ray imaging, CT and PET, 
MRI is well known for its non-invasive and non-destructive nature because this technique does not 
rely on potentially harmful ionising radiation. Owing to these unique advantages, MRI has been 
extensively applied as a powerful medical diagnostic tool for visualising either the whole body or 
specific tissue by providing qualitative or quantitative three-dimensional (3D) anatomical images. 
  Based on the principles of nuclear magnetic resonance (NMR), a variety of nuclei which have odd 
number of protons (or neutrons) can be employed for MRI, including 
1
H, 
13
C, 
19
F, 
23
Na, 
31
P, etc.
3, 4
 
These isotopes exhibit nuclear magnetic resonance under an external magnetic field due to their 
non-zero magnetic moment. The NMR properties of several isotopes are listed in Table 1-1. 
Although all these isotopes are theoretically suitable for MRI, 
1
H and 
19
F have been the most 
commonly studied and practically utilised nuclei because both of them possess large gyromagnetic 
ratio, high sensitivity and rich natural abundance among all the candidates. 
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Table 1-1 NMR properties of a few selected isotopes.
5
  
Nucleus Spin Gyromagnetic 
ratio, γ/2π (MHz/T) 
Sensitivity 
(%) 
Natural 
abundance (%) 
Biological abundance 
(% of mass) 
1
H 1/2 42.576 100 99.985 10 
2
H 1 6.536 0.965 0.015 0.0015 
3
He 1/2 -32.434 44 0.000138 ─ 
7
Li 3/2 16.546 29 92.5 0.0003 
13
C 1/2 10.705 1.59 1.10 0.198 
14
N 1 3.077 0.101 99.634 3.0 
15
N 1/2 -4.316 0.104 0.366 0.011 
17
O 5/2 -5.772 2.91 0.048 0.025 
19
F 1/2 40.053 83.4 100.0 0.004 
23
Na 3/2 11.263 9.25 100.0 0.15 
31
P 1/2 17.235 6.63 100.0 1.0 
39
K 3/2 1.987 0.051 93.26 0.23 
43
Ca 7/2 2.865 0.640 0.135 0.002 
129
Xe 1/2 -11.78 2.12 26.4 ─ 
 
 
1.1.1 1H MRI Contrast Agents 
Since the pioneering work in the 1970s,
6-8
 proton magnetic resonance imaging (
1
H MRI) has 
advanced rapidly and has been the dominant MRI in routine clinical scans. Basically, there are two 
reasons why 
1
H MRI has been the most prominent MRI. First, 
1
H has those aforementioned 
intrinsic advantageous NMR characteristics that ensure strong signals. For another, 
1
H is abundant 
in water and fat in living organisms, making the tissues readily visualised by 
1
H MRI. As the 
relaxation times of 
1
H differ in various environments, 
1
H MRI is able to distinguish different 
tissues. Moreover, 
1
H MRI can also be used to differentiate tumour tissue from healthy tissue based 
on the difference in relaxation times.
6
 Nonetheless, 
1
H MRI often fails to provide unambiguous 
images due to insufficient differences (contrast) in relaxation times between normal and diseased 
states.  
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  Apart from utilising higher magnetic field strengths, introducing contrast agents (CAs) is another 
feasible way to improve the image contrast and obtain accurate and reliable information from MRI 
scans.
9
 CAs have been used in MRI to alter the longitudinal relaxation time (T1) and transverse 
relaxation time (T2) of the protons in surrounding water molecules, thus enhancing the image 
contrast for specific tissues.
10
 Based on their effects on imaging, 
1
H MRI CAs can be divided into 
two categories, i.e., positive agents (producing positive image contrast) and negative agents 
(generating negative image contrast). In general, positive agents are often based on lanthanides 
(mostly gadolinium Gd(III) chelates) that can reduce T1 of the surrounding water protons, while 
negative agents are mainly represented by superparamagnetic iron oxide nanoparticles (SPIONs) 
which can shorten T2 of the neighbouring water protons.
1, 11
 As two representative 
1
H MRI CAs, 
Gd(III)- and SPIONs-based CAs are introduced in Sections 1.1.1.1 and 1.1.1.2, respectively. 
 
1.1.1.1 T1 Contrast Agents 
As pioneers of Gd(III)-based CAs, small molecule gadolinium Gd(III) chelates have been the most 
commonly administrated CAs in the clinic, accounting for more than 30% of MRI scans.
12
 As 
illustrated in Figure 1-1, a number of Gd(III) chelate-based CAs are commercially available for 
clinical MRI scans because of their high paramagnetism, effective contrast enhancement, relatively 
high stability and inertness, etc.
11
 Owing to their small size, these CAs can achieve rapid 
equilibration between intravascular and interstitial space as well as being able to often reach usually 
inaccessible tissue after intravascular injection,
1, 11, 13
 facilitating the diagnosis of a variety of 
diseases including diseases of central nervous system (CNS) where there is breakage of blood-
brain-barrier (BBB) and neurodegenerative diseases.
14-18
 Nevertheless, Gd(III) chelate-based CAs 
suffer from several drawbacks, such as short blood circulation time, relatively low relaxivity and 
non-selectivity.
11, 13
 These shortcomings greatly limit their applications in both clinical MRI scans 
and biomedical research.  
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Figure 1-1 Chemical structures of the commercial Gd(III) chelates used in clinical MRI as CAs. 
Adapted from Zhou et al.
11
 
  To overcome these challenges, macromolecular Gd(III) contrast agents have been designed and by 
conjugating Gd(III) chelates to macromolecules. Compared with their small molecule counterparts, 
macromolecular Gd(III) CAs possess several inherent advantages because of their complex 
structures and unique properties. For example, macromolecular Gd(III) CAs have higher relaxivity 
owing to the slower molecular tumbling caused by their larger size, potentially reducing the clinical 
dosage.
11, 19
 In addition, since the renal excretion is reduced, the blood circulation time is prolonged, 
resulting in favourable pharmacokinetics and imaging timing.
19, 20
 Besides, the numerous 
functionalities existing in macromolecules allow for further chemical modifications which can 
introduce biodegradability, targeting or environmentally-responsive properties to the CAs.
21
 
Furthermore, macromolecular Gd(III) CAs are prone to accumulate in tumour tissue sites with leaky 
vasculature via enhanced permeability and retention (EPR), thus the diagnosis of tumour tissue is 
improved and the imaging time window is enlarged.
22, 23
 
  Over the past two decades, a wide variety of macromolecular materials have been chosen for the 
fabrication of macromolecular Gd(III) CAs, including linear polymers,
24-37
 star polymers,
26, 38
 
hyperbranched and dendritic polymers,
26, 38-52
 proteins, liposomes, micelles and capsids,
53-57
 etc. To 
meet the increasing demand of specific applications, considerable efforts have been dedicated to the 
development of „smart‟ macromolecular Gd(III) CAs, such as biodegradable,25, 29, 30, 32, 42 stimuli-
Chapter 1 Introduction 
 
 
5 
 
responsive
54, 58-61
 and tumour-targeting
34, 46, 51
 CAs. The great diversity of structure offered by 
macromolecular Gd(III) CAs allows control by rational design of size, relaxivity and customisable 
properties 
  Overall, Gd(III)-based CAs have been well studied, established and commercialised, and they are 
currently playing an essential role in clinical MRI scans. However, safety issues need to be taken 
into consideration even for commercial products. Free Gd(III) ion is known to be toxic on 
accumulation in bones, liver and spleen and disrupt physiological Ca
2+
 signalling.
2, 13, 21
 Therefore 
stability is a priority for the design of Gd(III)-based CAs to avoid the release of free Gd(III) ions 
from CAs compounds. Last but not least, detailed investigations are needed for a better 
understanding of the new Gd(III) CAs, and these include studies on pharmacokinetics, clearance 
from the human body, long-term toxicity as well as reproducible preparations.  
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1.1.1.2  T2 Contrast Agents 
Iron oxides, which are ferrites consisting of maghemite (Fe2O3) or magnetite (Fe3O4), have been 
serving as another group of 
1
H MRI CAs for over three decades.
62
 Unlike Gd(III) chelates, iron 
oxide compounds mainly increase the rate of T2 relaxation (R2, 1/T2) by shortening the T2 of the 
nearby protons, providing negative images for T2-weighted MRI, albeit in some cases they can also 
be used as T1 CAs. With the rapid advances in nanotechnology, nano-sized iron oxides have 
attracted increasing attention as 
1
H MRI CAs, and include superparamagnetic iron oxide 
nanoparticles (SPIONs) and ultra-small superparamagnetic iron oxide nanoparticles (USPIONs).
63-
66
 Similar to Gd(III) based CAs, there have been a number of commercial SPIONs that gained 
regulatory approvals for clinical MRI, as listed in Table 1-2. 
Table 1-2 Details of important commercial SPIONs-based 
1
H MRI CAs.
66
 
Brand Coating agent Size (nm) Application Company 
Endorem
®
 
Feridex
®
 
Dextran T10 120-180 Liver imaging, 
cellular labelling 
Guerbet， 
Advanced Magnetics 
(Current name AMAG 
Pharma) 
Sinerem
®
 
Combidex
®
 
Dextran T10, T1 15-30 Metastatic lymph 
node imaging, 
blood pool agent, 
cellular labelling 
Guerbet， 
Advanced Magnetics 
(Current name AMAG 
Pharma) 
Lumirem
®
 
Gastromark
®
 
Silicon 300 Oral 
gastrointestinal 
imaging 
Guerbet， 
Advanced Magnetics 
(Current name AMAG 
Pharma) 
Resovist
®
 Carboxydextran 60 Liver imaging, 
cellular labelling 
Schering 
Supravist
®
 Carboxydextran 21 Blood pool agent, 
cellular labelling 
Schering 
Ferristene 
Abdoscan
®
 
Sulphonated 
styrene-
divinylbenzene 
copolymer 
3500 Oral 
gastrointestinal 
imaging 
GE-Healthcare 
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  Besides these conventional CAs, there is still growing interest in the synthesis of multifunctional 
CAs. Historically, iron oxide nanoparticles (NPs) have been synthesised via diverse methods, such 
as chemical coprecipitations, microemulsions, sol-gel syntheses, sonochemical reactions, 
hydrothermal reactions, etc.
65, 67
 By the combination of these synthetic techniques and surface 
modifications, CAs with customised morphology, size, composition, and property can be designed 
and used for more specific or complicated applications.
68
 In recent years, there has been a trend 
toward the development of next-generation SPIONs-based CAs that have multifunctional 
characteristics and can be exploited for a variety of applications, such as tumour-targeted 
imaging,
69-73
 multimodal imaging
74-77
 and theranostics.
78-80
  
  Through careful design, SPIONs with tailored properties have been developed and actively studied 
in biomedical research. Despite this, there are several problems to be addressed. For example, 
although SPIONs can be prepared via a number of methods following different mechanisms, 
reproducible, cost-effective and scalable synthesis still remains a tough goal, in particular for 
industrial manufacturing.
65
 In addition, attaching specific molecules onto the SPIONs by surface 
chemistry has already been extensively studied, but the precise control over the density and species 
of the functional groups remains challenging, resulting in the fact that the CAs often vary from 
batch to batch.
81
 Furthermore, more functions give rise to more complicated systems, hence the 
pharmacokinetics, biodistribution, cytotoxicity as well as the relationship between particle 
characteristics and relaxivity need to be thoroughly studied and established.
65
 It could be expected 
that a better fundamental understanding of properties would pave the way to accurate diagnosis and 
successful treatment of cancer diseases using multifunctional SPIONs-based CAs. 
 
1.1.2 19F MRI Contrast Agents 
19
F MRI was introduced only four years later than 
1
H MRI in 1977 by Holland et al.
82
 As listed in 
Table 1-1, 
19
F nuclei have fairly comparable properties to 
1
H, including spin 1/2, large 
gyromagnetic ratio (only 6% lower than 
1
H), high sensitivity (83% relative to 
1
H) and virtually 
100% of natural isotopic abundance. These characteristics naturally make 
19
F another suitable 
candidate for MRI. Furthermore, the most attractive feature is the physiological rarity of 
19
F, which 
can eliminate the unwanted background in imaging because the concentration of endogenous 
19
F 
nuclei in body is negligible and barely detectable by 
19
F MRI.
83, 84
 Owing to this intrinsic 
advantage, 
19
F MRI is highly selective and quantitative when contrast agents (CAs) are employed. 
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  In the past four decades, tremendous effort has been dedicated to the development of 
19
F MRI 
CAs, which can be categorised as 
19
F salts, 
19
F-containing small molecules, perfluorocarbon (PFC) 
emulsions and 
19
F-containing macromolecules.
83-86
 The design of 
19
F MRI CAs has been facilitated 
by the nature of 
19
F. For instance, unlike the radioactive 
18
F used for PET, 
19
F is a stable isotope, 
easing both the preparation of CAs and procedures for imaging. Additionally, fluorine atoms are 
usually incorporated to the CAs in the form of highly-stable carbon-fluorine covalent bonds, thus 
reducing the risk of loss (or decomposition) of imaging moieties which may potentially occur with 
Gd(III) chelates.
84
 Moreover, 
19
F can exist in numerous organic compounds ranging from small 
molecules to macromolecules, offering more opportunities for the development of 
19
F CAs.  
  As reviewed by Yu et al.,
87
 quite a few 
19
F-containing small molecules have been exploited as 
reporters and sensors for the detection of changes of biological conditions (e.g. pH, metal ions and 
oxygen content) as well as the study of drug metabolism. However, in the following sections, 
perfluorocarbons (PFCs) and partially-fluorinated polymers will be introduced given that they 
represent two major categories of 
19
F MRI CAs. 
 
1.1.2.1 Perfluorocarbons (PFCs) as 19F MRI Contrast Agents 
Perfluorocarbons (PFCs) are synthetic organic molecules (typically alkanes and their derivatives) 
for which all hydrogen atoms are replaced by fluorine atoms.
85
 PFCs can be divided into five types 
based on their chemical structure including aromatic and unsaturated PFCs, saturated linear PFCs, 
saturated ring system PFCs, perfluoroamines and perfluoroethers.
86
 A number of typical PFCs are 
illustrated in Figure 1-2. Owing to their unusual chemical structures, PFCs have several unique 
properties, such as highly hydrophobicity and lipophobicity, low surface tension, low 
intermolecular cohesion, chemical inertness and low cytotoxicity.
86
 A number of these 
characteristics make them suitable candidates for various biological applications. 
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Figure 1-2 Chemical structures of some typical PFCs.
86
 
  PFCs were initially explored as blood substitutes in the 1960s and 1970s due to their excellent 
capacity for carrying oxygen.
88, 89
 In recent years, PFCs have been used as CAs for ultrasonography 
owing to their micro-bubble-forming capability.
90, 91
 Since the appearance of 
19
F MRI in 1977, 
PFCs have attracted considerable attention as 
19
F MRI CAs.
83, 86, 87, 91, 92
 PFCs possess quite a few 
advantages as 
19
F MRI CAs: (1) PFCs have a high 
19
F content that is required for generating an 
intense 
19
F signal; (2) PFCs are inert due to the stable carbon-fluorine bond, hence they can tolerate 
harsh preparation conditions (e.g. emulsification) as well as avoid undesired reactions with other 
compounds;
92
 (3) PFCs have already been extensively used as blood substitutes, so their biological 
properties such as biodistribution and biocompatibility have been well investigated and 
documented.
91, 92
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Figure 1-3 Chemical structures of five representative PFCs and their 
19
F NMR spectra and MRI 
images. Clearly, non-identical 
19F atoms in PFCs (A─D) show multiple peaks in 19F NMR spectra 
and thus result in images with ghost artefacts. In contrast, chemically-equivalent 
19
F nuclei in a 
symmetric structure (E) display only a single resonance peak in 
19
F NMR and no artefacts in the 
images. Adapted from Srinivas et al.
93
 
  To be successful 
19
F MRI CAs, PFCs should fulfil two criteria: (1) a symmetric structure for single 
and narrow 
19
F resonance to avoid reduced detection sensitivity and chemical shift imaging 
artefacts;
85, 86
 (2) a short T1 to minimise scanning time and long T2 to increase imaging quality.
86
 
The importance of identical 
19
F nuclei for 
19
F MRI has been pointed out in previous studies,
93
 and is 
also illustrated in Figure 1-3. A single and sharp resonance from symmetric PFCs is favourable for 
19
F MRI as it can avoid the use of selective MRI pulse sequences, and thus provide images with no 
ghost artefacts as well as maximised signal-to-noise ratio (SNR).
86, 93
  
  PFCs are highly hydrophobic and lipophobic and therefore they are normally formulated into 
stable emulsions, in particular nanoemulsions, for biological applications. Through high energy 
processing such as microfluidisation or sonication, PFC nanoemulsions with size of 20~500 nm 
have been prepared by using small amounts of surfactants.
86
 For human use, PFC nanoemulsions 
must be stable and non-toxic. It is well known that surfactants play an essential role in the 
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fabrication of PFC nanoemulsions since they affect both the stability and biocompatibility. 
Therefore, biocompatible phospholipids and Pluronic F68
TM
 (BASF) which are two effective 
surfactants have been commonly chosen for the preparation of PFC nanoemulsions.
94
 The latter is a 
triblock copolymer of poly(ethylene oxide)-block-poly(propylene oxide)-block-poly(ethylene oxide) 
(PEO-b-PPO-b-PEO) that has been approved by the FDA for many applications.
95, 96
 However, it 
was also suggested that the stability of PFC nanoemulsions was mostly determined by the structure 
of the PFCs rather than the type of surfactant, and PFCs having longer chain lengths or larger 
molecular weights are preferred to form emulsions with higher stability.
97, 98
 Therefore, the stability 
of PFC nanoemulsions remains a relatively complicated issue which needs more detailed 
investigations before certain rules are established. 
  PFCs can introduced to specific tissues after ex vivo incubation with cells, while they can also be 
introduced via direct intravenous injection or oral administration.
87, 99
 Generally, there are two ways 
that PFCs can act as 
19
F MRI CAs. First, PFCs can be introduced as an exogenous 
19
F source to be 
directly visualised and quantified by 
19
F MRI owing to the absence of background 
19
F signal. For 
example, PFCs have been extensively used as 
19
F MRI CAs for cell tracking and labelling
100-112
 as 
well as imaging of diseased tissue.
99, 113-118
 Second, since the relaxation times of 
19
F nuclei can be 
affected by environmental factors such as oxygen content, PFCs have been employed as probes to 
monitor these changes in biological tissues. As noted earlier, PFCs were first developed as blood 
substitutes because of their high oxygen-loading capacity. The rate of T1 relaxation (R1 = 1/T1) is 
linearly related to the partial pressure oxygen (pO2) for some types of PFCs and can also be affected 
by temperature and magnetic field, whereas it is barely sensitive to other conditions such as pH and 
CO2.
87, 119
 By making use of this feature, PFCs can be used as sensors for the measurement of pO2 
in different tissues including oximetry in tumour tissue under the conditions of fixed magnetic 
fields and temperatures.
120-127
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Figure 1-4 Schematic illustration of the synthesis of PFCE/silica core-shell nanoparticles (FLAME) 
a) Structure and functions of FLAME and b) Synthetic routes for FLAME. Adapted from 
Matsushita et al. 
128
 
  Owing to their chemical inertness, the application of PFCs has been restricted by the lack of sites 
for chemical modification. In an attempt to tackle this problem, considerable effort has been 
devoted to the fabrication of PFC-based multifunctional NPs for multimodal molecular imaging. By 
introducing a coating layer around the PFC emulsion particles, functional moieties can be attached 
to or incorporated in the coating materials which can be polymeric, inorganic or lipidic materials. 
Pisani et al.
129
 fabricated core-shell structured microparticles/nanoparticles comprised of liquid 
perfluorooctylbromide (PFOB) as the core and biocompatible and biodegradable poly(lactic-co-
glycolic acid) (PLGA) as the shell. The multifunctional particles, with tunable size and shell 
thickness, were evaluated as bimodal CAs for in vivo ultrasound imaging and in vitro 
19
F MRI. Lim 
et al.
130
 synthesised IRDye800-coated nanoemulsions as bimodal CAs, which were used for the in 
vitro and in vivo labelling and imaging of dendritic cells by 
19
F MRI and near-infrared (NIR) 
fluorescence imaging. As illustrated in Figure 1-4, Matsushita et al.
128
 developed core-shell NPs by 
coating perfluoro-15-crown-5-ether (PFCE) emulsion particles with a silica shell, which was further 
conjugated with reporter proteins and polyethylene glycol (PEG) chains. Such biocompatible and 
water-dispersible NPs were assessed as 
19
F MRI CAs for in vitro monitoring of gene expression in 
living cells and in vivo imaging tumour tissue as well. Bae et al.
117
 encapsulated PFCE and 
Rhodamine with lipids and then conjugated folate molecules onto the lipid layer. The as-formed 
bimodal NPs were used for both fluorescence imaging and 
19
F MRI with tumour-targeting.  
  Finally, PFCs and other 
19
F-containing small molecules have been extensively explored as 
19
F 
MRI CAs for a broad range of biological implementations. The progress achieved in the last three 
decades confirms the great potential of 
19
F MRI as a prominent imaging modality. In spite of 
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numerous efforts, 
19
FMRI have not been routinely used in the clinic mainly due to the lack of 
efficient and reliable CAs. In light of the extremely high 
19
F loading, there seems to be no doubt 
that PFCs are effective candidates for 
19
F MRI CAs. However, the stability of PFC emulsions is a 
major issue because the emulsion can be slowly destabilised and decomposed due to the 
unavoidable process of Ostwald ripening, which is a molecular diffusion phenomenon of the 
gradual growth of larger particles at the expense of smaller ones.
86
 Moreover, the relatively large 
size (100~250 nm) hampers a number of applications such as visualising the vasculature and cell 
labelling because of the impermeability of capillaries to particles of this size. Furthermore, although 
19
F MRI takes advantage of the minimal endogenous back ground signal, a sufficient concentration 
of 
19
F nuclei in the target voxel is required to generate an adequate signal. One feasible way to 
overcome this is to functionalise PFCs with targeting moieties so that they accumulate in desired 
tissues to enhance the signal intensity. Despite a few successful examples, the functionalisation of 
PFCs remains an elusive goal owing to the chemical inertness and the complicated process of 
emulsification. Therefore, further innovative work on the development of CAs is required for the 
maturation and clinical application of 
19
F MRI.  
1.1.2.2  Partly-Fluorinated Polymers as 19F MRI Contrast Agents 
After decades of development of PFC CAs, virtually no candidate has received regulatory approval 
for clinic use, due in large part to the obstacles discussed in the last section. In recent years, partly-
fluorinated polymers have drawn increasing attention as alternative 
19
F MRI CAs. Compared to 
small molecules and inorganic materials, polymers have considerable intrinsic advantages as CAs 
for molecular imaging, such as high diversity depending on monomer type, molecular weight, 
tacticity and topology, long circulation time owing to large size and complex chemical structure, 
capability to carry functional sites for incorporating multimodal imaging modalities, targeting 
moieties and therapeutic agents, etc.
131
 In recent years, the precise synthesis of polymers with 
tailored architectures and functionalities has been achieved by controlled polymerisation 
techniques,
132, 133
 facilitating the development of partly-fluorinated polymers for 
19
F MRI. A broad 
class of 
19
F-containing polymers, in which the 
19
F nuclei are usually incorporated through the 
copolymerisation of 
19
F-containing monomers, have been developed as 
19
F MRI CAs for both 
diagnosis and cancer therapy. Based on the polymer topology these can be classified as linear 
polymers, dendritic polymers, hyperbranched polymers, and other polymers. 
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1.1.2.2.1 Linear Polymer CAs 
Linear homopolymers have simple structures, and are relatively facile to synthesise and easy to 
control over a wide composition range. Mehta et al. reported an early study on 
19
F MRI probes 
based on partly-fluorinated linear polymers.
134
 In their work, polylysine, a cationic polymer that is 
preferentially internalised by tumour cells, was modified with 
19
F-containing molecules (S-
ethyltrifluorothioacetate and trifluoroacetamidosuccinic anhydride) at the sites of reactive amino 
groups. The resulting 
19
F-containing polymers showed a single sharp peak in the 
19
F NMR spectrum 
and thus had the potential to be 
19
F MRI CAs, although the authors did not demonstrate their utility 
in MRI.  
  Amphiphilic block copolymers have been applied in numerous fields because they can form 
various ordered structures via self-assembly processes.
135
 Peng et al. pioneered the study of partly-
fluorinated amphiphilic block copolymers as 
19
F MRI CAs.
136, 137
 As displayed in Figure 1-5, 
amphiphilic block copolymers of poly(acrylic acid)-b-poly(n-butyl acrylate-co-2,2,2-trifluoroethyl 
(meth)acrylate) (PAA-b-P(nBA-co-TFE(M)A) were synthesised via atom transfer radical 
polymerisation (ATRP). The block copolymers were self-assembled into stable micelles with 
diameter of 20~45 nm in water or water/organic mixed solvents. After that the NMR and imaging 
properties of the micelles were evaluated by 
19
F NMR and MRI, respectively. It was found that the 
choice of 
19
F-containing monomer played a vital role in imaging performance. Acrylate backbones 
with a lower glass transition temperature (Tg) (in the bulk state) exhibited higher flexibility than 
methacrylate backbones, and therefore they have 
19
F nuclei with higher mobility and longer T2 
relaxation times which resulted in better imaging properties. In addition, the solvent was another 
key parameter because it not only determined the morphology and structure of the micelles but also 
affected the rigidity of the micelle core. Overall, this work revealed for the first time the potential of 
partly-fluorinated block polymers as 
19
F MRI CAs, and also elucidated a number of important 
criteria for the design of successful CAs. 
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Figure 1-5 Synthetic route for amphiphilic block copolymers PAA-b-P(nBA-co-TFE(M)A). 
Adapted from Peng et al.
137
 
  Following this work, Nurmi et al. developed block and statistical copolymers consisting of 
TFEMA and 2-(dimethylamino)ethyl methacrylate (DMAEMA) units as 
19
F MRI CAs.
138
 The 
statistical copolymers P(TFEMA-co-DMAEMA) and block copolymers PTFEMA-b-P(TFEMA-co-
DMAEMA) displayed pH-responsiveness owing to the existence of DMAEMA segments which 
were introduced to modulate the confirmation of copolymer chains in solution. Larger micelle sizes 
and longer T2 relaxation times of 
19
F were observed at low solution pH because of the protonation 
of DMAEMA segments, which increased the hydrophilicity of P(TFEMA-co-DMAEMA) chains 
and accordingly enhanced the mobility of the 
19
F nuclei in the corona. Moreover, the NMR 
properties were found to be related to polymer composition, salt concentration and polymer 
concentration. Therefore Nurmi et al. demonstrated that achieving high mobility of the 
19
F nuclei 
and high 
19
F content was necessary for superior imaging performance, and this was consistent with 
the findings reported by Peng et al.
137
 Furthermore, this work also presented a straightforward 
method to modulate the relaxation times of 
19
F by simply copolymerising 
19
F-containing monomer 
with a pH-responsive monomer. 
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Figure 1-6 (a) Schematic illustration for ON/OFF regulations of the 
19
F MRI probes based on 
partly-fluorinated amphiphilic block copolymers. (b) Chemical structures of the block copolymers. 
(c) 
19F MRI images of the mixed polymer probes in solutions of different pH. The „barcode map‟ 
concept was employed to realise pH readout by encoding each voxel with an activation barcode 
through the combination of 
19
F NMR and MRI. Adapted from Huang et al.
139
 
  Using a similar concept, Huang et al. have recently designed pH-responsive 
19
F MRI probes with 
tuneable ON/OFF transitions.
139
 A series of amphiphilic block copolymers were synthesised 
through ATRP, comprised of PEO as the first block and copolymers of tertiary amine/ammonium 
monomers and 
19
F-containing monomers as the second block. As shown in Figure 1-6 (a) and (b), 
the hydrophilicity of the 
19
F-containing segments could be tuned by adjustment of the pH owing to 
the protonation and deprotonation of the tertiary amine/ammonium segments, and hance the 
morphology was switchable between micelles and unimers. To be more specific, the 
19
F nuclei in 
the rigid micelle cores were not 
19
F NMR detectable due to restricted motion, whereas those in the 
flexible umimers were detectable because of enhanced mobility. By assigning each polymer with a 
certain „barcode‟, these polymers can be used as multi-chromatic 19F NMR/MRI probes for 
quantitative pH measurement (Figure 1-3 (c)), indicating their future application in a number of 
pathological indications including cancer, inflammation and osteoporosis. 
Very recently, Zhang et al. reported the RAFT synthesis of thermo- and ionic-responsive 
copolymers of PEGMA and TFEA.
140
 Those water soluble copolymers displayed lower critical 
solution temperature (LCST) transitions only in salt solutions. The LCST property was dependent 
on the composition of polymers as well as the type of salt. In addition, the motion of protons was 
not only affected by the temperature of salt solutions but also related to their position in the polymer 
chains. Although the 
19
F NMR and MRI were not conducted, it could be expected that the 
19
F 
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resonance would exhibit the similar changes to those of protons. Therefore these linear copolymers 
can be used as dual responsive CAs for
19
F MRI  
 
Figure 1-7 Chemical structures of several partly-fluorinated polyethylene glycol (PEG) 
derivatives.
141-143
 
  In the past few years, CAs based on partly-fluorinated PEG have gained much attention.
141-143
 
Partly-fluorinated PEG derivatives were synthesised by end modification of linear PEG with 
perfluoro-alcohol such as perfluoro-tert-butyl alcohol and perfluoropinacol, and tested as 
19
F MRI 
CAs (Figure 1-7). These novel compounds exhibited several favourable properties, including simple 
chemical structures, high 
19
F content, hydrophilicity, a single 
19
F resonance, etc. However, the 
future exploration of these CAs may be limited by the lack of handles for chemical functionalisation 
and potentially very short blood circulation time. 
  The development of linear CAs has also been moving toward multimodal systems. Lu et al. 
designed a series of statistical linear copolymers consisting of the monomeric aggregation-induced 
emission (AIE) fluorophore, N-(2-hydroxypropyl) methacrylamide (HPMA), [2-
(methacryloylxy)ethyl]trimethylammonium chloride (MATMA) and 2,2,2-trifluoehtyl methacrylate 
(TFEMA).
144
 After self-assembling into micelles, these non-toxic and cell permeable polymers 
were exploited as CAs for fluorescence bioimaging and also showed feasibility for 
19
F MRI. 
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1.1.2.2.2 Dendrimer CAs 
Dendrimers are „tree-like‟ macromolecules that have repeating branching units emanating from a 
central core.
145
 In the past few years, dendrimers have been considered as an excellent platform for 
the design of 
19
F CAs.
85
 Compared to linear polymers, dendrimers can accommodate a larger 
amount of chemically-identical 
19
F nuclei in one molecule, generating an enhanced single 
19
F 
signal. In addition, the increased hydrodynamic size can prolong the blood circulation time, 
facilitating a number of biological applications. 
  As a typical and commercially-available dendrimer, polyamidoamine (PAMAM) has been 
extensively chosen for the fabrication of 
19
F MRI CAs. As reported by Criscione et al.,
146
 PAMAM 
was surface modified with heptafluororobutyric acid anhydride (HFAA), trifluoroacetic acid 
anhydride (TFAA) and pentafluoropropionic acid anhydride (PFAA), respectively. Through self-
assembly process, the resulted partly-fluorinated PAMAM formed microparticles (0.7~3.3 μm) in 
water, which were pH-sensitive and utilised for controlled drug release. Moreover, the site-specific 
accumulation of the microparticles in vivo was also revealed by 
19
F MRI. This work confirmed the 
potential applications of partly-fluorinated PAMAM dendrimers as multifunctional 
19
F MRI CAs.  
 
Figure 1-8 Synthesis of partly-fluorinated star-like dendrimers via ATRP. (a) PAMAM-OH, (b) 
PAMAM-Br macroinitiator, and (c) partly-fluorinated star-like dendrimers. Adapted from Ogawa et 
al.
147
  
  Recently, controlled radical polymerisation has also been employed for the functionalisation of 
PAMAM. Ogawa et al. modified PAMAM with bromine end groups and then used these molecules 
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as macroinitiators for the polymerisation of 2,2,3,3-tetrafluoropropyl methacrylate (TFPMA) and 
TFEMA via ATRP (Figure 1-8).
147
 Fluorinated star-like dendrimers with targeted degree of 
polymerisation (DP) and narrow molar-mass dispersity (ĐM) were prepared, and they could form 
NPs in organic solvents with size of 2~25 nm. The 
19
F resonance of these NPs was also confirmed 
by 
19
F NMR, demonstrating their potential used as 
19
F MRI CAs. By extending this approach, 
Ogawa et al. later functionalised PAMAM with amphiphilic block copolymers of TFPMA and a 
zwitterionic monomer.
148
 Interestingly, owing to the short T1 (110~240 ms) and T2 (8.4~13 ms), the 
as synthesised star-like dendrimers could be used for T1-weighted 
19
F MRI by carefully selecting 
the repetition time (TR) and echo time (TE). More recently, Ogawa et al. functionalised PAMAM 
with amphiphilic statistical copolymers consisting of TFPMA and tert-butyl methacrylate 
(tBMA).
149
 The PtBMA was then hydrolysed to poly(methacrylic acid) (PMAA) and converted into 
its sodium salt. The obtained dendrimers had a size of 12-25 nm and showed relatively short T1 
(400 ms) and long T2 (70~80 ms), which were favourable for 
19
F MRI. The in vitro 
19
F MRI 
revealed that these NPs could be detected at very low polymer concentration (0.2 μM), while the in 
vivo 
19
F MRI visualised the accumulation of NPs in liver and kidneys of a rat with 10 min. These 
results indicated that the star-like dendrimers could be used as a new type of 
19
F MRI CAs. 
Nevertheless, the use of PTFPMA is not ideal because while it provides a high 
19
F content it also 
has multiple 
19
F NMR resonances.  
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Figure 1-9 Fabrication of theranostic NPs based on partly-fluorinated linear polymers and star-like 
dendrimers. Green colour stands for hydrophobic segments and blue colour represents hydrophilic 
segments. Adapted from Porsch et al.
150
 
  Owing to their 3D globular architecture and multiple functional groups, dendrimers have also been 
exploited for the development of theranostic agents. Porsch et al. prepared a series of 
19
F MRI CAs 
using ditrimethylolpropane (di-TMA)-based dendrimers (Figure 1-9).
150
 Dendritic initiators of 
either 4 or 16 end groups were used to synthesise statistical copolymers consisting of TFEMA and 
poly(ethylene glycol) methyl ether methacrylate (PEGMA) units, resulting in star-like dendrimers 
composed of hydrophobic and dendritic cores and amphiphilic P(TFEMA-co-PEGMA) arms. NPs 
(6~9 nm) were formed through self-assembly in phosphate buffered saline (PBS), and were loaded 
with an anticancer drug doxorubicin (DOX). The DOX-loaded NPs could be taken up by breast 
cancer cells and showed dose-dependent toxicity. Moreover, these 
19
F-containing NPs were 
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visualised by 
19
F MRI in 10 min at a concentration of 10 mg/mL in PBS. Therefore, this work 
demonstrated an excellent example of 
19
F MRI-based theranostic system by using partly-fluorinated 
star-like dendrimers. 
 
Figure 1-10 Chemical structure of 
19
FIT. Adapted from Jiang et al.
151
 
  Apart from perfectly symmetrical dendrimers, partially symmetrical dendrimers comprised of two 
different hemispheres (dendrons) have also been designed for 
19
F MRI. 
19
FIT, a bispherical 
fluorocarbon molecule comprised of an H-spherical cone and a
19
F-spherical cone, was developed as 
19
F MRI CAs by Jiang et al. (Figure 1-10).
151
 Such structure could ensure high fluorine content 
while remaining water soluble. In addition, modification at the H-spherical cone did not affect the 
symmetry of the 
19
F atoms, avoiding unwanted multiple 
19
F resonances. The amphiphilic 
19
FIT 
molecule showed several outstanding properties, such as high 
19
F content (27.1 wt%), single 
19
F 
resonance, short T1 (163 ms), non-toxicity and chemical stability. The in vivo imaging performance 
of 
19
FIT was demonstrated by whole body 
19
F MRI using mouse models at doses of 60 mmol/kg 
and 30 mmol/kg 
19
F. The molecules were initially visualised in several organs, but they were only 
detected in the bladder after 1-2 hours, indicating rapid excretion and an in vivo residence half-life 
time of about 0.5 day. It should be noted that the physicochemical properties of 
19
FIT could also be 
modulated by using fluorous mixture synthesis (FMS) to obtain dendrimers of multiple 
generations.
152
 
  As with PFC emulsions, the relaxation times of partly-fluorinated dendrimers can also be tuned by 
introducing Gd(III)-chelates. Huang et al. designed a dendrimer-based platform with 
19
F atoms 
around the periphery and Gd(III)-chelates conjugated nearby.
153
 Owing to the existence of 
bifunctional Gd(III)-chelates, the T1 was significantly shortened from 860 to 140 ms, reducing the 
scanning time without sacrificing the image quality. Moreover, the toxicity of these CAs could be 
effectively reduced by shielding the dendrimer surface with hydrophilic groups. The imaging 
performance was also confirmed by fast in vivo 
19
F MRI which showed that the CAs could be 
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detected in the rat at a comparably low dose (11.7 mmol/kg 
19
F). Therefore these fluorine-rich 
dendrimers are promising for molecular imaging using 
19
F MRI. 
1.1.2.2.3 Hyperbranched Polymer CAs 
Hyperbranched polymers (HBPs) are a special class of dendritic polymers that have highly-
branched, 3D globular structures. Unlike perfectly branched and monodisperse dendrimers, HBPs 
are relatively non-symmetric and irregular owing to the random distribution of dendritic, linear and 
terminal units along the polymer backbone.
154
 Therefore, the synthesis of HBPs is much simpler 
and affordable than that of dendrimers, at a cost of perfect architecture.
155
 HBPs have several 
unique properties, such as compact structure, low viscosity, high solubility and high functionality, 
and hence they have been widely investigated in the field of biomedicine.
154, 156, 157
  
  Du et al. reported HBP-based NPs as 
19
F MRI CAs.
158
 First, HBPs with bromine or chlorine end 
groups were synthesised by a self-condensing vinyl (co)polymerisation. Then the HBPs were 
utilised as macroinitiators for the copolymerisation of TFEMA and tert-butyl acrylate. After 
hydrolysis, star-like polymers with a hydrophobic hyperbranched core and amphiphilic P(TFEMA-
co-AA) arms were obtained and then self-assembled into micelles with a hydrodynamic diameter 
(Dh) of 20~25 nm. As characterised by 
19
F NMR, these micelles showed a single and narrow 
19
F 
signal and favourable T1 (~500 ms) and T2 (~50 ms). 
19
F MRI also confirmed the capability of these 
micelles as 
19
F CAs. However, the scanning time was quite long (13 hours) due to the relatively low 
19
F concentration (1~4 mM 
19
F). Therefore a higher 
19
F loading should be achieved for future 
19
F 
MRI applications. Using the same HBPs as platform, Du et al. developed a theranostic system.
159
 
Cascade blue, a fluorescence reporter, was incorporated into the amphiphilic arms by 
copolymerisation. The resulted micelles were used as drug carriers for the loading and releasing of 
DOX, and the high toxicity of DOX-loaded micelles to U87-MG-EGFRvIII-CBR cells was 
confirmed by MTT assays. Finally, the 
19
F signal from cell engulfed micelles was detected by 
19
F 
NMR. This study showed a successful example of mutilfunctional HBPs as theranostic agents for 
anticancer drug delivery, fluorescence imaging and 
19
F MRI.   
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Figure 1-11 Synthetic routes for partly-fluorinated HBPs with carboxyl acid (P1), alkyne (P2) and 
mannose (P3) end groups, respectively. Adapted from Thurecht et al.
160
 
  Although a variety of dendritic polymer-based CAs have been developed, the dendrimers and 
HBPs were usually utilised as „core‟ materials. In those cases, 19F nuclei were placed around the 
periphery of cores through surface functionalisation. Therefore the advantage of the 3D globular 
structure of HBPs has not been fully exploited. To further explore HBP materials, Thurecht et al. 
pioneered and detailed the synthesis of HBP-based CAs in which larger amounts of 
19
F nuclei are 
placed with the 3D hyperbranched structure.
160
 As displayed in Figure 1-11, partly-fluorinated 
HBPs were synthesised via RAFT copolymerisation of 2-(dimethylamono)ethyl acrylate (DMAEA) 
and 2,2,2-trifluoroethyl acrylate using a bifunctional monomer ethylene glycol dimethacrylate 
Chapter 1 Introduction 
 
 
24 
 
(EGDMA) as a branching agent (crosslinker). Then the as-synthesised HBPs were used as macro 
chain transfer agents (CTAs) and chain extended with PEGMA to increase hydrophilicity and 
biocompatibility. The significance of such an innovative is profound. On one hand, the positioning 
of 
19
F nuclei within the 3D hyperbranched structure by direct copolymerisation not only increases 
the 
19
F loading but also improves the mobility of 
19
F as the association of 
19
F segments is prevented. 
On the other hand, RAFT polymerisation allows for the precise synthesis of HBPs with well-
defined structures as well as the introducing various functional end groups. As a result, these novel 
HBP CAs formed NPs (~10 nm) in aqueous solution after chain extension with PEGMA, and they 
showed low cytotoxicity according to MTS assays. As measured by 
19
F NMR, these CAs had a T1 
of 480 ms and T2 of 88 ms, which are preferable parameters for imaging. The imaging performance 
and excretion by kidneys were also observed by in vivo 
19
F MRI conducted on a mouse. Overall, 
this work proposed a new design concept for highly efficient and multifunctional HBP-based 
19
F 
CAs. Very recently Thurecht et al. furthered this work and developed a multimodal system for 
theranostic.
161
 HBPs comprised of TFEA, PEGMA and EGDMA were synthesised via RAFT 
polymerisation using an alkyne-terminated CTA. Next the HBPs were labelled with fluorescence 
moieties (Rhodamine B and NIR-797) and also conjugated with a targeting molecule (folic acid). 
By combining highly sensitive optical imaging and high resolution 
19
F MRI, these multifunctional 
HBPs were evaluated as multimodal imaging agents in vivo and in vitro with very high targeting 
efficiency to B16 melanoma cells. Therefore this study demonstrated a powerful HBP-based 
platform by using robust synthetic techniques for advanced multimodal imaging.  
1.1.2.2.4 Other Polymer CAs 
Apart from linear and dendritic polymers, other polymeric materials have also been chosen for the 
design of 
19
F MRI CAs, and these include proteins, nanogels and hydrogels. 
  Mehta et al. reported the early work on protein-based 
19
F MRI CAs.
162
 Three proteins, serum 
albumin, γ-globulin and purified immunoglobulin (IgG), were conjugated with S-ethyl 
trifluorothioacetate molecules by reaction with the amino groups. The biocompatible partly-
fluorinated proteins were examined by in vivo 
19
F magnetic resonance spectroscopy (
19
F MRS), 
showing the potential for 
19
F MRI as intravascular CAs. Recently, Sun et al. developed lectin-based 
19
F MRI CAs for specific detection and imaging of glycoproteins.
163
 When the 
19
F-labelled lectins 
were bound with glycoproteins, the T2 of 
19
F was shortened due to the increased apparent molecular 
mass (Mr). By utilising this characteristic, these 
19
F-labelled lectins could be employed as ON/OFF 
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probes to distinguish glycoproteins from other small molecules saccharides on the basis of 
differences in their Mr.  
  Several types of 
19
F-containing nanogels have been prepared through crosslinking reactions. Oishi 
et al. synthesised partly-fluorinated nanogels that were comprised of PEG, TFEMA and 2-
(diethylamino)ethyl methacrylate (DEAEMA) units.
164
 Owing to the pH-responsiveness of 
DEAEMA segments, the Dh of nanogels was highly dependent on the solution pH values. At low 
values of pH, the nanogels swelled and resulted in high 
19
F mobility, while they shrank and led to 
low 
19
F mobility at high pH. Consequently, the fluorine signal was detected only in acidic 
conditions, indicating that these nanogels were promising pH-sensitive drug carriers and tumour-
specific 
19
F MRI CAs. Bailey et al. prepared a series of 
19
F-containing copolymer NPs in the 
presence of a crosslinker by free radical polymerisation.
165, 166
 These NPs (200~500 nm) were 
formed through the copolymerisation of 
19
F-containing monomer, N-vinylformamide, and (1,5-N-
vinylformamido) ethyl ether (crosslinker) using polyvinylpyrrolidone (PVP) as a surfactant. The 
abundant amide groups in the nanoparticles were hydrolysed to the corresponding amines for future 
conjugation of functional moieties. 
19
F NMR of the NPs using different 
19
F-containing monomers 
showed the potential of these NPs for 
19
F MRI. 
  More recently, Yang et al. reported a 
19
F-labelled injectable hyaluronic acid (HA) hydrogel for 
both 
1
H and 
19
F MRI.
167
 HA hydrogel was synthesised by rapid carbazone reaction, and TFEA was 
attached to the hydrogel via orthogonal Michael addition to generate single 
19
F resonance. The 
shape and interior structure of the HA hydrogel was effectively imaged by a combination of 
1
H and 
19
F MRI, suggesting potential clinical applications of this biocompatible, injectable and MRI-
trackable hydrogel. 
  In summary, the design of 
19
F MRI CAs has been facilitated by the vast range of polymers that 
possess a number of advantages such as flexible synthesis, numerous topologies, various kinds of 
functionalities, etc. Previous studies have provided new impetus to the development of 
19
F CAs 
using polymers. Recent progress has also spotlighted the prominence of hyperbranched polymers 
and dendrimers as versatile platforms for the fabrication of multifunctional theranostic systems. By 
applying multidisciplinary studies involving chemistry, biology and radiology, polymeric CAs have 
been emerging as the next-generation 
19
F MRI CAs for advanced molecular imaging and 
theranostics.  
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1.2 Reversible Addition─Fragmentation Chain Transfer (RAFT) 
Polymerisation 
RAFT polymerisation, a powerful controlled radical polymerisation technique, was developed by 
CSIRO researchers in 1998.
168
 The mechanism of RAFT polymerisation is described in Scheme 1-
1.
169
 At the beginning of a RAFT polymerisation, monomer is initiated by a radical to form a 
propagating radical (Pn•), which then undergoes chain transfer to the thiocarbonylthio compound 
[RSC(Z)=S] to generate a polymeric thiocarbonylthio compound [PnSC(Z)=S] and a new radical 
(R•) after fragmentation of the intermediate radical. The new radical (R•) reacts with monomer to 
produce a new propagating radical (Pm•). Since the equilibrium between the active propagating 
radicals (Pn• and Pm•) and dormant polymeric thiocarbonylthio compound [PnSC(Z)=S] is very fast, 
the chain growth is thus controlled to yield polymers with narrow molar mass distribution. At the 
end of polymerisation, the thiocarbonylthio functionality is retained in the final polymers. The 
sequence of addition─fragmentation equilibria minimises the chance of radical-radical termination 
and disproportionation which are two typical characteristics of free radical polymerisation, resulting 
in polymer chains with tightly defined degree of polymerisation.  
 
Scheme 1-1 Mechanism of RAFT polymerisation. Adapted from Chong et al.
169
  
  According to the mechanism above, the use of chain transfer agent (CTA) [RSC(Z)=S] is a key 
component of RAFT polymerisation. Moreover, it should be stressed that the choice of CTA is of 
utmost important for RAFT polymerisation,
170
 since each type of CTA is suitable for certain types 
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of monomers, as determined by the R and Z groups. In addition, the CTA also introduces end-group 
functionality to the polymers.  
  Owing to its convenience and versatility, the past fifteen years have witnessed a rapid growth in 
the use of RAFT polymerisation for the synthesis of a broad class of polymers with various 
structures and properties.
171-175
 Due to the great depth and breadth of this field, the introduction of 
RAFT polymerisation is limited to the synthesis of linear, star and hyperbranched polymers that are 
commonly employed in the area of polymeric nanomedicine in the following sections. 
1.2.1 Synthesis of Linear Polymers by RAFT Polymerisation 
RAFT polymerisation is a robust and convenient protocol for the synthesis of different types of 
linear polymers, including homopolymers, statistical/gradient copolymers, alternating copolymers, 
and block copolymers, as has previously been comprehensively reviewed.
171-174
 By carefully 
selecting the CTAs, RAFT polymerisation is versatile for a very wide range of monomers and 
tolerant of diverse synthetic conditions. In the past decade, the synthesis of nanostructured 
functional polymers using the RAFT process has been an intensively active research field. 
  RAFT polymerisation has been commonly exploited as a versatile synthetic tool for the synthesis 
of stimuli-responsive linear polymers, which are intellectual materials responsive to environmental 
changes.
176-178
 Becer et al. synthesised a library of homopolymers and copolymers of methacrylic 
acid (MAA), mono(ethylene glycol) methyl ether methacrylate (MEOMA), di(ethylene glycol) 
methyl ether methacrylate (MEO2MA), oligo(ethylene glycol) methyl ether methacrylate 
(OEGMA475 and OEGMA1100), and oligo(ethylene glycol) ethyl ether methacrylate (OEGEMA246) 
via RAFT polymerisation,
179
 The thermo-responsive behaviour of these polymers was investigated. 
It was found that the copolymers P(MAA-co-OEGMA1100) had both pH- and thermo-responses at 
certain monomer ratios, though neither of the corresponding homopolymer exhibited LCST 
behaviour. Benoit et al. synthesised pH-responsive diblock copolymers PDMAEMA-b-
P(DMAEMA-co-AA-co-BMA) by using a folate-conjugated CTA.
180
 These diblock copolymers 
were utilised as tumour targeted-carriers for small interfering RNA (SiRNA) for in vitro gene 
knockdown. The cationic DMAEMA segments were employed for the binding and protection of 
siRNA as well as achieving pH-responsive endosomolytic behaviour. Roy et al. prepared block 
copolymers composed of 3-acrylamidophenylboronic acid (APBA) and N,N-dimethylacrylamide 
(DMA) via RAFT polymerisation.
181
 As boronic acids are uniquely responsive to pH as well as diol 
concentration, the block polymers PAPBA-b-PDMA displayed pH- and sugar-responsiveness. 
Chapter 1 Introduction 
 
 
28 
 
Unimer NPs (~7 nm) were observed at pH 10.7 (pKa ≈ 9) owing to the soluble anionic boronic acids 
units. However, when the pH was slowly reduced to 8.7, larger aggregates (~35 nm) were formed 
after dialysis because of the insoluble neutral boronic acids segments, and these aggregates were 
then disassembled into unimer NPs (~9 nm) again upon the addition of sugar due to the formation 
of soluble boronate esters. This study showed the first example of RAFT polymerisation of 
unprotected boronic acid monomers with pH- and sugar-responsive properties. 
  Recently, the RAFT technique has received increasing attention in the fabrication of 
nanostructures based on amphiphilic block copolymers. As mentioned in Section 1.1.2.2.1, 
amphiphilic block copolymers are attractive materials because they can form nano-sized micelles 
via self-assembly process in aqueous solution at concentrations above critical micelle concentration 
(CMC). However, the micelles disassemble when the concentration drops below CMC, e.g., 
dilution by bloodstream after intravenous administration.
182
 One of the most common solutions to 
the disassembly is the development of shell/core cross-linked micelles.
177, 178, 183
 Hales et al. 
reported shell-crosslinked vesicles based on block copolymers of poly(D,L-lactide) (PLA) and 
poly(N-isopropyl acrylamide) (PNIPAAm).
184
 A macroCTA was synthesised via ring-opening 
polymerisation between D,L-lactide and a hydroxyl-functionalised trithiocarbonate. Subsequently the 
macroCTA was chain extended with N-isopropyl acrylamide for the synthesis of PLA-b-
PNIPAAm, which was further chain extended with a crosslinker hexanediol diacrylate to form 
shell-crosslinked particles (165~280 nm) in methanol. It was found that the thermal transition 
behaviour of the aggregates was significantly changed by the core crosslinking process, as revealed 
by turbidity study using UV spectroscopy. Using RAFT polymerisation, Duong et al. synthesised 
amphiphilic block copolymers composed of POEGMA, polystyrene (PS) and poly(3-isopropenyl-
α,α-dimethylbenzyl isocyanate) (PTMI) (POEGMA-b-P(ST-co-TMI)), which were then self-
assembled into micelles in aqueous solution and core-crosslinked using a platinum(IV)-containing 
difunctional amine.
185
 These core-crosslinked micelles were stable in water but released the 
anticancer drug cisplatin slowly in the presence of reducing agent. In addition, cytotoxicity to A549 
human lung cancer cells was revealed by in vitro experiments, suggesting the potential applications 
of these micelles as drug containers.  
  Apart from the self-assembly process after synthesis, RAFT polymerisation-induced self-assembly 
(PISA) has evolved as another useful methodology for the in situ fabrication of nano-objects based 
on block copolymers.
186, 187
 Some monomers are soluble in water but their polymers are water 
insoluble, such as 2-hydroxypropyl methacrylate (HPMA) and 2-methoxyethyl acrylate (MEA).
188, 
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189
 Therefore, RAFT polymerisation of these monomers in aqueous solution using hydrophilic 
macroCTAs will gradually increase the hydrophobicity of the formed block copolymer chains, 
leading to the in situ formation of nanostructures (spherical micelles, vesicles, worms/rods, 
lamellae, etc) via self-assembly. For example, Sugihara et al. reported the systematic study of 
forming nano-objects by RAFT PSIA in aqueous solution.
188
 As depicted in Figure 1-12, a 
hydrophiphilic macroCTA, poly(2-(methacryloyloxy)ethylphosphorylcholine) (PMPC), was 
synthesised by RAFT polymerisation, and then used as macroCTA for the polymerisation of 
HPMA. The resultant amphiphilic block copolymers were self-assembled in situ to form nano-
objects with different morphologies depending on the chain length ratio of PMPC to PHPMA as 
well as total solid concentration. A detailed phase diagram was also proposed first time for such a 
system, enabling the future preparation of nano-objects via RAFT PSIA with predictable 
morphologies. 
 
Figure 1-12 Synthetic routes for PMPC-b-PHPMA block copolymers, and the transformation of 
morphology regulated by total solid concentration and DP of PHPMA block. Adapted from 
Sugihara et al.
188
 
1.2.2 Synthesis of Star Polymers by RAFT Polymerisation 
Star polymers, which are polymers having multiple linear polymer arms attached to a central core or 
point, have been extensively exploited for a variety of applications owing to their 3D globular 
structures and unique properties.
190
 In the past decade, RAFT polymerisation has been proven to be 
a robust and versatile technique for the synthesis of star polymers. Basically, the synthesis of star 
polymers by RAFT polymerisation can be classified as „core-first‟ and „arm-first‟ techniques, as 
illustrated in Figure 1-13.
191-193
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Figure 1-13 Illustration of RAFT techniques for the synthesis of star polymers. Adapted from 
Barner et al.
192
 
  The „core-first‟ technique includes the R-group and Z-group approaches. For the R-group 
approach, the CTA is attached to the core through the R-group. During RAFT polymerisation, the 
core acts as a macro-leaving group that carries multiple radicals, therefore one intrinsic drawback of 
this approach is unavoidable star-star coupling side reactions, which result in broadened molar mass 
distributions. Nonetheless, this problem could be alleviated, to some extent, by adopting the 
following strategies: (1) reducing the radical/CTA ratio in the system; (2) introducing a stable 
intermediate as a „radical storage reservoir‟; (3) minimising the CTA functionality on the core.192 
As an example, Chaffey-Millar et al. investigated the aforementioned design criteria for the RAFT 
synthesis of star polymers via the R-group approach.
194
 As verified by simulated and experimental 
results, it was found that star-star coupling could be minimised by using retarded CTA with lower 
amount of arms and reduced concentration of free radical initiator.  
  For the Z-group approach, the CTA functionality is covalently anchored to the „core‟ material, and 
the arm propagation proceeds nearby in the solution. Since the growing species are isolated from 
the core, star-star coupling can be effectively avoided, and the couplings between two living chains 
mainly account for the increased molar mass distributions. Therefore, compared with the R-group 
approach, this approach can produce well-defined star polymers with significantly narrower molar 
mass distributions. However, as the monomer conversion increases, the growing arms are becoming 
less accessible to the core due to steric effects, and these living chains are more likely to be 
terminated by chain-chain coupling to form dead polymers than to reach the core.
192
 Even though, 
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the Z-group approach is an effective alternative to the R-group approach for the synthesis of well-
defined star polymers with high yield. Liu et al. synthesised six-armed biodegradable star polymers 
using the Z-group approach. A hexa-functional CTA containing disulfide bond was prepared for the 
RAFT polymerisation for star polymers with arms of PS, poly(polyethylene glycol acrylate) 
(PEGA) and the PS-b-PEGA, respectively. Gel permeation chromatography (GPC) showed 
unimodal peaks for all the star polymers with ĐM below 1.3, confirming the advantage of the Z-
group approach. Additionally, the six arms were successfully cleaved from the core the in the 
presence of reducing agents such as DL-dithiothreitol (DTT) and glutathione (GSH), indicating the 
potential use of this approach for the synthesis of well-defined star polymers with biodegradability. 
  Lately, growing attention has been given to the synthesis of star polymers via the arm-first 
method, which includes the synthesis of linear arms and attachment of the arms to a core through 
radical polymerisations, ring-open polymerisations, click chemistry, etc.
195
 The main advantage of 
the arm-first technique is that it enables the synthesis of star polymers having a large number of 
arms with predesigned structures and compositions. Core-crosslinked star (CCS) polymers, which 
are representative products of the arm-first technique, have been increasingly attractive because of 
their facile synthesis by arm-first radical polymerisations using divinyl monomers as well as the 
unique properties resulting from their nano-sized architectures.
191
 However, this technique produces 
star polymers with broad ĐM owing to side reactions of formation of intermediate radicals and 
core/chain shielding effects.
191
 This can be overcome, to some degree, by carefully adjusting the 
polymerisation conditions. Ferreira et al. reported the optimisation of reaction parameters for the 
RAFT synthesis of CCS polymers.
196
 CCS polymers were synthesised through the chain extension 
of a series of homopolymers and block copolymers with different crosslinkers via RAFT 
polymerisation. By adjusting the conditions (arm molecular weight, solvent, crosslinker type, 
reaction time), well-defined star polymers (ĐM < 1.2) were obtained with relatively high arm 
incorporation (> 90%). It was revealed that the solubility of the crosslinker was the key parameter 
for a successful synthesis. High arm incorporation was achieved using crosslinkers with poor 
solubility in the chosen solvent because of the possible nano-phase separation inducing 
compartmentalisation of the polymerisation. To some extent, this approach is related to the PISA 
process, as mentioned in Section 1.2.1.  
  An and coworkers have presented several examples of the synthesis of CCS polymers using RAFT 
aqueous dispersion polymerisation.
189, 197-202
 For instance, CCS polymers were synthesised through 
the chain extension of PPEGMA macroCTA with MEA and a crosslinker poly(ethylene glycol) 
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diacrylate (PEGDA). This work featured the formation of amphiphilic block copolymer (PPEGMA-
b-PMEA) micelles via PSIA as well as the subsequence core-crosslinking using PEGDA. As a 
result, CCS polymers with low ĐM (1.1~1.2) and small size (40~60 nm) were prepared at very high 
arm incorporation (~98%).
189
 In the case of hydrophilic homopolymers as arms, crosslinker and 
spacing monomer played an essential role in the formation of well-defined CCS polymers. It was 
found that longer crosslinkers were helpful for forming CCS polymers due to the more flexible 
core, while hydrophobic spacing monomers could enhance the driving force to produce CCS 
polymers. Moreover, the arm incorporation was significantly reduced using arms with higher 
molecular weights owing to increased steric hindrance.
197
 
1.2.3 Synthesis of Hyperbranched Polymers by RAFT Polymerisation 
Hyperbranched polymers (HBPs) were previously synthesised mainly by step-growth 
polymerisation until Frechet et al. reported the synthesis of HBPs with irregular structures via self-
condensing vinyl polymerisation (SCVP).
203
 In the past few years, this concept has been extended 
to the synthesis of HBPs via RAFT polymerisation. Owing to the nature of the RAFT process, the 
HBPs produced in this way have more uniform structures and better defined properties. 
  Liu et al. pioneered the RAFT synthesis of HBPs about a decade ago.
204
 HBPs were synthesised 
through the RAFT copolymerisation of MMA and crosslinker ethylene glycol dimethacrylate 
(EGDMA) using a dithiobenzoate CTA. The highly-branched structure was revealed by NMR and 
GPC analyses. Moreover, the HBPs were able to be further chain extended with styrene, confirming 
the living characteristic of the HBPs by RAFT polymerisation. This work opened an avenue to the 
controlled synthesis of HBPs via RAFT polymerisation, and a wide range of HBPs have been 
synthesised following this concept. However, the structure of the HBPs is greatly related to the 
experimental conditions such as the crosslinker/CTA ratio and monomer concentration, and 
sometimes unfavoured macroscopic gelation occurs.
205-207
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Figure 1-14 Synthetic routes for highly-branched (co)polymers via RAFT SCVP. Adapted from 
Carter et al.
208
 
  RAFT SCVP, which utilises polymerisable CTAs to prepare HBPs in the absence of crosslinkers, 
seems to be a promising way to avoid gelation and obtain HBPs with relatively narrow ĐM. Carter 
et al. present the earliest work on the synthesis of HBPs via RAFT SCVP.
208-210
 As shown in Figure 
1-14, a polymerisable CTA, 4-vinylbenzylimidazole dithioate was designed and copolymerised with 
NIPAM to form highly-branched polymers with low ĐM value. The characteristics of HBPs could 
be easily tuned by using different polymerisation parameters in particular NIPAM/CTA ratio. Later 
on, the method was extended to the synthesis of HBPs that contain segments of block copolymers 
or statistical copolymers for improved one-step protein purification.
210
 
  RAFT SCVP has been further exploited for the synthesis of HBPs with complex structure and 
multifunctionality. For example, Zhang et al. synthesised HBPs with adjustable degree of branching 
(DB) using a polymerisable trithiocarbonate by varying the monomer/CTA ratio, and they also used 
these HBPs for the synthesis of star polymers with a hyperbranched core.
211
 By combing RAFT 
SCVP with other post modification techniques, the Gao group has recently developed a platform 
based on HBPs bearing multiple functional groups for fluorescence-related applications.
212-215
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Scheme 1-2 Synthesis of hyperbranched block copolymers via thiol-yne chemistry. Adapted from 
Konkolewicz et al.
216
 
  Very recently, HBPs have been synthesised through the combination of RAFT polymerisation and 
thiol-yne chemistry.
216, 217
 Block polymers were first synthesised using an alkyne-terminated 
trithiocarbonate CTA via RAFT polymerisation. Then the trithiocarbonate groups were converted to 
thiol groups through aminolysis using isopropyl amine, followed by the photo-initiated thiol-yne 
reaction for the formation of HBPs. The HBPs were able to self-assemble into micelles in aqueous 
and showed pH-responsive behaviour. This innovative method broadened the synthetic techniques 
for HBPs with designable segmental characteristics and tuneable properties.  
  In conclusion, over a decade‟s research has proven that RAFT polymerisation is an extremely 
versatile and robust technique for the precise synthesis of a vast range of polymers. Owing to its 
excellent tolerance to a wide range of monomer types as well as polymerisation conditions, RAFT 
polymerisation has been a prominent and flexible toolbox for the synthesis of well-defined 
polymers with targeted architectures and desired properties for diverse applications.  
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1.3 Stimuli-responsive Imaging Agents 
Stimuli-responsive polymers are polymers that have reversible physicochemical properties in 
response to the surrounding milieu.
218
 Based on their special properties, they are also named „smart 
polymers‟, „intelligent polymers‟ or „environmentally-sensitive polymers‟.219 The environmental 
conditions that stimuli-responsive polymers can respond to are generally classified as physical 
stimuli (temperature and light), chemical stimuli (pH and redox potential), and biological stimuli 
(enzymes and carbohydrates).
219, 220
 In recent years, as emerging advanced materials, stimuli-
responsive polymers have been playing an increasingly significant role in many fields in particular 
biomedical applications such as molecular imaging, drug/gene delivery, tissue engineering, etc.
221
  
  Stimuli-responsive agents are of special interest for molecular imaging and cancer therapy. For 
one thing, imaging performance can be reversely switchable in responsive to specific stimuli, 
enabling selective imaging of specific environments or areas. For another, the integration of stimuli-
responsiveness to imaging agents is beneficial for the fabrication of multimodal agents for 
theranostics.
222
  
  pH-responsive polymers have been extensively exploited for the design of imaging agents to 
visualise acidic environments such as tumour tissues.
223, 224
 As mentioned in Section 1.1.2.2, pH-
responsive polymers that contain tertiary amines were utilised for the design of „smart‟ 19F MRI 
CAs, which could be turned on and off based on the environmental pH.
139, 164
 For example, Zhou et 
al. developed block copolymer-based micelles as pH-responsive agents for fluorescence imaging.
225
 
Block copolymers PEO-b-(PR-co-TMR) were synthesised, in which PR stands for segments 
containing tertiary amines and TMR are units incorporated with a pH-insensitive dye (tetramethyl 
rhodamine). At higher pH values, the PR-co-TMR block was hydrophobic, therefore the 
amphiphilic block copolymers were self-assembled to form micelles, quenching the fluorescent 
signals through mechanisms of Förster resonance energy transfer between TMR molecules (homo-
FRET) and photo-induced electron transfer (PeT) from tertiary amines to TMR. In contrast, at lower 
pH values, the micelles were dissembled into separated chains, dramatically increasing the 
fluorescence emission because of the disassociated TMR units and the reduced PeT. Hence, by 
choosing different PR monomers, the fluorescence emission could be activated and deactivated at 
desired pH values, enabling the precise imaging of specific cells and tissues. 
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Figure 1-15 Schematic illustration of the theranostic platform based on multifunctional core-shell 
NPs. Adapted from Wu et al.
226
 
  Thermo-responsive property has already been widely utilised for controlled release of drug 
molecules.
218
 Recently, thermo-responsive imaging agents have been developed for cancer 
theranostics. As shown in Figure 1-15, Wu et al. reported a theranostic platform based on hybrid 
NPs, which were comprised of Ag-Au NPs as core and OEGMA-containing thermo-responsive gel 
as shell.
226
 Fluorescent light was emitted from the bimetallic core, and the photoluminescence (PL) 
intensity was dependent on temperature with an ON/OFF switchable behaviour. In addition, these 
NPs were used as carriers for a hydrophilic anticancer drug temozolomide (TMA), and the drug 
release could be accelerated by either temperature increase of the local microenvironments or the 
heat generated by NIR irradiation. Furthermore, the NPs were also employed as effective 
photothermal agents without drug loading. The work presented multimodal NPs as targeted 
theranostic agents for fluorescence imaging, photothermal therapy and chemotherapy.  
  Imparting biodegradability to imaging agents can facilitate the clearance of NPs from the body as 
well as controlled drug release. Katz et al. prepared functional polymersomes using biodegradable 
diblock copolymers that were incorporated with both fluorescent and photocleavable moieties.
227
 
When exposed to UV, the polymersomes gradually collapsed, and a rapid release of biocytin was 
observed. Moreover, the polymersomes were visualised by fluorescence microscopy after 
incubation with immature dendritic cells. Hence this work developed a useful method for the 
preparation of biodegradable polymersomes based on block copolymers for both fluorescence 
imaging and UV-triggered drug delivery.  
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  The desire for higher information content in imaging has led to the design of agents which are 
responsive to two or more stimuli. Mosaiab et al. designed pH- and thermo-responsive fluorescence 
imaging agents comprised of graphene oxide (GO) and graft copolymers (PEG-g-P(DMA-co-
NIPAAm)) containing dye molecules borondipyrromethane.
228
 Owing to the pH-responsiveness of 
PDMA and thermo-responsiveness of PNIPAAm, the fluorescence emission could be switched on 
only at low pHs and a lower temperature (25 
o
C), whereas they were not able to be detected at 
above physiological pH and a higher temperature (37 
o
C). Moreover, the NPs acted as DOX carriers 
with high loading efficiency (76.25%), and the drug release was much faster at pH 5.0 than that at 
pH 7.4. Thus these dual-responsive nanoparticles could be utilised for the detection of tumour 
tissues as well as controlled drug delivery. 
  Overall, tremendous effort has been devoted to the development of stimuli-responsive imaging 
agents, which have been increasingly attractive in nanomedicine and molecular imaging. For future 
clinical applications, detailed investigations on toxicity, biodistribution, and pharmacokinetics are 
to be carried out.  
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1.4 Multimodal Imaging Agents 
The diverse modern imaging techniques play a vital role in both clinical diagnosis and biomedical 
research. However, the choice of imaging modalities is a common conundrum because each 
modality has its advantages and disadvantages, as summarised in Figure 1-16.
229
 For example, 
optical imaging with high sensitivity lacks spatial resolution, whereas MRI with high spatial 
resolution has low sensitivity. Therefore, it is understandable that no single modality is sufficient to 
provide all the necessary information. In fact, clinical diagnosis often suffers from partial or 
ambiguous information when using single imaging modality. 
 
Figure 1-16 A summary of the currently used modalities for molecular imaging. Adapted from Lee 
et al.
229
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  To tackle this problem, the combination of two or more modalities has become a mainstream to 
obtain complementary information in molecular imaging.
131, 229-232
 With the commercial appearance 
of multimodal fused instruments, there has been a surge in the development of multimodal 
molecular imaging agents, which has been greatly facilitated and accelerated by the rapidly 
advancing field of nanotechnology.
229, 231
 As introduced in Section 1.1, MRI is a powerful and non-
invasive imaging modality for producing 3D anatomical images with high resolution. The low 
sensitivity, a major problem of MRI, can be improved through multimodal imaging by combining 
MRI and other sensitive techniques, such as optical imaging, PET/SPECT, ultrasonography, etc.
131
 
Therefore, the development of imaging agents that contain both MRI and other imaging 
functionality is of great importance for multimodal molecular imaging.  
  Owing to their diverse architectures and functionalities, polymers have gained considerable 
attention as excellent materials for the construction of nano-sized multimodal imaging agents.
222, 233
 
The synergistic integration of different imaging moieties to a polymeric system can be achieved by 
a variety of approaches, including polymerisation, conjugation, non-covalent incorporation, etc. In 
addition, as introduced in Section 1.2, the size and structure of polymers can be precisely designed 
by employing controlled polymerisation techniques, providing robust and flexible methods for the 
design of polymeric agents with tuneable physicochemical and biological characteristics. 
Furthermore, the facile attachment and conjugation of other functionalities such as drug and 
targeting moieties to polymers allows for the fabrication of theranostic agents for both imaging and 
therapy.  
  The development of MRI/optical imaging agents is of great interest as these two modalities can 
produce images with both high resolution and sensitivity. Additionally, the wide class of fluorescent 
molecules adds more opportunities to the design of imaging agents. Howes et al. reported the 
preparation of MRI/optical imaging agents based on phospholipid micelles that were encapsulated 
with iron oxide nanoparticles and different hydrophobic conjugated polymers.
234
 The bimodal 
imaging performance was examined by both fluorescence imaging and MRI. Successful cell uptake 
and low cytotoxicity were also observed. It should be highlighted that the two imaging moieties 
could be replaced by other commercial products. Therefore, this work presented a useful method for 
the preparation of MRI/optical imaging agents.  
  Star polymers and dendritic polymers are prefect candidates for multimodal imaging agents due to 
the 3D globular structure as well as abundant functionalities. Adkins et al. synthesised CCS star 
polymers via RAFT arm-first approach using PAA arms and a fluorescent crosslinker.
235
 Then the 
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CCS polymers were conjugated with Gd(III) and Eu (III), followed by the further attachments with 
dopamine derivatives, cell penetrating units, and targeting moieties. High NMR relaxivities (r1 = 85 
mM s
-1
, r2 = 100 mM s
-1
) were achieved, resulting in MRI with greatly enhanced contrast. 
Moreover, the in vitro uptake of CCS polymers by 3T3 mouse fibroblast cells was confirmed by 
confocal microscopy. These results demonstrated multifunctional CCS polymers as an outstanding 
platform for the design of MRI/optical imaging agents. As indicated before, multifunctional HBPs 
synthesised via RAFT polymerisation have been proven to be robust theranostic agents for both in 
vitro and in vivo 
1
H MRI/
19
F MRI/optical imaging.
161
 It should be emphasised that the overlay of 
both 
1
H MRI and 
19
F MRI allows imaging of the tissues as well as tracking of the CAs. 
  The combination of MRI and PET/SPECT can afford highly sensitive and quantitative imaging 
with temporal and spatial resolution.
236
 Functional polymers have been attractive in the preparation 
of MRI-PET/SPECT bimodal imaging agents due to the facile conjugation with MRI moieties 
(SPIONs and Gd(III)-chelates) as well as radio-isotopes for PET/SPECT. Locatelli et al. reported 
the preparation of SPIONs/
68
Ga/block copolymers hybrid nanoparticles as MRI/PET bimodal 
imaging agents.
237
 SPIONs were encapsulated into micelles of PLGA-b-PEG block copolymers that 
had -COOH end groups. Then 2,2‟-(7-(4-((2-aminoethyl)amino)-1-carboxy-4-oxobutyl)-1,4,7-
triazonane-1,4-diyl) diacetic acid (NODA) molecules were attached to the surface of the as-formed 
hybrid NPs via the -COOH groups, followed by the chelation of 
68
Ga to NODA. These non-toxic 
radiolabelled SPIONs NPs were evaluated as imaging agents by both MRI and PET, demonstrating 
a successful example for the fabrication of MRI/PET bimodal imaging agents. 
  Polymers have been widely exploited as coating materials for the stabilisation of MRI-
PET/SPECT imaging agents. de Rosales et al. developed 
99m
Tc-labelled SPIONs as MRI-
PET/SPECT bimodal imaging agents.
238
 
99m
Tc-bisphosphonate chelates were attached to the surface 
of commercial SPIONs coated with dextran (Endorem/Feridx, liver MRI CAs). Although the 
99m
Tc-
bisphosphonate chelates were proven to be conjugated directly with SPIONs rather than the dextran, 
the dextran layer was essential to stabilise the colloidal suspension. The capability of these NPs as 
imaging agents was tested and confirmed by MRI and SPECT-CT, and biodistribution studies 
revealed that NPs mainly accumulated in the liver and spleen. This work presented the first example 
of radiolabelled SPIONs as multimodal imaging agents. 
  Owing to their inherent nature, MRI and CT are more suited for imaging of soft and hard tissues, 
respectively. Therefore, the combination of MRI and CT seems promising as the information 
provided by each modality can complement each other. In recent years, the design of MRI/CT 
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bimodal imaging agents has been an emerging field. Kim et al. reported the preparation of hybrid 
nanoparticles coated with amphiphilic copolymer for MRI/CT bimodal imaging.
239
 Using an 
emulsification process, oleylamine-stabilised hybrid Au-Fe3O4 NPs were encapsulated by 
amphiphilic statistical copolymers comprised of dodecyl methacrylate (DMA), methacrylic acid 
(MA) and PEGMA segments. Owing to the presence of Au and Fe3O4, these organic-inorganic 
hybrid NPs could be used for both CT and MRI. The excellent dual-imaging performance was 
confirmed by in vivo MRI/CT experiments on hepatoma-bearing mice, suggesting the potential 
application of these NPs as bimodal imaging agents for the diagnosis of hepatoma. 
  In conclusion, multimodal imaging is a continuously developing field that can greatly facilitate the 
accurate imaging and diagnosis by offering complementary information. Recently, the appearance 
of commercial fused instruments (e.g., MRI-PET) has significantly boosted the development of 
multimodal imaging agents. Polymers possess an almost infinite range of structural variations and 
the opportunity for multiple functionalities, and hence it could be foreseen that polymeric agents 
have the great potential to evolve as the next-generation multimodal imaging agents for improved 
theranostics.  
1.5 Aims of This Project 
Since its appearance in 1977, 
19
F MRI has been proven to be a prominent modality because it has 
almost zero background signal owing to the absence of appreciable endogenous fluorine in the 
body. By using molecular imaging CAs, 
19
F MRI provides not only the 3D anatomical images but 
also the specific location of CAs. Therefore it is a useful tool for a variety of biomedical 
applications, including cell labelling/tracking, tissue imaging, drug metabolism study, etc. Despite 
the attractive advantages, 
19
F MRI is not routinely used in clinical. The main impediment to clinical 
uptake is the lack of suitable CAs. After nearly four decades of research, few 
19
F MRI CAs have 
gained regulatory approval.  
  In recent years, polymeric 
19
F MRI CAs have been emerging as next-generation CAs. Thanks to 
controlled polymerisation techniques and conjugation chemistry, partly-fluorinated polymers with 
well-defined architectures and desired functionalities have been synthesised for 
19
F MRI as well as 
theranostics. As revealed by previous studies, two main design criteria for efficient polymeric CAs 
are high 
19
F loading and highly mobile 
19
F nuclei. More recent research has further demonstrated 
that partly-fluorinated HBPs are excellent candidates for 
19
F MRI because they can fulfil both 
criteria through rational chemical design. Moreover, owing to the abundant functionality, they are 
Chapter 1 Introduction 
 
 
42 
 
preferred materials for fabricating multifunctional imaging agents for theranostics (e.g., 
1
H/
19
F 
MRI, fluorescence imaging, anticancer drug delivery, etc). Nevertheless, information on how 
imaging performance is determined by hyperbranched structure is dearth. For example, the 
influence of hyperbranched architecture and chain sequence distribution on 
19
F MRI performance 
needs to be explored. In addition, stimuli-responsive CAs should be developed as they are 
increasingly important „smart‟ CAs. Furthermore, the combination of 19F MRI and other imaging 
modalities will certainly afford more opportunities to the area of multimodal molecular imaging. 
Thus, the aims of this project are as follows. 
1. to synthesise partly-fluorinated polymers with star and hyperbranched architectures as 19F 
MRI CAs;  
2. to study the influence of polymer architecture and chain sequence distribution on 19F MRI 
performance; 
3. to develop pH-responsive and partly-fluorinated polymers for selective imaging of diseased 
tissues 
4. to design HBPs that contain both fluorine and iodine for 19F MRI/CT bimodal molecular 
imaging; 
5. to build up a robust RAFT polymerisation approach for partly-fluorinated HBPs as 19F MRI 
CAs. 
6. To gain a molecular level understanding for the design of highly-efficient 19F MRI CAs. 
  In terms of these objectives, this thesis is divided into seven chapters. Chapter 2 describes the 
RAFT synthesis of partly-fluorinated and pH-responsive star-like HBPs as „smart‟ 19F MRI CAs. 
These novel polymers were synthesised via the RAFT copolymerisation of TFEA, DMAEMA, and 
EGDMA (crosslinker) using PPPGMA homopolymers as macoCTAs. In such star-like system, the 
19
F nuclei were positioned together with pH-responsive PDMAEMA segments within the 
hyperbranched core, which was shielded with hydrophilic and biocompatible PPEGMA arms. After 
forming nanoparticles by direct dissolution in aqueous solution, the pH-dependence of Dh and NMR 
relaxation times (T1 and T2) were studied. Finally the 
19
F NMR and MRI were conducted at 
different pH values. This work intends to establish a pH-responsive hyperbranched structure for 
„smart‟ 19F MRI CAs with ON/OFF property. 
  Following Chapter 2, it was hypothesised that the imaging performance would change by placing 
the 
19
F nuclei exterior to the hyperbranched core. To investigate this further, Chapter 3 explores 
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the capability of CCS polymers as 
19
F MRI CAs. Through RAFT aqueous dispersion 
polymerisation, CCS polymers were synthesised by using amphiphilic block copolymers PPEGMA-
b-P(TFEMA-co-DMAEMA) as arms and a disulfide-containing bifunctional monomer DSDMA as 
crosslinker. The polymerisation kinetics were investigated. A series of CCS polymers with different 
19
F content were synthesised and the pH-dependence of Dh and relaxation times (T1 and T2) studied. 
In order to verify the degradability, the CCS polymers were treated with reducing agents such as 
glutathione (GSH) and tris(2-carboxyethyl)phosphine hydrochloride (TCEP). Furthermore, the CCS 
polymers nanoparticles were evaluated by 
19
F NMR and MRI at four different pH values. The 
influence of polymer architecture on imaging performance was compared to those obtained in 
Chapter 1. 
  To further the application of 
19
F MRI, Chapter 4 endeavours to develop HBP-based 
19
F MRI/CT 
bimodal imaging agents. Biodegradable HBPs containing iodine were synthesised via RAFT 
copolymerisation of an iodo-monomer, PEGMA and DSDMA. Then they were chain extended with 
TFEA and PEGMA to form star-like HBPs containing iodine in the hyperbranched core and 
fluorine in the arms. The polymer structure was comprehensively studied. The bimodal imaging 
performance was investigated by both 
19
F MRI and CT. To date, this study is the first example of 
polymeric 
19
F MRI/CT bimodal imaging agents. 
  According to both previous publications and our own experience, the RAFT synthesis of HBPs 
using crosslinkers is highly dependent on the experimental conditions. The structure can be affected 
by a number of factors, including crosslinker/monomer/CTA ratio, initiator/CTA ratio, monomer 
concentration, polymerisation time, solvent type, etc. Hence it is necessary to develop a more 
flexible methodology for the synthesis of HBP-based 
19
F MRI CAs. Chapter 5 describes the 
investigation on RAFT self-condensing vinyl polymerisation (SCVP) for the synthesis of 
segmented and highly-branched polymers (SHBPs). A polymerisable trithiocarbonate CTA was 
designed for the RAFT process as well as formation of branching structure. A series of SHBPs 
consisting of TFE(M)A, PEG(M)A and CTA were synthesised. The polymerisation parameters, 
such as polymerisation time, monomer/CTA ratio, monomer concentration, were studied and 
optimised to produce well-defined SHBPs. SHBPs containing different types of monomers 
(acrylates and methacrylates) were prepared to study the influence of polymer backbone on the 
motion of fluorine nuclei. The relationship between fluorine content and fluorine mobility was also 
investigated by 
19
F NMR. In addition, the influence of degree of branching on fluorine mobility was 
studied. The tuneable and selective imaging performance of these SHBPs was examined by 
19
F 
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MRI, demonstration that RAFT SCVP is a robust way for the synthesis of SHBPs with tailored 
structures and imaging proterties. 
  To develop theranostic agents combing 
19
F MRI and drug delivery, Chapter 6 explores the RAFT 
synthesis of star polymers with a polyhedral oligomeric silsesquioxanes (POSS) core and eight 
partly-fluorinated arms. Star polymer were synthesised by R-group approach us a macroCTA 
consisting a POSS core and eight CTA moieties for the copolymerisation of TFEA and PEGA. The 
synthetic conditions were investigated and optimised for well-defined star polymers with high 
yields. The molecular structure was characterised. The influence of arm length on fluorine mobility 
was analysed by 
19
F NMR. The potential 
19
F MRI performance was preliminarily confirmed by 
comparing the theoretical imaging intensities with the previous results. Such star polymers were 
promising theranostic agents for 
19
F MRI and drug delivery. 
  Finally, Chapter 7 provides a comparison of all the polymeric agents developed in this thesis as 
well as a summary of the findings reported in this thesis.  
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Chapter 2  
pH-Responsive Star-like Hyperbranched Polymers 
for Selective F-19 MRI 
The key design criteria of polymeric 
19
F MRI contrast agents are to achieve high 
19
F content and 
highly mobile 
19
F nuclei in aqueous solution. This chapter explores hyperbranched structures for the 
fabrication of 
19
F MRI contrast agents. Star-like polymers with a hyperbranched core were 
synthesised using the arm-first approach by RAFT polymerisation. The fluorine-rich units were 
positioned in a three-dimensional (3D) hyperbranched structure, which was shielded by hydrophilic 
poly(ethylene glycol) brushes as arms. The mobility of the 
19
F nuclei was expected to be enhanced 
through the separation of fluorinated segments by the hyperbranched structure. In addition, the 
mobility of the 
19
F nuclei was expected to be dependent on the solution pH due to changes in 
polymer conformation regulated by the presence of pH-responsive segments. The star-like polymers 
could be imaged only in acidic environments, suggesting potential applications in the diagnosis of 
cancer diseases. 
2.1 Introduction 
Early and accurate detection of cancerous tissue is of crucial importance for successful treatment. 
As a key diagnostic modality, magnetic resonance imaging (MRI) has attracted considerable 
attention because of its non-invasive and non-destructive properties as well as its capability to 
provide high resolution images including three-dimensional images with detailed anatomic 
contrast.
1, 2
 So far, MRI has been extensively studied and utilised for the detection, assessment and 
therapeutic monitoring of a variety of cancer diseases, such as prostate cancer, breast cancer, brain 
cancer, etc.
3 In the past few decades, 1H MRI has been the dominant imaging modality in clinical 
MRI. However, due to the large background signal arising from the abundance of protons in human 
tissue, it is often difficult for 
1
H MRI to generate unambiguous images and discriminate tumour 
tissue from the surrounding normal tissues, especially in the early stages of disease, and at the 
tumour margins.
4
  
  Since its first appearance in 1977,
5
 
19
F MRI has been considered as a promising alternative to 
1
H 
MRI because of the advantages of negligible 
19
F background in the living body, high gyromagnetic 
ratio, favourable sensitivity and high natural abundance of 
19
F.
6, 7
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  In many MRI examinations, contrast agents are required to improve the image quality or visualize 
specific body tissues. 
1
H MRI measures the abundant water molecules and hence provides high 
quality images.
8 
To achieve the same image quality as 
1
H MRI, 
19
F MRI requires a high 
concentration of 
19
F nuclei in the targeted tissue area. For this reason, contrast agents with high 
content of detectable 
19
F nuclei are indispensable for 
19
F MRI. During the past few decades, 
tremendous effort has been devoted to the development of 
19
F MRI contrast agents. A range of 
19
F-
containing compounds, from small molecules to polymers, have been designed and studied as 
candidate 
19
F MRI contrast agents.
8, 9
 
  Recently, 
19
F-containing polymers have been considered as a potentially new generation of 
19
F 
MRI contrast agents. Compared to their small molecule counterparts, polymeric agents have a 
number of favourable characteristics, such as potentially high loading of the NMR-active fluorine 
nuclei, versatile molecular structures and abundant possibilities for functionalisation. In recent 
years, a number of polymers have been synthesised and evaluated as 
19
F MRI contrast agents, 
including linear polymers,
10-13
 polymeric nanogels
14, 15
, dendrimers
16-19
 and hyperbranched 
polymers.
20-22
 Among these, water-soluble star polymers are especially advantageous owing to 
several features. First, they can form stable nanoparticles in aqueous solution without involving 
self-assembly processes and hence their stability is not compromised due to presence of a critical 
micelle concentration. Thus, unlike block copolymer micelles, star polymers will not suffer from 
potential problems arising from disassembly and collapse in vivo.
21
 Secondly, in a three-
dimensional branched or star structure, the 
19
F nuclei can be well separated thus maintaining high 
molecular mobility, ensuring long transverse relaxation times, the generation of a strong 
19
F signal 
and good MRI image quality.
22
 Thirdly, the abundant functional groups in star polymers provide 
many possibilities for post-modification to satisfy various demands, such as conjugation with 
complementary imaging agents or targeting groups. In the past few years, the above aspects have 
been leading to a wave of interest in the fabrication of branched polymeric 
19
F MRI contrast agents. 
  More recently, the development of stimuli-responsive imaging agents has attracted significant 
interest.
9, 23, 24
 Imaging agents sensitive to environmental conditions (pH, temperature, metal 
concentration, etc.), termed “smart” imaging agents, can be designed to be only visible (detectable) 
in specific circumstances. pH-Responsive imaging agents are especially attractive because of the 
well-known variation in pH in tissue types and in diseased tissue.
25, 26
 Polymers that bear tertiary 
amino groups, such as poly 2-(dimethylamino)ethyl methacrylate (PDMAEMA) and poly 2-
(diethylamino)ethyl methacrylate (PDEAEMA), have been widely exploited in various applications 
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as pH-responsive materials.
26
 As a result of the protonation and deprotonation of the tertiary amino 
groups, these polymer chains can swell and shrink upon a change in pH across the pKa. Although a 
few examples have been reported,
11, 14, 18
 there is still a dearth of data on the development of pH-
responsive 
19
F MRI agents. 
  In this Chapter, we study the synthesis of pH-responsive and 
19
F-containing star-like polymers 
with a branched core and their potential application as "smart" 
19
F MRI contrast agents. First, 
poly(poly(ethylene glycol) methyl ether methacrylate) (PPEGMA) was synthesised by reversible 
addition-fragmentation chain transfer (RAFT) polymerisation. Then it was used as a macro chain 
transfer agent (macroCTA) for the copolymerisation of 2,2,2-trifluoroethyl acrylate (TFEA, 
19
F-
containing monomer), 2-(dimethylamino)ethyl methacrylate (DMAEMA, pH-responsive monomer) 
and ethylene glycol dimethacrylate (EGDMA, cross-linker), forming star-like polymers with a 
branched core and PPEGMA brush arms. The star-like polymers were directly dissolved in 
phosphate-buffered saline (PBS, pH = 7.4) to form nanoparticles. The pH responsiveness was 
examined by measurement of particle size by cryo-transmission electron microscopy (cryo-TEM) 
and 
19
F spin-lattice (T1) and spin-spin (T2) relaxation times by 
19
F nuclear magnetic resonance (
19
F 
NMR). Preliminary in vitro 
19
F MRI measurements confirmed a strong change in image intensity 
across the pKa. 
  An advantage of these star-like polymers compared with the hyperbranched platforms reported 
previously by our group
22, 27
 is the ability to simply tune the core density through the arm-first 
method. This potentially provides greater control of the response of the imaging agent to an external 
stimulus, in this case a change in pH. 
2.2 Experimental Section 
2.2.1 Materials 
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. Poly(ethylene glycol) 
methyl ether methacrylate (PEGMA, Mn = 475), 2-(dimethylamino)ethyl methacrylate 
(DMAEMA), 2,2,2-trifluoroethyl acrylate (TFEA), and ethylene glycol dimethacrylate (EGDMA) 
were passed through basic alumina columns to remove inhibitors prior to use. 2,2′-azobis(2-
methylpropionitrile) (AIBN) was recrystallized twice from methanol before use. The RAFT agent, 
4-cyano-4-(dodecylsulfanylthiocarbonyl)sulfanyl pentanoic acid (denoted as CTA), was synthesised 
according to a previously reported procedure.
28, 29
 Dialysis tubing with molecular weight cut off 
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(MWCO) of 3.5 or 100 kDa was purchased from Thermo Fisher Scientific Inc. and Spectrum 
Laboratories Inc., respectively. PBS (1×) was prepared using PBS tablets purchased from 
AMRESCO. Milli-Q water was used for the preparation of aqueous solution and for dialysis of the 
polymers. 
2.2.2 Synthesis 
2.2.2.1 Synthesis of Alkyne-Terminated CTA (Alkyne-CTA) 
CTA (1.70 g, 4.22 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 
1.21 g, 6.31 mmol), 4-(dimethylamino)pyridine (DMAP, 0.77 g, 6.31 mmol ) were dissolved in 30 
mL of dichloromethane (DCM) in a 50 mL round bottom flask and bubbled with nitrogen for 30 
min in an ice bath. Propargyl alcohol (1.25 mL, 21.42 mmol) was injected drop-wise into the flask 
under nitrogen flow. After injection, the reaction was kept at 0 
o
C for 1 h, and then stirred at room 
temperature overnight. Finally, the resultant brown solution was washed with 1 M HCl (4×50 mL) 
and brine (4×100 mL) in sequence, dried over MgSO4 and then the solvent was removed by rotary 
evaporation, yielding a brownish-yellow oil. The structure was confirmed by 
1
H nuclear magnetic 
resonance (
1
H NMR) (500 MHz, δ, ppm, CDCl3): 0.88 (t, 3H, CH3CH2CH2), 1.26 (br s, 18H, 
(CH2)9), 1.69 (m, 2H, CH2CH2S), 1.87 (s, 3H, CH3), 2.37-2.70 (m, 4H, CH2CH2-COO), 2.49 (t, H, 
OCH2C≡CH), 3.32 (t, 3H, CH2CH2S), 4.70 (d, 2H, OCH2C≡CH). 
13
C NMR (125 MHz, δ, ppm, 
CDCl3): 170.63 (COOCH2), 118.87 (CN), 75.20 (C≡CH), 52.41(C≡CH), 46.21 (C(CH3)CN)), 37.03 
(C(=O)CH2CH2), 33.62 (C(=O)CH2CH2), 31.85, 29.56, 27.61, 24.81, 22.63 (overlapping 
13
C 
signals), 14.07 (CH3CH2CH2). 
2.2.2.2 Synthesis of PPEGMA Macro-CTA by RAFT Polymerisation 
PEGMA (9.5 g, 20 mmol), alkyne-CTA (0.441g, 1 mmol) and AIBN (32.8 mg, 0.2 mmol) were 
dissolved in 20 mL of toluene in a 50 mL round bottom flask equipped with a magnetic stirrer bar 
and sealed with a rubber septum. The solution was purged with nitrogen for 45 min in an ice bath, 
followed by being immersed in an oil bath thermostated at 70 
o
C. Samples were removed at 
intervals using a gas-tight syringe for kinetic studies. After 180 min, the polymerisation was 
quenched by placing the flask in an ice bath and exposing to air for 5 min. The crude polymer 
solution was precipitated into hexane twice and then further purified by dialysed against water for 
24 h using dialysis tubing with MWCO of 3.5 kDa. A yellowish viscous oil was obtained after 
freeze drying (5 g, yield: 86%). The molecular weights of the final product were determined by both 
gel permeation chromatography (GPC) and 
1
H NMR. GPC: Mn = 8100, Mw /Mn = 1.12. 
1
H NMR: 
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Mn = 14,200, degree of polymerisation (DP) = 29. 
2.2.2.3 Synthesis of Star-like Polymers by RAFT Polymerisation using PPEGMA Macro-CTA 
In a typical experiment, PPEGMA macroCTA (0.9 g, 0.061 mmol), TFEA (0.063 mL, 0.5 mmol), 
DMAEMA (0.253 mL, 1.5 mmol), EGDMA (0.094 mL, 0.5 mmol), and AIBN (3.28 mg, 0.02 
mmol) were dissolved in 5 mL of tetrahydrofuran (THF) in a 25 mL flask equipped with a magnetic 
stirrer bar and sealed with a rubber septum. The flask was then deoxygenated by being purged with 
nitrogen for 15 min in an ice bath before it was placed in an oil bath thermostated at 70 
o
C for 24 h. 
The polymerisation was stopped by immersing the flask in an ice bath and exposing the solution to 
air for 5 min. The crude polymer solution was precipitated into hexane twice and then purified by 
extensive dialysis in water (MWCO: 100 kDa) for 5 days to remove the small molecular weight 
impurities. A yellowish and viscous solid was obtained after freeze drying. Yield: 0.71 g, 55%. 
2.2.2.4 Preparation of Star-like Polymer Nanoparticles in PBS  
Solutions of the star-like polymers were prepared by direct dissolution in PBS (pH = 7.4). 
Typically, 20 mg of the sample was dissolved in 20 mL of PBS, which was stirred for 2 h at room 
temperature (20 
o
C) to form a clear solution. HCl and NaOH aqueous solution (both 1 M) were used 
to adjust the pH to desired values for further characterisation. 
2.2.3 Characterisation 
Gel Permeation Chromatography (GPC)  
Molecular weights and molecular weight distributions were determined by GPC using a Waters 
Alliance 2690 Separations Module equipped with Waters 2414 Refractive Index (RI) Detector, 
Waters 2489 UV/Visible Detector, Waters 717 Plus Autosampler and Waters 1515 Isocratic HPLC 
Pump. Samples were dissolved in THF/triethylamine (95/5, v/v) and passed through 0.45 µm filters 
before each measurement. THF was used as mobile phase at a flow rate of 1 mL min
-1
. The system 
was calibrated using polystyrene (PS) standards, to which the number average molecular weight 
(Mn) and weight average molecular weight (Mw) were referenced. For measuring absolute molecular 
weights of the star-like polymers, a multi angle laser light scattering (MALLS) detector (DAWN 8
+
, 
Wyatt) was attached to the GPC, and the polymer sample solutions were eluted at a flow rate of 1 
mg mL
-1
 in THF. The refractive index increment, dn/dc, was calculated for each sample after 
measuring the refractive indices of a series of dilute polymer/THF solutions with a range of 
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concentrations, and was found to be around 0.055 ml g
-1
 for the star-like polymers in THF at 25 
o
C. 
 
1
H Nuclear Magnetic Resonance (
1
H NMR)  
1
H NMR analysis was performed on a Bruker Avance 500MHz spectrometer with either TXI5 or 
BBO5 probe at 25 
o
C using an internal lock (CDCl3) and referenced to the residual non-deuterated 
solvent (CHCl3). A 90
o
 pulse of either 7.85 or 13.7 µs was applied in all experiments, the relaxation 
delay was 4 s and the acquisition time was 3.9 s. Data were collected using a spectrum width of 5.5 
kHz, 43k data points and 256 scans. 
19
F Nuclear Magnetic Resonance (
19
F NMR) 
All 
19
F NMR spectra were acquired at 470.55 MHz without 
1
H decoupling on a Bruker Avance 500 
spectrometer using a 5 mm broadband inverse probe (BBI5) for which the inner coil was double-
tuned for 
19
F and 
1
H. The samples were prepared by dissolving the star-like polymers in H2O/D2O 
(90/10, v/v) at a concentration of 20 mg mL
-1
. All measurements were performed at 25 
o
C. A 90
o
 
pulse of 15.1 µs was applied in all measurements, the relaxation delay was 2 s and the acquisition 
time was 0.7 s. Data were collected using a spectrum width of 23 kHz, 32k data points and 128 
scans. 
  
19
F spin-spin relaxation times (T2) were measured using the Carr-Purcell-Meiboom-Gill (CPMG) 
pulse sequence at 25 
o
C. The samples were dissolved in H2O/D2O (90/10, v/v) at a concentration of 
20 mg mL
-1
. The relaxation delay was 3 s and the acquisition time was 0.7 s. For each 
measurement, the echo times were from 2 to 770 ms and 15 points were collected, which could be 
described by exponential functions for the calculation of T2.  
  
19
F spin-lattice (T1) relaxation times were measured using the standard inversion-recovery pulse 
sequence. For each measurement, the recovery times were from 2 ms to 3 s and 15 points were 
acquired. Values for the major peak at around -72.8 ppm are reported. 
19
F MRI  
19
F MRI images were acquired at 376.5 MHz (9.4 T) on a Bruker BioSpec 94/30 USR small animal 
imaging system using a 40 mm internal diameter 
1
H/
19
F volume coil. Star-like polymers were 
dissolved in PBS (20 mg mL
-1
) and loaded in clear glass vials (8 × 30 mm, 0.75 mL), which were 
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then placed in a 
1
H/
19
F dual resonator 40 mm volume coil. Scan parameters were chosen to 
optimize acquisition for 
19
F density contrast and minimize the effect of T1 and T2 on signal 
attenuation. RF basic frequency and RF pulse width and attenuation were calibrated manually. A 
multi slice multi echo (MSME) sequence acquiring a single echo per excitation was used (repetition 
time (TR) = 1000 ms, echo time (TE) = 6.2 ms, number of excitations (NEX) = 1024) with matrix 
(MTX) of 32 × 32 × 1 over a field of view (FOV) of 30 × 30 × 20 mm giving a total scan time of 9 
h and 6 min. 
Cryo-Transmission Electron Microscopy (Cryo-TEM)  
Samples (20 mg mL
-1
 in PBS at pH 6 and 9) were plunge frozen on C-flat holey carbon grids 
(Protochips, Raleigh, NC, USA) into liquid ethane using an FEI Vitrobot Mark 3 (FEI Company, 
Eindhoven, The Netherlands). The optimal blot time was 4 seconds, with the chamber maintained at 
100% humidity at 4 ºC. Frozen/vitrified samples were viewed on a Technai T12 TEM (FEI 
Company) operating at 120 kV, and imaged at 30,000× magnification (8.4 electrons/Å
2
) and 
52,000× magnification (26 electrons/Å
2
), using an FEI Eagle 4k CCD (FEI Company), and 
SerialEM image acquisition software. 
2.3 Results and Discussion 
2.3.1 Design Concept 
It is well established that for spin-echo MR imaging, the intensity of the observed MRI signal in 
any volume element depends on the number of spins in that volume, and the relaxation times (T1 
and T2), as described by the following equation.
30
 
 
 
(2-1) 
 
  In Equation (2-1), I is the imaging intensity, N(F) is the NMR detectable 
19
F nuclei density, and 
TR and TE are the pulse sequence repetition time and echo delay times, respectively. Equation (2-1) 
informs that a long T2 and short T1 are required to achieve high MRI signal intensity. The spin-spin 
relaxation time, T2, is determined by the strength of the dipolar coupling of the 
19
F nuclei with near-
neighbour fluorine and proton nuclei, and hence is sensitive to the spatial arrangement of the 
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nuclear spins and their relative mobility. We have previously demonstrated in studies of partially-
fluorinated block copolymers that flexible fluorine segments with highly mobile 
19
F-containing 
groups result in longer T2 relaxation times and higher imaging signal-to-noise ratios.
12, 31
 
  Polymeric 
19
F imaging agents are promising because of their advantageous chemical structure, e.g. 
high fluorine content, small size, multifunctional properties and numerous possibilities for 
functionalisation. However, the fluorinated segments tend to aggregate in aqueous solution due to 
their hydrophobic nature, and this can significantly restrict local modes of motion leading to a 
shortening of the T2 relaxation times.
11, 12, 31
 As described above this leads to poor MRI signal 
intensity. Therefore, to develop high performance imaging agents, it is necessary to prevent the 
association of the 
19
F nuclei. 
  Our approach to achieve the separation of the fluorinated monomers is by statistical 
terpolymerisation of TFEA with DMAEMA in the presence of the branching/crosslinking monomer 
EGDMA by the RAFT technique, generating star-like polymers with a hyperbranched core and 
hydrophilic poly(ethylene glycol) brushes as arms. The detailed synthetic methodology is illustrated 
in Scheme 2-1. The hyperbranched core contains DMAEMA and TFEA monomeric units, which 
provide pH-responsiveness and 
19
F signal, respectively. The EGDMA units act as crosslinking 
agents to form branched structures and assist to prevent the association of the TFEA monomers.
22
 It 
is worth highlighting that the 
19
F-containing segments are well separated and dispersed in the 3D 
branched structure through the RAFT-controlled, statistical copolymerisation of the monomers, thus 
generating strong signal intensity.
22
 The arms are comprised of PEGMA brush polymer chains, an 
approach commonly used in biomaterials because PEG is hydrophilic, biocompatible, and approved 
by the United States Food and Drug Administration (FDA) for human use.
32-37
 Such water-soluble 
star-like polymers can form nanoparticles in aqueous solution directly, and no self-assembly 
procedure is needed, which greatly facilitates potential applications in vivo. 
Chapter 2 pH-Responsive Star-like Hyperbranched Polymers for Selective F-19 MRI 
 
 
65 
 
 
Scheme 2-1 Schematic illustration of the synthesis of the star-like hyperbranched polymers.  
2.3.2 Synthesis of PPEGMA Macro-CTA 
Well-defined PPEGMA macro-CTA polymers were prepared by RAFT polymerisation.
38
 The chain 
transfer agent (CTA) used here is an alkyne-terminated trithiocarbonate which has a tertiary 
cyanoalkyl R group (see Appendix A Figure A2.1 for the 
1
H and 
13
C NMR spectra), as shown in 
Scheme 2-1. As displayed in Figure 2-1 (A), the polymerisation exhibited pseudo-first-order 
kinetics, indicating that the radical concentration was constant. In addition, the Mn measured by 
GPC in THF using a RI detector was linearly dependent on monomer conversion and the molar 
mass dispersity remained low at around 1.10 (Figure 2-1 (B)). Furthermore, as revealed in Figure 2-
1 (C), the GPC traces with narrow ĐM also evolved toward high molecular weight (low retention 
time) with polymerisation time and monomer conversion. All the above results confirmed a well-
controlled RAFT polymerisation of PEGMA. 
  It should be mentioned that another frequently used trithiocarbonate, S-1-dodecyl-S'-(α,α'-
dimethyl-α''-acetic acid) trithiocarbonate, was also evaluated for the RAFT polymerisation of 
PEGMA. However, it showed poor control over the polymerisation, and bimodal GPC curves with 
broad molar mass distributions were observed, mainly caused by the low transfer coefficient of the 
Chapter 2 pH-Responsive Star-like Hyperbranched Polymers for Selective F-19 MRI 
 
 
66 
 
alkyl R leaving group (see Appendix A Figure A2.2). Normally, the choice of R group is very 
crucial for RAFT polymerisation of methacrylates,
39
 and a guideline for the selection of proper 
RAFT agents has been proposed by Moad and co-workers.
40
 Accordingly, trithiocarbonates with 
tertiary cyanoalkyl groups are good RAFT agents for the polymerisation of PEGMA, as has been 
demonstrated by these results. 
 
Figure 2-1 RAFT polymerisation of PPEGMA RAFT-CTA. (A) Pseudo-first-order kinetic plot of 
the conversion of monomer to polymer. (B) Dependence of number average molecular weight (Mn, 
determined by GPC) and molar mass dispersity (ĐM) on monomer conversion. (C) GPC traces 
during the polymerisation.  
 
2.3.3 Synthesis of Star-like Polymers 
PPEGMA of number-average molecular weight equal to 14,200 (by 
1
H NMR) was used as the 
macro-CTA for the synthesis of star-like polymers through chain extension with TFEA, DMAEMA 
and EDGMA at 70 
o
C for 24 h. After polymerisation, the crude sample was collected by 
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precipitating the mixture into hexane. In Figure 2, a bimodal elution curve was obtained for the 
crude sample, with the major species eluting at a much shorter retention time compared to that of 
the macro-CTA, indicating the evolution from linear homopolymer to star-like polymer by the 
successful chain extension of PPEGMA macro-CTA. 
 
Figure 2-2 GPC traces of the sample Star-1 before and after dialysis. [Macro-
CTA]:[TFEA]:[DMAEMA]:[EGDMA]:[AIBN] = 1:4:28:8:0.2. Polymerised in THF at 70 
o
C for 24 
h, [monomer] = 0.5 M. See Appendix A Figure A2.3 for the GPC data of Star-2 and Star-3. 
  The star-like polymers were synthesised by an arm-first approach, and hence there may be linear 
chains remaining in the crude sample. This was confirmed by the observation of a shoulder peak at 
a retention time of 16.5 minutes in the GPC curve (dash line, Figure 2-2). In the synthesis of star 
polymers via the arm-first approach, the presence of linear residue precursors in the samples is 
unavoidable as some linear chains cannot be incorporated into the pre-formed hyperbranched cores 
due to steric hindrance during the formation of star-like polymers.
41
 The crude polymers were 
further purified by extensive dialysis against water for 5 days using tubing with 100 kDa MWCO. 
After dialysis, most of the impurities having low molecular weights were removed, resulting in the 
purified star-like polymers having molar mass distributions of 1.5~1.6, as shown in Figure 2 and 
Table 2-1. This relatively broad molar mass distribution reveals that the samples are comprised of 
star-like polymers with cores of a range of degrees of branching, which is one characteristic of 
branched polymers synthesised using multi-functional monomers.
42-44
 On the basis of the GPC 
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results, we conclude that star-like polymers were successfully synthesised through the chain 
extension of PPEGMA macro-CTA with TFEA, DMAEMA and EGDMA. 
 
Figure 2-3 
1
H NMR spectra of the macro-CTA and star-like polymers in CDCl3 at 25 
o
C. (The 
letter „e‟ represents the two protons of the CH2 adjacent to the ester bond). The inset shows a 
magnification of the spectra between 4.0 and 4.8 ppm. 
  The as-synthesised star-like polymers with different TFEA molar fractions were characterised by 
1
H NMR (Figure 2-3). The characteristic peaks of TFEA (a) and DMAEMA (b, c, and d) are 
identified in the spectra, while they are absent in the spectrum of the macro-CTA, demonstrating the 
successful chain extension, in agreement with the GPC results. Star-like polymers with three 
different compositions were synthesised by varying the ratio of TFEA to DMAEMA, and the 
composition was determined by comparing ratios of the integrations of characteristic peaks of each 
monomer unit. As shown in the inset in Figure 2-3, the intensity of the peak for the protons of CH2 
adjacent to CF3 becomes obviously stronger with an increase of TFEA in the feed. The fluorine 
content was from 1.4, to 5.3 wt% for the three star-like polymer samples. The detailed structural 
characteristics of the polymers are summarised in Table 2-1. As shown in Scheme 2-1, the as-
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synthesised star-like polymers are expected to possess a hyperbranched core and PPEGMA arms. 
The branched core contains fluorinated units (TFEA) and pH-responsive (DMAEMA) monomers, 
thus it can be utilized to generate 
19
F NMR signals and will be pH-responsive. The PPEGMA bush 
polymer is hydrophilic and can shield the cytotoxic PDMAEMA component to enhance the 
biocompatibility of the nanoparticles. 
Table 2-1 Details of the structure of the star-like polymers. 
 
a
 The experimental composition, fluorine content and Mn of the samples were determined by 
1
H 
NMR. The feed ratios of TFEA to DMAEMA are provided in the brackets. 
b
 Mn and molar mass 
distribution, ĐM, were measured by GPC using RI detector and THF as eluent. 
c
 Absolute molecular 
weights were obtained using he GPC-MALLS technique. 
d
 The number of arms was calculated 
through the following equation: Narms = Mn (MALLS)/Mn (
1
H NMR), assuming that the 
hyperbranched structure was formed via intermolecular reaction of the linear chains rather than 
intramolecular reaction during the RAFT polymerisation. 
2.3.4 Preparation and Properties of Nanoparticles of Star-like Polymer 
Unlike block copolymer micelles that usually require a self-assembly process, water-soluble star 
polymers can readily form nanoparticles when dissolved in aqueous solution owning to the complex 
branched architecture in the cores and the presence of stabilizing PEGMA chains in the arms. This 
lack of a CMC is desirable for in vivo applications as it negates disassembly when the polymer 
concentration falls on dilution in the blood stream.
45
  
Sample TFEA to 
DMAEMA 
Ratio
a
 
19
F 
wt.%
a
 
Mn 
(
1
H NMR)
a
 
Mn 
(RI)
b
 
ĐM
b
 Mn 
(MALLS)
c
 
Narms
d
 
PPEGMA  - 14,200 8,100 1.12 - - 
Star-1 1:6.4 (1:7) 1.4 20,500 18,000 1.6 225,000 11 
Star-2 1:3.5 (1:3) 2.8 22,500 15,700 1.5 243,000 11 
Star-3 1:1.2 (1:1) 5.3 21,400 13,800 1.5 76,000 3.6 
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  Star-like polymer nanoparticles were formed by direct dissolution of the samples in PBS, and the 
morphology of the nanoparticles in solution was characterised by cryo-TEM. As shown in Figure 2-
4, the nanoparticles exhibited spherical morphology with a diameter between 20 and 25 nm at pH 6, 
a size close to that reported from cryo-TEM images of a similar highly-branched polymer.
27
 By 
contrast, only irregular particles with diameter of approximately 5 nm were observed at pH 9. This 
dramatic size change is attributed to the deprotonation and hence loss of charge of PDMAEMA 
units, which has a pKa of around 7.4-7.8.
46
  
 
Figure 2-4 Cryo-TEM images of frozen solutions of Star-1 at pH 6 and 9, respectively. Sample 
solutions were prepared by dissolving Star-1 in PBS (20 mg mL
-1
). 
  When the environmental pH is below the pKa, the PDMAEMA chains tend to expand due to 
electrostatic repulsion between the charged chains (swollen state). In contrast, when the pH is above 
the pKa, the polymer chains are relatively compact (shrunken state). A number of previous studies 
on hyperbranched polymers containing PDMAEMA segments also demonstrated this dependence 
of polymer dimensions on the pH. 
47-49
 
  These results demonstrate that nanoparticles with a branched core and PPEGMA shell were 
fabricated, and the particle size is highly dependent on the environmental pH, i.e. from 20-25 nm at 
pH 6 to approximately 10 nm at pH 9. 
2.3.5 19F NMR and MRI Studies 
The 
19
F NMR of the star-like polymer nanoparticles was also investigated at a range of values of pH 
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from 4 to 9. The results of these measurements are displayed in Figure 2-5 (A). A major peak was 
observed at around -72.7 ppm, due to 
19
F nuclei in the branched core of the particles, while the 
small peak at -76.6 ppm of very low intensity (<< 1%) can be assigned to residual fluorinated 
compounds (including monomer) in the sample. In Figure 2-5 (B), the intensity and width of the 
major peaks remained almost constant when the pH of the solution was below 7.4. However, this 
peak became broader and less intense when the pH was increased to above 7.4. This behaviour is 
clearly revealed in the magnified and superimposed spectrum (Figure 2-5 (C) and (D)). Based on 
these results, it can be concluded that the 
19
F signal intensity is heavily dependent on the pH of the 
aqueous solution.  
 
Figure 2-5 
19
F NMR results for solutions of Star-1. (A) Stacked 
19
F NMR spectra of Star-1 in PBS 
at different values of pH. (B) The dependence of integrated peak intensity on pH. (C) Superimposed 
19
F NMR spectra of Star-1. (D) Superimposed and normalised 
19
F NMR spectra of Star-1. Samples 
were dissolved in H2O/D2O (90/10, v/v) at 20 mg mL
-1
 for all 
19
F NMR measurements. 
  According to Equation (2-1), the 
19
F MR imaging performance depends on the number of 
19
F 
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nuclei (which remains constant) and the relaxation times (T1 and T2). These last two properties were 
measured by 
19
F NMR. As demonstrated previously,
11
 long values of the transverse relaxation time, 
T2, are required for acquiring images with good signal-to-noise ratio, while a short T1 can reduce the 
MRI scan time. The T2 relaxation times of the three star-like polymers were first measured at pH 5. 
As presented in Figure 2-6, Star-2 and Star-3 had measured values of T2 of 15.7 and 13.0 ms, 
respectively, whereas Star-1 had a T2 of 38.8 ms. We suggest that the relatively short T2 of Star-2 
and Star-3 can be attributed to the comparatively high 
19
F content, so that the probability of 
association of hydrophobic 
19
F segments in aqueous solution increased, resulting in reduced 
mobility of the fluorinated segments. In Figure 2-6, the T2 of Star-1 was found to be highly 
dependent on pH and showed the same trend with pH as the NMR intensity. In contrast, the T1 
relaxation time was almost constant at approximately 450 ms, irrespective of pH. This indicates that 
the spectral density of motions in the 500 MHz frequency range was not affected by the change in 
polymer conformation. Previous studies of block copolymer micelles also showed that the T1 
relaxation time was less sensitive to changes in packing and conformation.
12
  
 
Figure 2-6 Spin-lattice (T1) and spin-spin (T2) relaxation times of the star-like polymer 
nanoparticles in PBS at different values of pH. 
  The pH-responsiveness of T2 can be utilized for the design of 
19
F MRI agents for the diagnosis of 
cancer diseases. The star-like polymer nanoparticles are expected to provide a weak 
19
F MR signal 
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at physiological pH of 7.4. However, tumour tissue has been reported to be more acidic than normal 
tissue, with an extracellular pH of 6.8-7.2.
50
 Furthermore if these nanoparticles can be delivered and 
internalised by the target cells, the lysosomes exhibit a pH as low as 4.5
51
 and a large change in 
NMR properties will be expected. 
  The potential of these molecules as imaging agents was demonstrated by 
19
F MRI of solutions of 
the three polymers in solutions of pH values equal to 6 and 9. In Figure 2-7, the 
19
F images (A) are 
on the left, and the 
1
H density images (B) of the same set of aqueous samples are displayed on the 
right to illustrate the location of the NMR tubes within the resonator. A very clear increase in 
intensity can be seen for all three star-like polymers in the acidic media. This is consistent with the 
dramatic change in spin-spin relaxation time reported in Figure 6 for one of the polymers, which in 
turn arises from the change in the dimensions of the hyperbranched core on change of pH. We 
conclude therefore that these star-like polymer nanoparticles have the potential to be applied as 
selective agents for the detection of changes in local pH in vivo as well as the identification of 
tumour tissue using whole body 
19
F MRI. 
 
Figure 2-7 (A) 
19
F image of 20 mg mL
-1
 solutions of the star-like polymers in PBS acquired using a 
spin-echo sequence (TR = 1000 ms, TE = 6.2 ms, NEX = 1024, MTX = 32 × 32 × 1, FOV = 30 × 
30 × 20 mm). The difference in signal intensity between polymers at pH 6 and pH 9 can clearly be 
seen. (B) 
1
H FLASH image used for localisation of the field of view. 
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2.4 Conclusions 
In summary, a well-defined PPEGMA macro-CTA was synthesised through RAFT polymerisation. 
Subsequently, pH-responsive and 
19
F-containing star-like polymers were prepared through chain 
extension of the macro-CTA. The polymer nanoparticles consisted of a hyperbranched core and 
hydrophilic PPEGMA arms. Nanoparticles were formed by dissolving the star-like polymers in 
aqueous solution, and the particle size was found to be highly dependent on the pH. 
19
F NMR 
showed that the T2 relaxation time was strongly related to both the 
19
F content and the pH of the 
polymer solution. A strong 
19
F signal and long T2 were only observed under acidic conditions (pH 
values below 6.5), as a result of enhanced mobility of fluorinated segments. Above the pKa, the T2 
relaxation time was significantly reduced. Preliminary 
19
F MRI measurements of the particles in 
solution also show a strong dependence of imaging performance on pH and therefore demonstrate 
the potential for these star-like polymer nanoparticles as contrast agents for selective 
19
F MRI in the 
diagnosis of cancer tissue. 
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Chapter 3  
Biodegradable Core Crosslinked Star Polymers for 
Selective F-19 MRI 
In Chapter 2, star-like polymers were synthesised and evaluated as pH-responsive contrast agents 
for 
19
F MRI. In those polymers, the 
19
F nuclei were dispersed within a 3D hyperbranched core that 
was shielded by hydrophilic PEG brushes. The 
19
F signal intensity was highly dependent on the 
solution pH owing to the presence of pH-responsive PDMAEMA segments in the core. We 
hypothesise that the 
19
F NMR properties could also be affected by the spatial structure in which the 
19
F nuclei are positioned. In this chapter, star polymers with a densely crosslinked core and partly-
fluorinated arms were designed and examined as pH-responsive contrast agents for 
19
F MRI. 
Compared with the star-like polymers in Chapter 2, the major difference is that the fluorine units 
are incorporated in the arms instead of the star core. Such a difference is expected to influence the 
19
F MRI performance. 
3.1 Introduction 
Magnetic resonance imaging (MRI), a commonly-used diagnostic modality, has proven to be an 
indispensable imaging technique since its first appearance in the early 1970s. Unlike other imaging 
procedures, in particular X-ray computed tomography (CT), MRI does not utilise ionizing radiation 
during image acquisition, and is therefore non-harmful to humans. 
1
H MRI in particular can provide 
spatial anatomical images with high quality and resolution, with contrast arising from differences in 
proton density and relaxation parameters. However, 
1
H MRI is intrinsically restricted by two 
factors. First, the abundant water molecules in the body generate strong background signals that 
make detection of small concentrations of particular tissue types or metabolites difficult. Secondly, 
the proton relaxation times in different tissues are often similar, resulting in poor image contrast.
1
 
To address these issues, tremendous effort have been devoted to the development of 
1
H MRI 
contrast agents. The principle classes of 
1
H MRI contrast agents include gadolinium-based 
chelates,
2-4
 superparamagnetic iron oxide nanoparticles,
5, 6
 manganese-based contrast agents,
7-11
 and 
other lanthanide-based contrast agents.
12, 13
 An alternative approach to improving image contrast is 
to consider other NMR-active nuclei, and 
19
F MRI has been considered to be an excellent option. 
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  Shortly after the appearance of 
1
H MRI, the first example of 
19
F MRI was reported in 1977.
14
 
Compared to other candidates, such as 
13
C, 
15
N and 
31
P, the 
19
F nucleus exhibits a number of 
attractive properties, e.g. 100% natural abundance, high sensitivity (83% relative to 
1
H), large 
gyromagnetic ratio (40.03 MHz T
-1
, 94% relative to 
1
H), and absence in the human body.
15-17
 The 
physiological rarity of mobile fluorine nuclei in the body guarantees essentially no background 
signal during imaging and highlights the distinctive advantage of 
19
F MRI. 
19
F MRI naturally relies 
on the use of 
19
F-containing contrast agents, and a high concentration of 
19
F nuclei is preferred in 
the target voxel to provide adequate signal for the acquisition of good quality images. During the 
past few decades, perfluorocarbons (PFCs) have been extensively exploited as 
19
F MRI contrast 
agents because of their high fluorine content as well as chemical and biological inertness.
17-19
 Due 
to their hydrophobicity, PFCs are normally formulated as emulsions for biological applications. 
Although a few PFC emulsions are commercially available for clinical use, this category of contrast 
agents has several drawbacks, such as emulsion stability, limited methods of functionalisation and 
long reticuloendothelial system (RES) clearance times.
20-22
 
  Recently, 
19
F MRI contrast agents based on polymers have been introduced by a number of 
groups. Several classes of polymeric agents have been developed and evaluated, including linear 
polymers,
23-28
 hyperbranched polymers,
29, 30
 dendrimers
31-34
 and nanogels.
35
 In Chapter 2, we 
suggested that polymeric 
19
F MRI agents should fulfil a list of criteria, i.e. high fluorine content, 
separation of fluorine segments, small particle size, low cytotoxicity and possibility for chemical 
modification of conjugation.
24, 25, 30
 We are particularly interested in polymeric contrast agents that 
have highly-branched structures because these polymers have the potential to fulfil the 
aforementioned requirements. In these molecules, a high concentration of highly separated fluorine 
segments retains high flexibility, resulting in efficient averaging of the dipolar coupling and 
therefore ensures strong signal intensity in 
19
F MRI. On the other hand, the abundant functional 
groups in the polymers are especially favourable for subsequent functionalisation for specific 
applications. 
  In recent years „smart‟ imaging agents, which are responsive to certain environmental conditions 
(pH, temperature, light, ionic strength, the presence of enzymes, redox potential, etc.), have elicited 
great scientific interest.
36-42
 In particular it is well known that compared to normal tissues, 
cancerous tissues have a slightly acidic extracellular pH (6.7-7.1),
43
 hence it has been suggested that 
they may be detected through selective imaging using contrast agents that can be triggered by a 
change in pH. The development of pH-responsive imaging agents has become an intensive research 
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field, and a variety of such imaging agents have been fabricated and show great potential for the 
early diagnosis of cancer diseases.
34, 44-50
. 
  Core crosslinked (CCS) star polymers, which are composed of a number of arms and a crosslinker 
core, have a spherical 3D structure and possess unique properties. In the past several years, CCS 
star polymers synthesised by reversible-deactivation radical polymerisation (also referred to as 
controlled radical polymerisation) via the arm-first approach have been studied in detail.
51
 Synthesis 
of CCS polymers via the arm-first method allows for the precise pre-design of arm precursors and 
can thus lead to star polymers with well-defined structures and compositions. In our previous study, 
star polymers with a branched core (composed of 
19
F-containing and pH-responsive units) and 
hydrophilic arms were prepared and utilised as selective 
19
F MRI contrast agents with the potential 
for the detection of diseased tissues.
52
 Although a number of branched polymers bearing 
19
F nuclei 
have been developed as 
19
F MRI contrast agents, to the best of our knowledge, CCS polymers with 
fluorinated units in the arms have not been reported as 
19
F MRI agents. In this chapter we 
investigate the effect of placement of 
19
F nuclei and pH-responsive units in the block copolymer 
arms instead of in the branched core. 
  In this study, we aim to synthesise core crosslinked star (CCS) polymers as 
19
F MRI contrast 
agents via the arm-first approach by reversible addition-fragmentation chain transfer (RAFT) 
polymerisation. As illustrated in Scheme 3-1, the arms are block copolymers that contain 2,2,2-
trifluoroethyl methacrylate (TFEMA) units to provide 
19
F NMR and MRI signal and 2-
(dimethylamino)ethyl methacrylate (DMAEMA) segments to achieve pH-responsiveness. In 
addition, the cores are comprised of bis(2-methacryloyl)oxyethyl disulfide (DSDMA) crosslinked 
homopolymer, which is degradable in the presence of reducing agents. It is expected that the 
protonation and deprotonation of DMAEMA units in the copolymer arms in aqueous solution will 
not only influence the size of the nanoparticles but also alter the mobility of 
19
F nuclei in the 
TFEMA segments, resulting in the variations in signal intensity and relaxation times of 
19
F nuclei 
with pH. Moreover, selective imaging can be realised in 
19
F MRI by utilising the pH-responsiveness 
of the 
19
F relaxation times. Last but not least, since the CCS polymers have abundant disulfide 
bonds in the crosslinked core, the as-formed nanoparticles can be degraded by reducing agents such 
as dithiothreitol (DTT), tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and glutathione 
(GSH),
53-55
 and this biodegradability is especially desirable for future in vivo applications.  
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Scheme 3-1 Schematic illustration of the synthesis of CCS polymers. 
 
3.2 Experimental Section 
3.2.1 Materials 
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. Poly(ethylene glycol) 
methyl ether methacrylate (PEGMA, MW = 475), 2-(dimethylamino)ethyl methacrylate 
(DMAEMA), 2,2,2-trifluoroethyl methacrylate (TFEMA), ethylene glycol dimethacrylate 
(EGDMA), butyl methacrylate (BMA) and 2-hydroxyethyl methacrylate (HEMA) were passed 
through basic alumina columns to remove inhibitors prior to use. The initiators, 2,2‟-azobis(2-
methylpropionitrile) (AIBN) and 4,4‟-azobis(4-cyanovaleric acid) (ACVA) were recrystallised from 
ethanol twice before use. 4-Methoxyphenol (MEHQ), 4-(dimethylamino)pyridine (DMAP), 
triethylamine (TEA), N,N‟-dicyclohexylcarbodiimide (DCC), tris(2-carboxyethyl)phosphine 
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hydrochloride (TCEP) and L-glutathione reduced (GSH) were used as received. The 
trithiocarbonate RAFT agent, 4-cyano-4-(dodecylsulfanylthiocarbonyl)sulfanyl pentanoic acid 
(denoted as CTA), was synthesised following a previously reported method.
56
 Milli-Q water with a 
resistivity of 18.4 MΩ.cm-1 was used for the synthesis and purification of polymers and preparation 
of aqueous solutions. Tetrahydrofuran (THF), dichloromethane (DCM) and toluene were obtained 
from a solvent purification system (SPS) and used directly. 
3.2.2 Synthesis 
3.2.2.1 Synthesis of Alkyne-Terminated Chain Transfer Agent (alkyne-CTA) 
The CTA (4.04 g, 10 mmol), propargyl alcohol (1.46 mL, 25 mmol) and DMAP (0.24 g, 2 mmol) 
were dissolved in 130 mL of DCM in a 250 mL flask, which was sealed with a rubber septum and 
then bubbled with argon for 30 min in an ice bath. Following this, DCC (4.13 g, 20 mmol) in 20 mL 
of DCM was injected dropwise into the flask. The reaction was kept in the ice bath and 
magnetically stirred for 2 h, followed by stirring at room temperature for 48 h. After the reaction, 
the mixture was filtered to remove the insoluble dicyclohexylurea precipitate. The filtrate was 
washed with water (100 mL × 2) and brine (100 mL × 2), and then dried over anhydrous MgSO4. 
Finally, the solvent was removed by rotary evaporation, and the residual oil was further purified by 
flash column chromatography (SiO2, gradient petroleum spirit/ethyl acetate, from 9/1 to 8/2), 
yielding a scarlet oil (3.7 g, 84% yield). 
1
H NMR (500 MHz, δ, ppm, CDCl3): 0.88 (t, 3H, 
CH3CH2CH2), 1.26 (br s, 18H, (CH2)9), 1.69 (m, 2H, CH2CH2S), 1.87 (s, 3H, CH3), 2.37-2.70 (m, 
4H, CH2CH2-COO), 2.49 (t, H, OCH2C≡CH), 3.32 (t, 3H, CH2CH2S), 4.70 (d, 2H, OCH2C≡CH). 
13
C NMR (125 MHz, δ, ppm, CDCl3): 170.63 (COOCH2), 118.87 (CN), 75.20 (C≡CH), 
52.41(C≡CH), 46.21 (C(CH3)CN)), 37.03 (C(=O)CH2CH2), 33.62 (C(=O)CH2CH2), 31.85, 29.56, 
27.61, 24.81, 22.63 (overlapping 
13
C signals), 14.07 (CH3CH2CH2). 
3.2.2.2 Synthesis of Poly PPEGMA macro-CTA 
PEGMA (24 g, 50 mmol), alkyne-CTA (0.886 g, 2 mmol), AIBN (66 mg, 0.4 mmol) were 
dissolved in 50 mL of toluene in a 100 mL flask, which was sealed with a rubber septum and 
bubbled with argon for 1 h in an ice bath. Then the flask was immersed in an oil bath maintained at 
70 
o
C and magnetically stirred. At given intervals, samples were withdrawn using a gas-tight 
syringe for measurement of extent of conversion. After 180 min, the polymerisation was quenched 
by cooling the flask in an ice bath and exposing the solution to air. The crude solution was 
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precipitated into cold hexane 3 times and then dialysed against water for 2 days. After 
lyophilisation, a yellow oil was obtained. Yield: 11 g, 94%). GPC: Mn = 7200, molar mass 
dispersity (ĐM, Mw/Mn) = 1.12. 
1
H NMR: DP = 14, Mn = 7100. 
3.2.2.3 Synthesis of PPEGMA-b-P(TFEMA-co-DMAEMA) Block Copolymers 
In a typical experiment, the macro-CTA (0.665 g, 0.094 mmol), TFEMA (0.144 mL, 1 mmol), 
DMAEMA (0.674 mL, 4 mmol) and AIBN (3.3 mg, 0.02 mmol) were dissolved in 4 mL of toluene. 
The solution was equally divided into 5 tubes, each of which was purged with nitrogen for 5 min in 
an ice bath before being placed in a 70 
o
C oil bath. The tubes were opened and cooled to 0 
o
C at 
various time intervals to allow measurement of conversion.  
  For the fully scaled-up synthesis, the macro-CTA (3.6 g, 0.51 mmol), TFEMA (0.771 mL, 5.4 
mmol), DMAEMA (3.649 mL, 21.6 mmol) and AIBN (17.8 mg, 0.102 mmol) were dissolved in 22 
mL of toluene in a 100 mL flask, which was sealed with a rubber septum and purged with nitrogen 
for 30 min in an ice bath. The flask was placed in a 70 
o
C oil bath for 2.5 h, followed by being 
cooled to 0 
o
C and exposed to air. The sample was purified by precipitation into cold hexane 3 
times and dried under vacuum. A yellowish viscous solid was obtained. Yield: 4.86 g, 86%. The 
degree of polymerisation (DP) was calculated from 
1
H NMR, and the composition of the block 
copolymer was confirmed to be PPEGMA14-b-(TFEMA5-co-DMAEMA19) (10500 by 
1
H NMR), 
ĐM= 1.21 (by GPC).  
3.2.2.4 Synthesis of CCS Polymers Using EGDMA as Crosslinker 
CCS polymers were synthesised by the arm-first approach through dispersion polymerisation. 
Typically, PPEGMA14-b-(TFEMA5-co-DMAEMA19) (0.210 g, 0.02 mmol), BMA (16 µL, 0.1 
mmol), EGDMA (20 mg, 0.1 mmol) and ACVA (1.12 mg, 0.004 mmol) were added to a mixture of 
2 mL ethanol and 2 mL water. The solution was stirred at room temperature for 30 min to form a 
clear solution, before being divided into 5 tubes containing stirrer bars. Each tube was sealed with a 
rubber septum, followed by being purged with nitrogen for 15 min in an ice bath. After that, the 
tubes were immersed in 70 
o
C oil bath, and were opened at given time intervals for GPC and DLS 
analysis.  
3.2.2.5 Synthesis of Bis(2-methacryloyl)oxyethyl Disulfide (DSDMA) 
Degradable crosslinker DSDMA was synthesised using a published procedure,
57
 with minor 
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modification. 2-Hydroxyethyl disulfide (7.7 g, 0.05 mol) and MEHQ (60 mg) were added to 150 
mL DCM in a 500 mL flask, and a heterogeneous mixture was formed. Then methacryloyl chloride 
(20 mL, 0.2 mol) was added to the mixture. The flask was immersed in an ice/water bath and TEA 
was added drop-wise using a dropping funnel over 40 min. During addition of the TEA, a white 
precipitate was gradually formed. After the addition of TEA, the mixture was stirred at 0 
o
C for 
another 30 min and then at room temperature for 24 h. After reaction, the mixture was filtered to 
remove the the insoluble triethylamine hydrochloride salt. Then the filtrate was washed with 1 M 
NaHCO3 solution (150 mL × 3) and water (150 mL × 3), and the organic phase was dried over 
anhydrous MgSO4 with 60 mg of MEHQ. After that, DCM was removed by rotary evaporation. The 
residual was purified by flash column chromatography (SiO2, gradient hexane/ethyl acetate, from 
90/10 to 60/40). A slightly yellowish oil was obtained and was stored in a freezer in dark. Yield: 8.9 
g, 61%. 
3.2.2.6 Synthesis of Biodegradable CCS Polymers Using DSDMA as Crosslinker 
PPEGMA14-b-(TFEMA6-co-DMAEMA20) (0.216 g, 0.02 mmol), DSDMA (58 mg, 0.2 mmol) and 
ACVA (2.24 mg, 0.005 mmol) were added to a mixture of 2 mL ethanol and 2 mL water, which 
was then stirred at room temperature for 30 min to form a clear solution. After that the solution was 
divided equally to 4 tubes, and each tube was purged with nitrogen for 10 min in an ice bath. 
Finally the tubes were placed in a 70 
o
C oil bath, and each tube was opened and cooled to 0 
o
C 
periodically. GPC measurements were carried out for each sample to monitor the formation of CCS 
polymer. 
  For the scale-up synthesis, PPEGMA14-b-(TFEMA6-co-DMAEMA20) (2.16 g, 0.2 mmol), 
DSDMA (0.58 g, 2 mmol) and ACVA (22.4 mg, 0.05 mmol) were added to a mixture of 20 mL 
ethanol and 20 mL water in a 100 mL flask, which was then sealed with a rubber septum and 
purged with nitrogen for 45 in an ice bath. Then the flask was immersed in 70 
o
C oil bath for 30 
min. After polymerisation, the sample was purified using centrifugal filter units (Amicon Ultra-15, 
100k) and then lyophilised.  
3.2.2.7 Degradation of CCS Polymer by Reduction with TCEP 
SP-1 (30 mg, 4.6× 10
-5
 mmol) was dissolved in 6 mL of methanol in a 20 mL schlenk tube, which 
was then magnetically stirred and purged with Ar. After 30 min, TCEP (86 mg, 0.3 mmol) was 
added to the polymer solution under the protection of Ar. The solution was stirred at RT for 7 hours, 
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followed by the injection of pre-deoxygenated TEA (100 µL, 0.72 mmol) and MMA (200 µL, 1.87 
mmol) to cap the formed thiol groups. After stirring at RT overnight, the reaction was stopped 
through exposure to air and an aliquot was withdrawn for GPC analysis. 
3.2.2.8 Degradation of CCS by Reduction with GSH 
SP-1 (15 mg, 2.3 × 10
-5
 mmol) was dissolved in 30 mL of PBS in a 100 mL flask and the pH was 
adjusted to 7.4 using 1 M NaOH solution. The flask was then sealed with a rubber septum and 
purged with Ar for 30 min, followed by the addition of GSH (92 mg, 0.3 mmol) under Ar flow. The 
solution was purged with Ar for another 30 min and stirred at 37 
o
C. After 72 h, pre deoxygenated 
TEA (200 µL, 1.44 mmol) and HEMA (250 µL, 2.06 mmol) were injected to the flask to cap the 
thiol groups that were formed after reduction. After another 24 h the sample was freeze dried and 
subjected to GPC analysis. 
3.2.3 Characterisation 
Gel Permeation Chromatography (GPC)  
Molecular weights and molecular weight distributions were determined by GPC using a Waters 
Alliance 2690 Separations Module equipped with Waters 2414 Refractive Index (RI) Detector, 
Waters 2489 UV/Visible Detector, Waters 717 Plus Autosampler and Waters 1515 Isocratic HPLC 
Pump. Samples were dissolved in THF/triethylamine (95/5, v/v) and passed through 0.45 µm filters 
before each measurement. THF was used as the mobile phase at a flow rate of 1 mL min
-1
. The 
system was calibrated using polystyrene (PS) standards, to which the number average molecular 
weight (Mn) and weight average molecular weight (Mw) were referenced. Absolute molecular 
weights of the star polymers were measured by a triple detection GPC (Polymer Labs GPC50) 
equipped with dual angle laser light scattering detector, viscometer and differential refractive index 
detector. N,N-dimethylacetamide (DMAc, HPLC grade, containing 0.03 wt % LiCl) was used as the 
eluent at a flow rate of 1.0 mL min
-1
. Separations were achieved using two PLGel Mixed B (7.8 × 
300 mm) columns connected in series and held at a constant temperature of 50 
o
C. The triple 
detection system was calibrated using a 2 mg mL
-1
 PSTY standard (Polymer Laboratories, Mw = 
110 K, dn/dc = 0.16 mL g
-1
 and IV = 0.5809). Samples of given concentrations were prepared in 
DMAc (containing 0.03 wt% LiCl) and passed through a 0.45 μm PTFE syringe filters prior to 
measurements. The absolute molecular weights and dn/dc values were determined by using 
Polymer Laboratories Multi Cirrus software based on the quantitative mass recovery technique.  
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Nuclear Magnetic Resonance (NMR)  
1
H NMR and 
13
C NMR analysis were performed on a Bruker Avance 500 MHz spectrometer 
equipped with a BBO5 probe at 25 
o
C using an internal lock (CDCl3) and referenced to the residual 
non-deuterated solvent (CHCl3). 
Dynamic Light Scattering (DLS)  
DLS measurements were carried out on a Nanoseries Zetasizer (Malvern, UK) at 25 
o
C. Sample 
solutions were prepared in PBS (1 mg mL
-1
) at different pH values and passed through 0.45 µm 
filters prior to each measurement. Each hydrodynamic diameter was the average value of 5 runs. To 
minimise the influence of large aggregates, number averaged diameters are reported.  
19
F Nuclear Magnetic Resonance (
19
F NMR)  
All 
19
F NMR spectra were acquired at 470.55 MHz without 
1
H decoupling on a Bruker Avance 500 
spectrometer using a 5 mm broadband inverse probe (BBO5) for which the inner coil was double-
tuned for 
19
F and 
1
H. The samples were prepared by dissolving the star polymers in PBS/D2O 
(90/10, v/v) at a concentration of 20 mg mL
-1
. All measurements were performed at 25 
o
C. A 90
o
 
pulse of 15.1 µs was used in all measurements, the relaxation delay was 2 s and the acquisition time 
was 0.7 s. Data were collected using a spectrum width of 23 kHz, 32k data points and 128 scans. 
  
19
F spin-spin relaxation times (T2) were measured using the Carr-Purcell-Meiboom-Gill (CPMG) 
pulse sequence at 25 
o
C. The samples were dissolved in PBS/D2O (90/10, v/v) at a concentration of 
20 mg mL
-1
. The relaxation delay was 3 s and the acquisition time was 0.7 s. For each 
measurement, the echo times were from 2 to 770 ms and 15 points were collected, which could be 
described by exponential functions for the calculation of T2.  
  
19
F spin-lattice (T1) relaxation times were measured using the standard inversion-recovery pulse 
sequence. For each measurement, the recovery times were from 2 ms to 3 s and 15 points were 
acquired. Values for the major peak at around -72.6 ppm are reported. 
19
F Magnetic Resonance imaging (
19
F MRI) 
Images of phantoms containing the solutions of the CSS particles were acquired on a Bruker 
BioSpec 94/30 USR 9.4 T small animal MRI scanner. CCS polymers were dissolved in PBS/D2O 
(90/10,v/v) to a concentration of 20 mg mL
-1
 and loaded in clear glass vials (8 × 30 mm, 0.75 mL), 
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which were then placed in a 
1
H/
19
F dual resonator 40 mm volume coil. 
1
H were acquired for 
localisation of the samples using a RARE sequence with an echo train length of 8 (TE = 28 ms, TR 
= 2 s, FOV = 40 × 40 × 1 mm, Matrix = 128 × 128 × 1). 
19
F images were acquired in the same 
stereotactic space as the 
1
H image using a RARE sequence with an echo train length of 8 (TE = 10 
ms, effective TE = 40 ms, TR = 1 s, FOV = 40 × 40 × 30 mm, Matrix = 32 × 32 × 1) with a total 
acquisition time of 1 hour 8 minutes. 
3.3 Results and Discussion 
3.3.1 Synthesis of PPEGMA macroCTA 
 
Figure 3-1 RAFT polymerisation of TFEMA and DMAEMA using PPEGMA macro-CTA. (A) 
Pseudo-first-order kinetic plots of the polymerisation. (B) Dependence of number-average 
molecular weight (Mn, determined by GPC) and molar-mass dispersity (ĐM) on the total monomer 
conversion. (C) GPC traces during the polymerisation. 
A trithiocarbonate chain transfer agent, 4-cyano-4-(dodecylsulfanylthiocarbonyl)sulfanyl pentanoic 
acid, was first end functionalised with propargyl alcohol and subsequently used for the synthesis of 
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PPEGMA macro-CTA, as reported in our previous study.
52
 The alkyne end group can offer the 
possibility of further modification of the CCS polymer through „click‟ chemistry. Furthermore, the 
alkyne end group facilitates the calculation of the degree of polymerisation (DP) using 
1
H NMR 
owing to the well-resolved peak (~4.7 ppm) due to the protons in the methylene group adjacent to 
the alkyne group. PEGMA was chosen because of its hydrophilicity and biocompatibility. The 
kinetics of the synthesis of PPEGMA was investigated, and the results confirmed a well-controlled 
RAFT polymerisation (see Appendix B Figure A3.1). The PPEGMA so-formed (DP = 14, Mn (
1
H 
NMR) = 7100, ĐM = 1.12) was used as the macro-CTA in subsequent steps.  
3.3.2 Synthesis of PPEGMA-b-P(TFEMA-co-DMAEMA) Block Copolymers 
The as-synthesised PPEGMA macro-CTA was chain extended with TFEMA and DMAEMA for the 
synthesis of PPEGMA-b-P(TFEMA-co-DMAEMA). As displayed in Figure 1, the polymerisation 
rates of both TFEMA and DMAEMA exhibited pseudo-first-order kinetics throughout the 
polymerisation to above 80% conversion (Figure 3-1 (A)). In addition, the number-average 
molecular weight increased linearly with monomer conversion while the molar-mass dispersity 
(ĐM) remained relatively low (Figure 3-1 (B)). Furthermore, in Figure 3-1 (C) the GPC curves also 
evolved from long retention time to short retention time with increase of reaction time and 
conversion. This confirms the successful synthesis of PPEGMA-b-P(TFEMA-co-DMAEMA) from 
the PPEGMA macro-CTA. To minimise the loss of trithiocarbonate end group, a monomer 
conversion of ~50% was targeted in the scale-up polymerisation. After purification, PPEGMA14-b-
(TFEMA5-co-DMAEMA19) was obtained (denoted as Arm-1, Mn = 10500 by 
1
H NMR, ĐM = 1.21). 
In order to prepare block copolymers with different compositions, Arm-2 (PPEGMA14-b-
(TFEMA11-co-DMAEMA15, Mn = 11300 by 
1
H NMR, ĐM = 1.20) and Arm-3 (PPEGMA14-b-
(TFEMA18-co-DMAEMA10, Mn = 11700 by 
1
H NMR, ĐM = 1.18) were then synthesised by varying 
the TFEMA/DMAEMA ratio and using the same polymerisation condition. The properties of the 
macro-CTA and block copolymers are summarised in Table 3-1. 
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Table 3-1 Properties of the macro-CTA and arm precursors. 
 
a
 Weight percentage of fluorine in the samples was determined by 
1
H NMR. 
b
 Mn and ĐM were 
measured by GPC RI detector. 
c
 Mn was calculated using the DP given by 
1
H NMR. 
3.3.3 Synthesis of CCS Polymers by the Arm-first Approach via RAFT 
polymerisation 
Recently, RAFT dispersion polymerisation has been exploited for the synthesis of CCS polymers 
by An and co-workers, and its benefits have been discussed and highlighted.
58-61
 Compared to 
conventional homogeneous polymerisation in organic solvents, the heterogeneous polymerisation in 
aqueous solution can significantly reduce the polymerisation time due to an accelerated monomer 
consumption. Furthermore, the method can increase the yield of star polymer by facilitating the arm 
incorporation process. As the three block copolymers were all water soluble due to the presence of 
hydrophilic PPEGMA segments, RAFT dispersion polymerisation in water/ethanol mixture was 
introduced for the synthesis of CCS polymers. 
  The CCS polymers were synthesised through the chain extension of arm precursors with the 
crosslinker EGDMA. The polymerisation was carried out in water/ethanol mixture (50/50, v/v) at 
70 
o
C using ACVA as initiator. It was found that the polymerisation time played a pivotal role in 
the formation of CCS polymers. Figure 3-2 shows the GPC traces of the samples withdrawn at 
different polymerisation times during the dispersion polymerisation. As one can see in Figure 3-2 
(A), although the peak of the arms became broader and started to shift toward shorter retention 
times, CCS polymer was not formed within 20 min. After 30 min, a peak appeared at retention time 
of 14.6 min and could be assigned to the CCS polymer owing to its larger hydrodynamic radius. 
Over the next 30 min the intensity of the CCS peak continued to increase while that of the linear 
Sample 
19
F 
wt%
a
 
Mn
b
 
(GPC) 
ĐM
b
 Mn
c
 
(
1
H NMR) 
Macro-CTA (PPEGMA14) - 7200 1.12 7100 
Arm-1 
(PPEGMA14-b-(TFEMA5-co-DMAEMA19) 
 
3.2 
 
9200 
 
1.24 
 
10500 
Arm-2 
(PPEGMA14-b-(TFEMA11-co-DMAEMA15) 
 
5.5 
 
8900 
 
1.20 
 
11300 
Arm-3 
(PPEGMA14-b-(TFEMA18-co-DMAEMA10) 
 
8.8 
 
8900 
 
1.18 
 
11700 
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polymer peak at 16.2~17.0 decreased gradually, indicating the increasing arm incorporation and 
yield of CCS polymer. Interestingly, as shown in Figure 2 (B), the intensity of the CCS polymer 
peak decreased by half after 2 hours, and then continued to be diminished over the next 4 hours 
before it completely disappeared after 8 hours. 
 
Figure 3-2 GPC traces during the synthesis of CCS polymer using EGDMA as crosslinker by 
dispersion polymerisation. Condition: [Arm-1]/[BMA]/[EGDMA]/[ACVA] = 1/5/5/0.2, [arm-1] = 5 
mM, in water/ethanol (50/50, v/v), 70 
o
C. 
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Figure 3-3 Top: Digital photographs of the samples withdrawn at different time intervals during the 
synthesis of CCS polymer by RAFT dispersion polymerisation. The samples were at room 
temperature (~25 
o
C). Bottom: DLS results of the samples at different polymerisation time before 
and after filtration using 450 μm syringe filters. Each size was the average of five measurements at 
25 
o
C. 
  Based on the GPC traces, the extent of formation of the CCS polymer through the chain extension 
of block copolymer with crosslinker reached a maximum after 1 h. However, due to monomer 
consumption and abundant vinyl groups in the core, after 1 h intermolecular coupling (or star-star 
coupling) started to dominate the polymerisation, and resulted in the formation of macroscopic gel 
particles, which consumed the as-formed CCS polymers and substantially reduced the CCS polymer 
yield. In support of this a digital photographs of the samples at increasing conversion demonstrates 
a change from clear solution to turbid dispersion (Figure 3-3 Top), confirming the gradual 
formation of larger and insoluble particles after 1 h. Furthermore, in Figure 3-3 (Bottom), the 
particle size (number averaged diameter) of the crude polymerisation solution increased 
significantly from 7.4 nm after 10 min to 13.4 nm after 1 h, slowly increased to 14.8 nm after 6 h 
before dramatically increasing to ~360 nm after 8 h After filtration, the particle size became smaller 
owing to the removal of large particles. 
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Figure 3-4 GPC traces of CCS polymers synthesised at (A) different water/ethanol ratios, (B) with 
or without spacer monomers and (C) different EGDMA/arm ratios. Conditions: (A) [Arm-
1]/[EGDMA]/[BMA]/[ACVA] = 1/5/5/0.2, [arm-1] = 5 mM, 70 
o
C,1 h. (B) [Arm-
1]/[EGDMA]/[Spacer]/[ACVA] = 1/10/10/0.2, [arm-1] = 5 mM, water/ethanol (50/50, v/v), 70 
o
C, 
1 h. (C) [Arm-1]/[ACVA] = 1/0.2, [arm-1] = 5 mM, water/ethanol (50/50, v/v), 70 
o
C, 1 h. (D) 
[Arm-1]/[EGDMA] = 1/10, [arm-1] = 5 mM, water/ethanol (50/50, v/v), 70 
o
C. 
  A number of other significant parameters in the polymerisation were also investigated. It was 
found that the water/ethanol ratio was a key factor since well-defined CCS polymers were only 
formed in water/ethanol (50/50, v/v) (Figure 3-4 (A)). This is understandable since a higher ethanol 
content in the polymerisation solvent (> 75 %) will result in homogeneous polymerisation; CCS 
polymers usually take much longer to form (typically 8~24 h) in organic solvents
62-65
 than in 
conventional dispersion polymerisation. However, the arm precursor has poor solubility when the 
ethanol content is too low (< 50 %). Therefore a moderate water/ethanol ratio is required for a 
successful dispersion polymerisation, so that the starting reagents dissolve well while the CCS 
polymer has poor solubility. In addition, unlike other reports,
59, 60, 62
 the use of the spacing monomer 
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did not improve the formation of CCS polymer (Figure 3-4 (B)). Moreover, the highest yield of 
CCS polymers was achieved when [EGDMA]/[arm-1] ratio was 10 or 15 (Figure 3-4 (C). As shown 
in Figure 3-4 (D), the CCS polymer yield was also increased by using a higher [ACVA]/[Arm-1] 
ratio (2/5). These results revealed that the arm-first synthesis of CCS polymer via RAFT dispersion 
polymerisation could be affected by a number of parameters and well-defined CCS polymers with 
high yield could be obtained by carefully selecting and controlling the polymerisation conditions.  
 
Figure 3-5 GPC traces of CCS polymer synthesised using DSDMA as crosslinker. (A) GPC traces 
at different polymerisation time. (B) GPC traces of CCS polymer prepared after 30 min. Condition: 
[Arm-1]/[DSDMA]/[ACVA] = 1/10/0.4, [arm-1] = 5 mM, in water/ethanol (50/50, v/v), 70 
o
C 
  A degradable crosslinker, bis(2-methacryloyl)oxyethyl disulfide (DSDMA), was then chosen for 
the synthesis the CCS polymers. As displayed in Figure 3-5 (A), well-defined CCS polymer can be 
synthesised within 30 min with the highest yield (74%). At longer reaction times star-star coupling 
became more significant, as evidenced by the decrease in the peak of CCS polymer. The as-
synthesised CCS polymer (denoted as CCS-1) was purified using centrifugal filter units. In Figure 
3-5 (B), one can see that most of the linear residues were removed after purification (black line).  
  The chemical structure of the arms and CCS polymers was characterised by 
1
H NMR. As shown in 
Figure 3-6 (A) and (C), all the characteristic peaks of monomer units are well assigned, indicating 
the successful synthesis of arms precursors and CCS polymers. After purification, the polymers in 
the filtrate (denoted as Filtrate-1) were also collected and analysed by GPC and 
1
H NMR. 
According to the GPC trace (green line), despite the presence of a small amount of CCS polymer 
(1.21%), the linear residues showed a smaller Mn compared to that of Arm-1while its ĐM was as low 
as that of Arm-1. In addition, in the 
1
H NMR spectra (Figure 3-6 (B)), for Filtrate-1, the peak 
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intensity of the protons of the CH2 adjacent to the trithiocarbonate considerably decreased 
compared with Arm-1, suggesting that the residual linear polymers had very low end group 
functionality. The structure of the residual polymer was confirmed to be PPEGMA14-b-P(TFEMA3-
co-DMAEMA8) by 
1
H NMR with Mn of 8400. We therefore conclude that the residual linear 
polymer collected from the filtrate is block copolymer in which the trithiocarbonate end groups 
have been lost during the synthesis of the arm precursor. This implies that the loss of CTA 
functionality is inevitable in the synthesis of PPEGMA-b-P(TFEMA-co-DMAEMA) block 
copolymers even with low monomer conversions. 
 
Figure 3-6 (A), (B) and (C) 1H NMR spectra of macro-CTA, Arm-1, filtrate-1 and CCS-1. „e‟ 
represents the two protons of the CH2 adjacent to −COO− in PEGMA. (D) 13C NMR spectrum of 
CCS-1. 
  In Figure 3-6 (C), the peaks at 5.7 and 6 ppm were assigned to the unreacted vinyl groups that 
were likely to be in the periphery of the core. Nevertheless, the DSDMA units could not be fully 
detected due to the highly rigid nature of the core.
66
 The 
13
C NMR spectrum (Figure 3-6 (D)) 
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further confirmed the absence of a peak at ~222 ppm from the trithiocarbonate carbons. It is well 
known that the increased dipolar couplings experienced in rigid cores of particles may prevent 
direct observation by solution-state NMR methods. 
Table 3-2 Details of the CCS polymers. 
Sample 19F wt%a Mn (GPC)
b ĐM
b Absolute MWc ĐM
c Narms
d 
CCS-1 2.3 32800 1.23 653,300 1.17 46 
CCS-2 3.9 43300 1.19 482,500 1.07 31 
CCS-3 6.1 28000 1.19 683,000 1.15 41 
a
 Fluorine content in the samples was determined by 
1
H NMR.. 
b
 Mn and ĐM of the crude CCS 
polymers were measure by GPC RI detector. 
c
 Absolute molecular weight and ĐM were measured 
by triple detection GPC. 
d
 Number of arms was calculated using a method described in Appendix B) 
A range of CCS polymers with different compositions were prepared by using Arm-2 and Arm-3 
for the synthesis of CCS-2 and CCS-3, respectively, and the resulting CCS polymers were purified 
using the same procedure described above for CCS-1. The GPC data of CCS-2 and CCS-3 are 
displayed in Appendix B Figure A3.2. The properties of the CCS polymers are listed in Table 3-2. 
 
Figure 3-7 Number-averaged diameter of CCS-1 in PBS (1 mg mL
-1
) at different pH at 25 
o
C. 
  The particle sizes of CCS-1 in PBS and at a range of pH values from 4 to 9 were measured by 
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DLS. As shown in Figure 3-7, the particle size was around 23 nm when the pH was below 6.5 and 
decreased progressively with an increase in pH and finally reached ~18 nm at pH 9. The change in 
particle size arises from the DMAEMA units present in the arms; PDMAEMA is well known as a 
pH-responsive polymer and has a pKa between 7.3~7.5. Specifically, in aqueous solution, the 
protonation of the tertiary amines below pKa renders the PDMAEMA segments charged and the 
chains undergo electrostatic repulsion, while on deprotonation above pKa the chains adopt a more 
contracted configuration. On the basis of the DLS results, the volume of CCS-1 nanoparticles at pH 
9 was reduced by 53% compared to that at pH 5, indicating a significant dependence of particle size 
on environmental pH. 
  In addition, the protonation and deprotonation process was revealed by a change in zeta potential 
at different pHs. (see Appendix B Figure A3.4)  
3.3.4 Degradation of CCS Polymer 
Disulfide-containing crosslinkers have been frequently used for the preparation of degradable 
materials because the disulfide group can be cleaved to thiols by reducing agents.
67
 As the core of 
the as-synthesised CCS polymer is comprised of PDSDMA homopolymer, it is expected that the 
core can be degraded when treated with reducing agents. The degradation of CCS-1 in methanol 
was first tested using TCEP as the reducing agent, and the GPC curve shifted to longer retention 
time after 7 hours while the ĐM
 
was as low as that of Arm-1 (Figure 3-8 (A)), confirming the 
successful cleavage of the disulfide bonds in the core. It should be noted that the thiol groups in 
solution are very sensitive to oxygen and can form disulfide again when exposed to air. For 
example, after reduction of the CCS-1 with DTT in THF, samples were withdrawn periodically for 
GPC analysis, and the GPC curves of the degraded polymer shifted progressively to longer 
retention time and the ĐM
 
became very large (39~98) owing to the re-formation of disulfide 
linkages in air (see Appendix B Figure A3.3). To avoid the re-formation of disulfides, after 
degradation the thiol groups were capped with MMA through based-catalysed Michael addition.
68, 
69
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Figure 3-8 GPC traces of CCS-1 before and after degradation by TCEP (A) and GSH (B), 
respectively 
  Since TCEP is not physiologically available, glutathione (GSH) was then chosen for the 
degradation of CCS-1. It has been reported that GSH is present in the human body at micromolar 
concentrations in blood plasma, ~10 mM in the cytosol, 
53, 70
 and at several times higher 
concentration in tumour cells than normal cells.
71, 72
 As shown in Figure 3-8 (B), two peaks 
appeared after degradation with TCEP. To be more specific, the major peak with Mn of 8700 was 
from the linear polymers after the degradation of the crosslinked core, while the minor peak with 
Mn of 74100 was caused by the re-formation of disulfide groups due to the incomplete degradation 
of the core. As the core was comprised of hydrophobic DSDMA units that were poorly accessible 
for water and the GSH concentration was also relatively low, we propose that the degradation of 
CCS-1 using 10 mM GSH in PBS would take much longer time than the degradation by TCEP. 
Based on these results, we conclude that the as-synthesised CCS polymers were biodegradable.  
3.3.5 19F NMR Studies 
In order to assess their potential as pH-responsive 
19
F MRI contrast agents, the CCS polymers were 
examined by 
19
F NMR in solutions with different values of pH. As displayed in Figure 3-9, only 
one peak at -72.6 ppm was observed in each spectrum of all the three samples, confirming a single 
19
F chemical environment in the CCS polymer structure. When the pH was raised, this peak became 
broader and the signal intensity decreased, as highlighted by the superimposed spectra in Figure 3-9 
(D), (E) and (F). As discussed above, the particle size was dependent on pH owing to the presence 
of the pH-sensitive monomer DMAEMA. An increase in pH leads to the deprotonation of 
PDMAEMA, thus the P(TFEMA-co-DMAEMA) block becomes hydrophobic and tends to 
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aggregate in aqueous solution, reducing the mobility of 
19
F nuclei. This leads to an increase in the 
NMR line width and a decrease in the 
19
F signal intensity. In addition, it can be seen that the 
increase of 
19
F content (from CCS-1 to CCS-3) also resulted in a considerable decrease in the signal 
intensity because of the increased likelihood of association of the 
19
F-containing segments. Overall, 
the 
19
F NMR results indicated that the 
19
F signal was dependent on both solution pH and 
19
F content 
 
Figure 3-9 
19
F NMR spectra of the CCS polymers in PBS/D2O (90/10, v/v) with 20 mg mL
-1
 
concentration at 25 
o
C. 
  Spin-lattice (T1) and spin-spin (T2) relaxations times were also measured at different values of pH. 
In Figure 3-10, for CCS-1, the T2 remained at around 35 ms when the pH was below pH 6.5 and 
then dropped drastically to less than 5 ms at pH 8. The T2 at pH 9 could not be measured due to the 
greatly attenuated signal. Meanwhile the T1 was not greatly affected by the change of pH, indicating 
that the spectral density of high MHz motions of the fluoroethyl segments is not greatly affected by 
the change in polymer dimensions. Similar conclusions were reached by Peng et al. in their study of 
the behaviour of linear block copolymers.
23, 25
 For CCS-2, the T2 was much lower than that of CCS-
1, but it showed a similar behaviour with changes in pH. As before, the T2 above pH 7 could not be 
measured, demonstrating the reduced mobility of the 
19
F nuclei. The T2 of CCS-3 could not be 
measured at all values of pH owing to the self-association of 
19
F-containing units and highly 
restricted motion, but was instead estimated from the width of the lines in the NMR spectra. 
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Figure 3-10 Relaxation times of CCS-1 (A), CCS-2 (B) and CCS-3 (C) at different pH. 
3.3.6 In vitro 19F MRI Evaluation  
Following the 
19
F NMR study, the CCS polymers were evaluated for in vitro 
19
F MRI. As depicted 
in Figure 3-11 (A), 
1
H RARE images were taken to allow localisation of the sample vials 
(phantoms). The 
19
F MR images are shown on the right-hand side of Figure 3-11 (A). CCS-1 and 
CCS-2 showed a clear change in imaging performance at the four values of pH. Specifically, CCS-1 
could be well visualised at pH 5, and the intensity decreased upon an increase of pH until being 
undetectable at pH 8. The figure demonstrates that CCS-2 was detected at pH 5 and 6.5 with poor 
signal-to-noise ratios, and exhibited no signal at pH 7.4 and 8. Unsurprisingly, CCS-3 could not be 
imaged at any pH owing to its very short T2 relaxation times. As shown in Figure 3-11 (B), a 
decrease in signal-to-noise ratio (SNR) was confirmed on an increase in pH of the polymer solution. 
On the basis of this 
19
F MRI study, CCS-1 and CCS-2 showed better imaging performance at acidic 
pH. Thus it can be expected that these particles could be visualised only at acidic pH, and are thus 
potential candidates for the detection of tumour tissues that have acidic environments. 
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Figure 3-11 (A) In vitro 
1
H and 
19
F MRI images of the CCS polymers in solutions at four values of 
pH. (B) Signal-to-noise ratio (SNR) of CCS-1 and CCS-2 at four pHs. 
  Our previous study of star polymers with fluorinated and DMAEMA units within the branched 
core also demonstrated a change in imaging performance with pH.
52
 However, the best performing 
polymer in this current work (CCS-1) exhibited much better imaging performance at a comparable 
19
F content. For this reason the MRI scan time could be notably shortened to 1 hour 8 minutes from 
9 hours 6 minutes. We hypothesise that this improvement is attributed to the greater flexibility of 
polymer chains around the core for the CCS polymer compared with the segments within the 
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relatively confined core-crosslinked structure.  
3.4 Conclusions 
In conclusion, CCS polymers were synthesised by RAFT dispersion polymerisation through the 
arm-first approach. The synthetic conditions were studied and optimised. The as-synthesised CCS 
polymer could form nanoparticles in aqueous solution and the particle size was dependent on pH. In 
addition, the CCS polymers were degradable due to the abundant disulfide bonds in the core. 
Moreover, 
19
F NMR confirmed that the 
19
F signal intensity was attenuated as the T2 relaxation time 
decreased upon an increase of pH of the polymer solution. In vitro 
19
F MRI indicated that the CCS 
polymers could be imaged well at acidic pH while they had poor imaging performance above 
physiological pH, demonstrating that these CCS polymers are promising 
19
F MRI contrast agents 
for the selective imaging of tumour tissues. 
  Compared with the 
19
F MRI results in Chapter 2, the improved imaging performance presented in 
this Chapter suggests that the mobility of 
19
F nuclei can be improved by placing the fluorine units in 
the arms around the core instead of in a densely-crosslinked and relatively confined structure. 
Therefore this chapter reveals that the imaging properties can be influenced by the polymer 
architecture. This finding can be used for the future design of polymeric contrast agents for 
19
F 
MRI. 
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Chapter 4  
Multifunctional Hyperbranched Polymers for 
 CT/F-19 MRI Bimodal Molecular Imaging  
4.1 Introduction 
In recent decades clinical diagnosis has advanced rapidly owing to the emergence of modern 
imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT), 
positron emission tomography (PET), single photon emission computed tomography (SPECT), 
optical imaging, ultrasonography, etc. Although these techniques are frequently employed in the 
clinic and in research, each modality has its own advantages and limitations. For instance, optical 
imaging has high sensitivity but poor tissue penetration, while MRI provides high spatial resolution 
and no tissue penetration limitations but suffers from low sensitivity and relatively long imaging 
time.
1
 Therefore, in some cases a single modality cannot offer sufficiently comprehensive data 
required for accurate diagnosis. In recognition of this the combination of two or more modalities 
has been a trend in both research and clinic applications in recent years.
2-5
 Compared to single 
modality imaging, complementary information can be obtained through multimodal imaging, such 
as PET/CT, PET/MRI and optical/MRI, facilitating accurate diagnosis as well as assisting 
treatment.  
  The development of nanotechnology has brought enormous possibilities for the design of 
nanoparticle (NP)-based molecular imaging agents. Owing to the unique physicochemical 
properties of NPs, NP-based agents have a number of advantages compared with their small 
molecule counterparts, e.g. longer circulation time, integration of different functionalities, 
controllable size and surface properties, etc.
2
 In the past decade a significant range of NP-based 
multimodal imaging agents have been developed, and this has greatly bolstered the prospects of 
multimodal imaging techniques. 
2, 6-8
  
  Magnetic resonance imaging (MRI) is a non-invasive and non-destructive imaging modality that 
can generate 3D anatomic images of patients with high resolution in particular for soft tissue. In 
contrast, X-ray CT can produce images with high spatial resolution for hard tissue but it has poor 
contrast for soft tissue. Therefore the synergetic application of MRI and CT is attractive as this can 
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enhance the imaging capability. In recent years, considerable attention has been paid to the design 
of CT/MRI contrast agents.
9-18
 Most proposed agents have been based on liposomes, inorganic NPs 
or polymer-containing hybrid NPs. Surprisingly, CT/MRI agents based on dendritic polymers 
including hyperbranched polymers (HBPs) and dendrimers have not been reported to this date, 
regardless of their advantages for nanomedicine such as long blood retention time, 3D globular 
structure, multifunctional sites for functionalisation, intramolecular cavity for drug loading, 
biocompatibility, biodegradability, etc.
19-23
  
  Since the first study in 1977,
24
 
19
F MRI has been recognised as a promising complementary 
modality to 
1
H MRI, which is currently the dominant MRI in routine clinic scans. 
19
F MRI has a 
number of advantages, the most remarkable being the physiological rarity of 
19
F in the human body 
which can eliminate confounding background signals and thus generate selective 
19
F MRI images.
25
 
In the past few years, polymeric 
19
F MRI agents have attracted increasing attention. A wide range of 
19
F-containing polymers have been synthesised and evaluated as 
19
F MRI contrast agents, including 
linear polymers,
26-29
 star polymers,
30, 31
 hyperbranched and dendritic polymers,
32-38
 nanogels,
39, 40
 
etc.  
  The combination of CT and 
19
F MRI can allow for the imaging for hard tissue as well as the 
visualising of imaging probes. To the best of our knowledge, there is no literature reporting the 
design of CT/
19
F MRI molecular imaging agents. Herein we report the design of multifunctional 
hyperbranched polymers containing iodine and fluorine and their application as CT/
19
F MRI 
bimodal imaging contrast agents. The synthetic route is described in Scheme 4-1. In the first step, a 
hyperbranched iodopolymer (HBIP) was synthesised via reversible addition-fragmentation chain 
transfer (RAFT) polymerisation based on a previously reported procedure.
41
 Specifically, the 
iodine-containing monomer, 2-(2',3',5'-triiodobenzoyl)ethyl methacrylate (TIBMA), was 
incorporated to introduce iodine atoms to provide X-ray opacity. The macromonomer, 
poly(ethylene glycol) methyl ether methacrylate (PEGMA, MW = 475 g mol
-1
), was copolymerised 
to provide hydrophilicity. The disulfide-containing bifunctional monomer, bis2-
(methacryloyl)oxyethyl disulfide (DSDMA), was chosen as a crosslinker to form branching 
structures and to achieve biodegradability. In the second step, the as-synthesised HBIP was used as 
a macro chain transfer agent (macro-CTA) and was chain extended with 2,2,2-trifluoroethyl 
acrylate (TFEA) and PEGMA. Finally hyperbranched iodopolymers containing 
19
F (HBIPF) were 
obtained. According to the chemical structure, the iodine atoms were positioned within the 
branched inner part while the 
19
F nuclei were dispersed in the outer copolymer chains. Since the 
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polymers contained both iodine and fluorine, it was thus expect that they could be utilised as 
molecular imaging agents for CT/
19
F MRI bimodal imaging. 
 
Scheme 4-1 Schematic illustration of the synthesis of hyperbranched polymer containing iodine and 
fluorine. 
 
4.2 Experimental Section 
4.2.1 Materials 
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. Poly(ethylene) glycol 
methyl ether methacrylate (PEGMA, MW = 475 g mol
-1
) and 2,2,2-trifluoroethyl acrylate (TFEA) 
were passed through basic alumina columns to remove inhibitors before use. 2,2'-Azobis(2-
methylpropionitrile) (AIBN) was recrystallised twice from methanol prior to use. Bis(2-
methacryloyl)oxyethyl disulfide (DSDMA) was synthesised following procedures published 
previously.
31, 42
 The chain transfer agent (CTA), 4-cyano-4-(2-phenylethane sulfanylthiocarbonyl) 
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sulfanylpentanoic acid (PETTC), was synthesised according to a previously reported method.
43
 4-
(Dimethylamino)pyridine (DMAP), tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and 
reduced L-glutathione (GSH) were used as received. N,N'-dicyclohexylcarbodiimide (DCC) were 
ordered from Alfa Aesar. Milli-Q water with a resistivity of 18.4 MΩ cm-1 was used for all the 
experiments that require water. Tetrahydrofuran (THF), dichloromethane (DCM) and N,N-
dimethylformamide (DMF) were obtained from a solvent purification system (MB-SPS-800-Auto, 
Mbraun) and used directly. All other organic solvents were of analytical grade. Amicon ultra-15 
centrifugal filter units (100k) were purchased from Merck Millipore.  
4.2.2 Synthesis 
4.2.2.1 Synthesis of 2-(2',3',5'-Triiodobenzoyl)ethyl Methacrylate (TIBMA) 
TIBMA was prepared following an approach published elsewhere.
44, 45
 Typically, 1,3,5-
triiodobenzoic acid (10 g, 20 mmol), 2-hydroxyethyl methacrylate (5.2 g, 40 mmol) and DMAP 
(0.54 g, 4.4 mol) were mixed in 150 mL of DCM in a 500 mL flask. DCC (9.08 g, 44 mmol) in 50 
mL of DCM was added dropwise to the above mixture over 10 min, and the solution was then 
stirred at room temperature for 24 h in the dark. After reaction, the mixture was filtered, and the 
filtrate was washed successively with HCl (2 M, 200 mL × 3) and saturated NaHCO3 (200 mL × 3). 
Then the filtrate was dried over anhydrous MgSO4, followed by filtration. The dark brown solution 
was collected and concentrated by rotary evaporation, then it was recrystallised from hexane/ethyl 
acetate (10/90, v/v) twice. Finally, the obtained pale soft powder was dried in vacuum at room 
temperature. Yield: 9.17 g, 75%. 
1
H NMR (500 MHz, CDCl3, ppm): 8.43 and 7.80 (2H, d, phenyl 
protons), 6.12 and 5.75 (2H, s, vinyl protons), 4.55 and 4.47 (4H, m, COOCH2CH2), 1.94 (3H, s, 
CH3). 
13
C NMR (125 MHz, CDCl3, ppm): 166.80, 148.71, 142.47, 136.80, 127.25, 115.36, 108.16, 
96.19, 64.81, 62.97, 18.91.  
4.2.2.2 Synthesis of Hyperbranched Iodopolymer (HBIP) 
The HBIP was synthesised by RAFT polymerisation. In a typical experiment, TIBMA (3.672 g, 6 
mmol), PEGMA (2.85 g, 6 mmol), DSDMA (0.174 g, 0.6 mmol), PETTC (0.102 g, 0.3 mmol) and 
AIBN (4.92 mg, 0.03 mmol) were dissolved in 7.12 mL of DMF in a 50 mL flask. Next the flask 
was sealed with a rubber septum and purged with argon for 30 min in an ice bath. Then the flask 
was placed in a 70 
o
C oil bath and magnetically stirred for 10 h. After that the polymerisation was 
quenched by immersing the flask in ice bath and exposing it to air. The crude solution was 
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precipitated into cold diethyl ether three times. Finally a brown viscous solid was obtained after 
drying in vacuum at room temperature. Yield: 6 g, 88%. GPC MALLS: Mn = 1.57 × 10
5
 g mol
-1
, 
molar mass dispersity (ĐM, Mw/Mn) = 2.2. 
4.2.2.3 Synthesis of Hyperbranched Iodopolymer Containing 19F (HBIPF) 
The HBIPF was prepared through chain extension of HBIPF with TFEA and PEGMA. By varying 
TFEA/PEGMA feed ratio, HBIPF-1, HBIPF-2 and HBIPF-3 with different compositions were 
synthesised. The synthesis of HBIPF-1 is described here as an example. HBIP (0.4 g, 2.55 ×10
-3
 
mmol, equivalent to 0.018 mmol of CTA), TFEA (0.055 g, 0.36 mmol), PEGMA (0.684 g, 1.44 
mmol) and AIBN (0.59 mg, 0.0036 mmol) were dissolved in 3.6 mL DMF in a 25 mL flask, which 
was then sealed with a rubber septum and purged with argon for 20 min in ice bath. After that the 
flask was placed in 70 
o
C oil bath and stirred for 4 h. Then the polymerisation was cooled down 
using an ice bath and exposed to air. The crude solution was precipitated into cold diethyl ether 
three times, and the collected polymer was further purified by centrifugal filtration (Amicon Ultra-
15, 100k). After lyophilisation, a yellowish viscous solid was obtained. According to 
1
H NMR, the 
monomer conversions of TFEA and PEGMA were 30% and 52%, respectively. GPC MALLS: Mn = 
2.27 × 10
5
 g mol
-1
, molar mass dispersity (ĐM, Mw/Mn) = 2.0. Yield: 0.65 g, 84%. 
4.2.2.4 Degradation of HBIP Using Reducing Agents 
In order to study the degradation using TCEP, HBIP (20 mg, 8.81 × 10
-4
 mmol) and TCEP (10.1 
mg, 0.035 mmol) were dissolved in 1 mL methanol. The solution was purged with argon for 20 min 
and then stirred at room temperature for 24 h. An aliquot was sampled for GPC analysis. 
  For the treatment by GSH, HBIP (20 mg, 8.81 × 10
-4
 mmol) and GSH (21.6 mg, 0.07 mmol) were 
dissolved in 7 mL of PBS. The concentration of GSH was 10 mM. The solution was purged with 
argon for 20 min and then stirred at room temperature for 24 h. An aliquot was withdrawn and 
lyophilised for GPC analysis.  
4.2.3 Characterisation 
Gel Permeation Chromatography (GPC)  
Molecular weights and molecular weight distributions were determined by GPC using a Waters 
Alliance 2690 Separations Module equipped with Waters 2414 Refractive Index (RI) Detector, 
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Waters 2489 UV/Visible Detector, Waters 717 Plus Autosampler and Waters 1515 Isocratic HPLC 
Pump. Samples were dissolved in THF and passed through 0.45 µm filters before each 
measurement. THF was used as the mobile phase at a flow rate of 1 mL min 
-1
. The system was 
calibrated using polystyrene (PS) standards, to which the number average molecular weight (Mn) 
and weight average molecular weight (Mw) were referenced. For measuring absolute molecular 
weights, a multi angle laser light scattering (MALLS) detector (DAWN 8+, Wyatt) was attached to 
the GPC, and the polymer solutions were eluted at a flow rate of 1 mg mL
-1
 in THF. The refractive 
index increment (dn/dc) was determined by using ATAGO Pocket Refractometer at room 
temperature. Briefly, polymers were dissolved in THF at a range of concentrations from 10 to 300 
mg mL
-1
, and the refractive index of each solution was measured 5 times to get the average value. 
The dn/dc for each sample was calculated based on those values. The dn/dc values for HBIP and 
HBIPFs were 0.085 and 0.070, respectively.  
Nuclear Magnetic Resonance (NMR)  
1
H NMR and 
13
C NMR were performed on a Bruker Avance 500 MHz spectrometer equipped with 
a BBO5 probe at 25 
o
C using an internal lock (CDCl3) and referenced to the residual non-deuterated 
solvent (CHCl3). 
Dynamic Light Scattering (DLS)  
DLS measurements were carried out on a Nanoseries Zetasizer (Malvern, UK) at 25 
o
C. Sample 
solutions were prepared in PBS (1 mg mL
-1
) at different pH values and passed through 0.45 µm 
filters prior to each measurement. Each hydrodynamic diameter was the average value of 5 
measurements. To minimise the influence of large aggregates, number averaged diameters are 
reported.  
 
Transmission Electron Microscopy (TEM) 
TEM experiments were conducted on a JOEL JEM-1010 transmission electron microscope at 80 
kV. Samples were prepared by dropping polymer solutions (5 mg mL
-1
 in water) onto copper grids 
coated with glow discharged carbon, which were then left at room temperature overnight until dry. 
For each sample, a number of areas on the grid were examined and different magnifications were 
applied. Representative images are provided in this chapter. 
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19
F Nuclear Magnetic Resonance (
19
F NMR)  
All 
19
F NMR spectra were acquired at 470.55 MHz without 
1
H decoupling on a Bruker Avance 500 
spectrometer using a 5 mm broadband inverse probe (BBO5) for which the inner coil was double-
tuned for 
19
F and 
1
H. The samples were prepared by dissolving the star polymers in PBS/D2O 
(90/10, v/v) at a concentration of 100 mg mL
-1
. All measurements were performed at 25 
o
C. A 90
o
 
pulse of 15.1 µs was used in all measurements, the relaxation delay was 2 s and the acquisition time 
was 0.7 s. Data were collected using a spectrum width of 23 kHz, 32k data points and 128 scans. 
  
19
F spin-spin relaxation times (T2) were measured using the Carr-Purcell-Meiboom-Gill (CPMG) 
pulse sequence at 25 
o
C. The samples were dissolved in PBS/D2O (90/10, v/v) at a concentration of 
100 mg mL
-1
. The relaxation delay was 3 s and the acquisition time was 0.7 s. For each 
measurement, the echo times were from 2 to 770 ms and 15 points were collected, which could be 
described by exponential functions for the calculation of T2. Only values for the major peaks are 
reported. 
  
19
F spin-lattice (T1) relaxation times were measured using the standard inversion-recovery pulse 
sequence. For each measurement, the recovery times were from 2 ms to 3 s and 15 points were 
acquired. Only values for the major peaks are reported. 
19
F Magnetic Resonance imaging (
19
F MRI) 
Images of phantoms containing the solutions of the HBIPF nanoparticles were acquired on a Bruker 
BioSpec 94/30 USR 9.4 T small animal MRI scanner. HBIPFs were dissolved in PBS/D2O 
(90/10,v/v) at different concentrations and were loaded in 30 × 8 mm clear vials， which were 
placed in a 
1
H/
19
F dual resonator 40 mm volume coil. 
1
H images were acquired for localisation of 
the samples using a RARE sequence with an echo train length of 8 (TE = 28 ms, TR = 2 s, FOV = 
40 × 40 × 1 mm, Matrix = 256 × 256 × 1). 
19
F images were acquired in the same stereotactic space 
as the 
1
H image using a RARE sequence with an echo train length of 8 (TE = 10 ms, effective TE = 
40 ms, TR = 1 s, FOV = 40 × 40 × 10 mm, Matrix = 40 × 40 × 1, No. Averages = 256) and a total 
acquisition time of 21 minutes. 
Computed Tomography (CT) 
Images of phantoms containing the solutions of the HBIPF nanoparticles were acquired on a 
Siemens Inveon Preclinical PET/CT scanner. HBPIFs were dissolved in PBS at different 
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concentrations and were loaded in 30 × 8 mm clear vials. Each sample was imaged individually to 
avoid the confound of X-ray attenuation across the sample space. Each sample was placed in the 
centre of the X-ray field and images were acquired using an X-ray source with the voltage set to 80 
kV and the current set to 500 µA. Scans were performed using 360° rotation with 180 rotation steps 
with low magnification and a binning factor of 4. Exposure time was 230 ms with an effective voxel 
size of 106 µm. CT images were reconstructed using the Cobra software package (Siemens) and 
normalised to a phantom containing pure water where Hounsfield units were set to 0 for pure water 
and -1000 for air. 
4.3 Results and Discussion 
4.3.1 Synthesis of Partly-fluorinated Hyperbranched Iodopolymers 
Since the pioneer work reported by Davy and co-workers,
44, 46
 2-(2',3',5'-triiodobenzoyl)ethyl 
methacrylate (TIBMA) has drawn much attention as a typical iodo-monomer for the synthesis of X-
ray-opaque polymeric materials.
13, 45, 47-53
 To date, most of the TIBMA-based polymeric agents have 
been microparticles prepared by conventional free radical polymerisation, whereas there are very 
few reports of TIBMA-based polymeric agents with hyperbranched or dendritic structures 
synthesised by controlled radical polymerisation.
54, 55
 As introduced above, hyperbranched 
polymers possess a number of unique advantages, thus it is desirable to explore the synthesis of 
TIBMA-based hyperbranched polymers. These can be prepared via controlled polymerisation 
methods such as RAFT polymerisation,
56
 which can be utilised for the synthesis of well-defined and 
complex architectures.
57, 58
 As the TIBMA homopolymer is hydrophobic, it is important to increase 
the hydrophilicity by copolymerisation with PEGMA. This approach introduces polyethylene glycol 
side chains and has been widely used for preparing hydrophilic and biocompatible materials.
59
 
Furthermore, the crosslinker DSDMA used here contains a disulfide bond that can be cleaved in the 
presence of reducing agents,
60-62
, facilitating the removal of the polymers from the body for in vivo 
applications. 
  The iodo-monomer TIBMA was synthesised by the esterification between 1,3,5-triiodobenzoic 
acid and 2-hydroxyethyl methacrylate, and was purified by recrystallisation (see Appendix C Figure 
A4.1 for 
1
H and 
13
C NMR spectra). The RAFT agents PETTC was chosen because of the well-
resolved peaks of its two aromatic protons at 8.43 and 7.80 ppm, facilitating the determination of 
degree of polymerisation by 
1
H NMR (see Appendix C Figure A4.2 for 
1
H and 
13
C NMR spectra). 
Hyperbranched iodopolymers (HBIPs) were synthesised from the monomers TIBMA, PEGMA and 
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DSDMA via RAFT polymerisation. The feed ratio of TIBMA/PEGMA/DSDMA/PETTC/AIBN 
was set to be 20/20/2/1/0.1. During the polymerisation, the conversion of the three monomers was 
monitored by 
1
H NMR, and reached above 97% within 10 hours, indicating a fast rate of 
polymerisation. As listed in Table 4-1, the as-synthesised HBIP had an absolute Mn of 157 kDa with 
a relatively low (for a hyperbranched structure) molar mass dispersity, ĐM, of 2.2. For each HBIP 
molecule, the number of CTA functionalities (NCTA) was calculated to be 7, confirming the highly 
branched structure of the HBIP. 
  The HBIP was then used as a macro-CTA and chain extended with TFEA and PEGMA for the 
synthesis of hyperbranched iodopolymers containing 
19
F (HBIPF). To investigate the effect of 
fluorine content on the 
19
F MRI performance, three feed ratios of TFEA/PEGMA/CTA were used, 
i.e. 20/80/1, 40/80/1 and 80/80/1. The polymerisations were allowed to proceed for 4 hours, and the 
conversions of TFEA and PEGMA were approximately 30% and 52%, respectively. The resultant 
HBIPF samples with different TFEA/PEGMA compositions were denoted as HBIPF-1, HBIPF-2 
and HBIPF-3, respectively. As shown in Table 4-1, all the HBIPFs had larger Mn than the HBIP 
macro-CTA, meanwhile the ĐM still kept low at 2.0, demonstrating successful chain extension of 
HBIP via RAFT polymerisation.  
 
Table 4-1 GPC and 
1
H NMR data for the HBIP and HBIPFs 
Sample TIBMA/PEGMA
/DSDMA 
in 1st block
a
 
TFEA/PEGM
A 
in 2nd block
a
 
Mn 
(each chain, 
kDa)
b
 
Absolute 
Mn 
(kDa)
c
 
ĐM
c
 NCTA
d
 
HBIP 20/20/2 ─ 22.7 157 2.2 7 
HBIPF-1 20/20/2 10/45 45.6 227 2.0 5 
HBIPF-2 20/20/2 10/34 40.4 238 2.0 6 
HBIPF-3 20/20/2 37/52 53.0 207 2.0 4 
a
 Degree of polymerisation (DP) was obtained from 
1
H NMR results. 
b
 Mn for each chain was 
calculated based on 
1
H NMR. 
c
 Absolute molecular weight was measured by GPC MALLS. 
d
 
Number of CTA functionalities per each molecule was estimated through the equation (NCTA) = Mn 
(GPC MALLS)/Mn (
1
H NMR),
32, 63
 presuming that the branched structure was formed by inter-
chain reaction rather than intra-chain cyclisation.  
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Figure 4-1 
1
H NMR spectra of HBIP and HBIPFs in CDCl3 at 25 
o
C. 
  As displayed in Figure 4-1, the chemical structures of HBIP and HBIPFs were characterised by 
1
H 
NMR. Specific peaks in the spectra were assigned to protons of TIBMA, PEGMA and DSDMA, as 
shown in the spectra. For all the samples, the protons of the aromatic ring were observed at 7.8 and 
8.3 ppm, respectively. In addition, for the samples after chain extension, the peak of the two protons 
in the methylene group adjacent to -CF3 was found to be overlapped with the peaks at 4.4~4.7 ppm, 
however the integral of this peak became larger with increasing TFEA/PEGMA feed ratio, 
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suggesting an increasing amount of TFEA incorporated into the second block. Therefore, 
1
H NMR 
results revealed the chemical structures of the samples and confirmed the successful chain extension 
of HBIP. Based on 
1
H NMR results, the DP of each polymer chain was calculated and the content 
of iodine and fluorine was obtained. As listed in Table 4-2, the iodine content of HBIPFs was 
relatively constant at 17  2.5 wt%. The weight percentages of 19F of both the polymer and the 2nd 
block were also provided in Table 4-2. The fluorine content of the polymer is required for the 
determination of 
19
F concentration for 
19
F MRI. However, the fluorine content of the 2
nd
 block is 
crucial for the study of 
19
F NMR properties of the polymers because it can directly affect the 
mobility of 
19
F nuclei in aqueous solution. 
Table 4-2 Properties of HBIP and HBIPFs  
Sample I wt%
a
 
of each 
molecule 
19
F wt%
a
 
of each 
molecule 
19
F wt%
a
 
of the 2
nd
 
block 
T1 (ms)
b
 T2 (ms)
b
 Dh (nm)
c
 
HBIP 33.6 0 - - - 12.24±2.31 
HBIPF-1 17.0 1.3 2.5 405 61 13.49±1.05 
HBIPF-2 19.0 1.4 3.2 374 38 13.09±1.28 
HBIPF-3 14.4 4.0 6.9 102 11 12.45±1.03 
a
 Iodine and fluorine weight percentages were calculated based on 
1
H NMR results. 
b
 T1 and T2 of 
19
F were determined by 
19
F NMR. 
c
 Hydrodynamic diameter (Dh) was measured by DLS in water at 
25 
o
C. 
4.3.2 Examination of 19F NMR Properties 
The HBIPFs were also characterised by 
19
F NMR. As shown in Figure 4-2, the peaks at -72~-74.4 
ppm confirmed the presence of 
19
F in the HBIPFs. The bimodal nature of the peaks indicated that 
there are possibly two chemical environments for the 
19
F nuclei. We propose that this is due to 
different sequence distributions caused by the largely different reactivity ratios of TFEA/PEGMA 
(0.22 and 2.46, respectively).
64
 Hence, segments of PTFEA homopolymer and P(TFEA-co-
PEGMA) statistical copolymer co-existed in the second block, resulting in two 
19
F resonances. 
Furthermore, the peak width also increased with 
19
F content, indicating that the 
19
F nuclei are 
experiencing stronger dipolar coupling at higher 
19
F content. The spin-lattice relaxation time (T1) 
and spin-spin relaxation time (T2), which are two important parameters for 
19
F MRI, were also 
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determined by 
19
F NMR. As displayed in Table 4-2, when the fluorine content was increased from 
0.6 to 4.0 wt%, T2 dropped from 61 to 11 ms. We previously reported that T2 could be significantly 
affected by the 
19
F content of similar polymers because of the hydrophobic nature of the fluorinated 
segments.
28, 30, 31
 To be more specific, in aqueous solution, a high fluorine
 
content can induce 
aggregation of these units, which reduces the mobility of the 
19
F nuclei resulting in short T2 values. 
In Chapter 2 and 3, it was observed that T1 was not greatly affected by the change in polymer 
dimensions. However, in this work, the T1 of HBIPF-3 was measured to be 102 ms, which is much 
shorter than those of HBIPF-1 and 2. This is not surprising because T1 generally decreases with T2 
in a certain range of correlation time in a fixed magnetic field.
65
 We thus assume that T1 could be 
significantly related to the composition or tacticity of the copolymer chain. Since long T2 and short 
T1 relaxation times are preferred for spin-echo imaging,
27
 it is essential to not only achieve high 
fluorine content but also prevent the fluorine nuclei from associating strongly. 
 
Figure 4-2 
19
F NMR spectra of HBIPFs. 
4.3.3 Studies of Morphology  
  Owing to the incorporation of significant concentrations of hydrophilic PEGMA monomer units, 
the as synthesised HBIP and HBIPFs were water soluble. Nanoparticles could be formed by direct 
dissolution of the polymers in water (1 mg mL
-1
), and the particle size was measured by dynamic 
light scattering (DLS) at 25 
o
C. As shown in Table 4-2, the number-averaged diameter of all three 
HBIPFs was approximately 13 nm, which was slightly larger than that of the HBIP, indicating an 
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increased size after chain extension. The size and morphology were also studied by transmission 
electron microscopy (TEM) (Figure 4-3), and the majority of HBIPF-1 nanoparticles exhibited a 
size of ~6 nm, which was smaller than the size provided by DLS. This is because DLS determines 
the hydrodynamic diameter of the nanoparticles in aqueous solution, which is generally larger than 
the size of dehydrated samples observed by TEM experiments.
66
 Moreover, a number of large 
particles (~12 nm) were also found in the TEM images. We propose that a small amount of 
aggregations were formed owing to the hydrophobic nature of fluorine and iodine units. Hence it 
could be concluded that the HBPIFs could form nanoparticles with size of ~13 nm in aqueous 
solution. 
 
Figure 4-3 Representative TEM images of HBIPF-1 nanoparticles in water. Inset is the number-
averaged size statistics graph acquired by DLS. 
4.3.4 Degradation of HBIP in Reducing Environment 
  As mentioned above, the crosslinker DSDMA contains a disulfide bond that is cleavable in the 
presence of reducing agents. Therefore the HBIP and HBIPFs are expected to be biodegradable. 
Test of the degradability were carried out by using either TCEP or GSH as reducing agents, and the 
resultant polymers were characterised by GPC. As shown in Figure 4-4, the original HBIP showed 
bimodal GPC peaks with retention times of 14.4 and 15.6 min, which is a typical characteristic of 
hyperbranched polymers synthesised by controlled radical polymerisation in the presence of 
crosslinkers.
41, 67, 68
 After being treated with TCEP in methanol for 24 h, the peak at shorter 
retention time (14.4 min) almost disappeared, and only a single peak at longer retention time (15.6 
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min) was observed, demonstrating degradation of the hyperbranched structure via cleavage of 
disulfide bonds. Similarly, the HBIP was also treated with GSH at a physiological concentration (10 
mM)
69
 in PBS for 24 h, and the majority of the hyperbranched polymers were degraded. It should 
be noted that the small peak at 13.2 min arises from polymers formed by re-formation of inter-
molecular disulphide bonds on the degraded fragments. We assume that the lower degradation 
efficiency of GSH was caused by the relatively low concentration of reducing agent. Overall, the 
GPC results confirmed that incorporation of the crosslinker DSDMA can impart biodegradability to 
the hyperbranched polymers.  
 
 
Figure 4-4 GPC traces for HBIP before and after treatment by TCEP and GSH. 
4.3.5 Imaging Performance: X-ray CT and 19F MRI 
The imaging performance of the HBIPFs was evaluated by in vitro X-ray CT and 
19
F MRI 
experiments. Each sample was dissolved in PBS at four different concentrations and loaded in clear 
glass vials (8 × 30 mm, 0.75 mL) for imaging tests. The detailed concentrations and results are 
listed in Table 4-3. 
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Table 4-3 Sample concentrations, CT values and signal-to-noise ratio (SNR) of 
19
F MRI.  
Sample 
 
[Polymer] [I] [F] CT values 
(HU) 
19
F MRI 
SNR mg mL
-1
 mg mL
-1
 M mg mL
-1
 M 
HBIPF-1 11.2 1.9 0.015 0.07 0.004 18.8±32.3 1.96 
 22.4 3.8 0.030 0.14 0.008 66.3±30.4 2.55 
 56 9.5 0.075 0.36 0.019 278.3±30.3 7.77 
 112 19 0.150 0.72 0.038 571.9±30.9 10.83 
HBIPF-2 10 1.9 0.015 0.10 0.005 33.6±28.8 2.30 
 20 3.8 0.030 0.20 0.010 90.6±28.5 23.23 
 50 9.5 0.075 0.50 0.025 304±29.8 9.82 
 100 19 0.150 1.00 0.050 591.6±30.4 15.29 
HBIPF-3 13.2 1.9 0.015 0.53 0.028 2.6±30.4 2.67 
 26.4 3.8 0.030 1.06 0.056 46.3±32.8 4.21 
 52.8 7.6 0.060 2.11 0.111 167.1±31.3 9.07 
 105.6 15.2 0.120 4.22 0.222 333.1±30.9 14.75 
 
  Owing to the high atomic number, and hence high x-ray cross-section of iodine, iodine-based 
materials have been extensively studied for CT molecular imaging.
70
 In recent years, iodine-
containing particles and polymers have drawn much attention, such as liposomes,
71, 72
 emulsion 
particles,
73-75
 block copolymer micelles,
55
 coordination polymers,
76
 etc. However, data on dendritic 
polymer-based agents is scarce. In this work, the radio-opacity of the HBIPFs was evaluated by in 
vitro CT experiments using an Inveon PET/CT scanner (Siemens). As shown in Figure 4-5 (A), all 
the sample solutions exhibited X-ray opacity, which increased with the polymer concentration. In 
addition, the CT attenuation (in Hounsfield units) of the region of interest (ROI) showed a linear 
relationship with iodine concentration (Figure 4-5 (B)). 
In a previous report, iodinated polymeric nanoparticles (58 wt% Iodine) were prepared using the 
same iodine-containing monomer by emulsion polymerisation.
51
 The radio-opacification was 
measured to be 362±1 HU for the nanoparticle dispersion at16 mg mL
-1
 in water (equals to 9.28 mg 
mL
-1
 iodine). In another paper, an emulsion based on iodinated oils was fabricated and stabilised by 
block copolymers.
75
 These nanoparticles were utilised for in vivo CT and tested using mouse 
models. The CT values for blood, spleen and liver were measured after injection. It was observed 
that the CT value was proportional to the iodine concentration in the organs, which was calculated 
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from the change in the CT values. For example, the CT values for iodine concentrations of 10 and 
20 mg ml
-1
 were 310±20 and ~620±40 HU, respectively. In our work, the CT values for the sample 
with 9.5 mg mL
-1
 iodine were 278.3±30.3 HU and 304±29.8 HU for HBIPF-1 and HBIPF-2, 
respectively, while the CT values for the sample with 19 mg mL
-1
 iodine were measured to be 
571.9±30.9 HU and 591.6±30.4 HU for HBIPF-1 and HBIPF-2, respectively. Because the CT 
values for specific iodine concentrations were close to those reported in the literatures, we suggest 
that the radio-opacity of the iodinated polymers was only related to the iodine concentration, and 
was not significantly affected by the architecture, morphology or composition of the polymeric 
materials. Notably, the CT values of in vitro and in vivo studies were relatively close, similarly 
suggesting that the radio-opacity was not affected by the physiological environment. Therefore 
these results confirm that the HBIPFs have the potential for application as in vivo CT agents. 
 
Figure 4-5 (A) In vitro CT phantom images of HBIPFs aqueous solutions with different iodine 
concentrations. For HBIPF-1 and HBIPF-2, C1 = 0.015 M, C2 = 0.030 M, C3 = 0.075 M, C4 = 
0.150 M. For HBIPF-3, C1 = 0.015 M, C2 = 0.030 M, C3 = 0.060 M, C4 = 0.120 M. (B) The 
corresponding CT values of ROI as a function of iodine concentration.  
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  The NMR detectable 
19
F nuclei were confirmed by 
19
F NMR, indicating that the HBIPFs 
developed here could have potential as contrast agents for 
19
F MRI. The same solutions of HBIPFs 
examined by x-ray CT were assessed by 
19
F MRI. As depicted in Figure 4-6 (A), the HBIPF 
nanoparticles provided positive signals at all concentrations. When the fluorine concentration was 
relatively high (C3 and C4 for all the samples), the nanoparticles could be particularly well imaged. 
From Figure 4-6 (B), one can see that the signal-to-noise ratio (SNR) was directly proportional to 
fluorine content. Moreover, the SNR for HBIPF-2 was slightly higher than that of HBIPF-1 because 
of the increase in fluorine content from 0.64% to 1%. However, the SNR for HBIPF-3 was 
significantly lower than for the other samples. This can be explained by the considerably increased 
fluorine content (4%) causing aggregation of fluorine nuclei in water and thus resulting in greatly 
shortened T2 relaxation times, as was revealed by 
19
F NMR. 
 
Figure 4-6 (A) In vitro 
19
F MRI phantom images of aqueous solutions of HBIPFs at different 
fluorine concentrations. The concentrations are the same as those in Figure 4-5. Note: 
1
H RARE 
images were used for the localisation of the field of view. (B) Signal-to-noise ratio (SNR) in 
19
F 
MRI as a function of fluorine concentration. 
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  As studied in Chapter 2 and Chapter 3, the T2 relaxation time was shortened with the increase of 
19
F content of the polymers due to the increased association of 
19
F segments in aqueous solution. 
For example, at pH 4~7.4, the T2s of the sample CCS-2 (3.9 wt% of 
19
F) were nearly half of those 
of the sample CCS-1 (2.3 wt% of 
19
F), indicating the dramatically increased aggregation of 
19
F units 
at higher 
19
F content. Consequently, the 
19
F MRI SNR of CCS-2 was significantly lower than that 
of CCS-1.
31
 In this Chapter, similar results were obtained. The observation of lowest SNR of 
HBIPF-3 is in accord with previous findings, supporting that long T2s (mobile 
19
F nuclei) are 
preferred for spin-echo imaging. However, the SNR of HBIPF-2 (1 wt% of 
19
F, T2 = 38 ms) was 
slightly higher than that of HBIPF-1 (0.6 wt% of 
19
F, T2 = 61 ms), confirming that 
19
F concentration 
was also another crucial factor for 
19
F MRI. Therefore both high 
19
F content and long T2 are 
prerequisite for the design of 
19
F MRI CAs with high efficiency. 
4.4 Conclusions 
In conclusion, multifunctional hyperbranched polymers containing iodine and fluorine were 
synthesised via RAFT polymerisation. The content of iodine and fluorine could be tuned by varying 
the monomer feed ratio for the chain extension reaction. The HBIPFs could be degraded by 
treatment of reducing agents such as GSH and TCEP, and thus the polymer would be likely 
excreted in vivo. By direct dissolution of the HBIPFs in water, nanoparticles were formed with 
diameters between 10~15 nm. In aqueous solution, the radio-opacity of these nanoparticles was 
confirmed by in vitro CT experiments. In addition, solutions of the nanoparticles could be 
visualised by 
19
F MRI. These results suggest that the HBIPFs are promising molecular imaging 
agents for CT/
19
F MRI bimodal imaging. 
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Chapter 5  
Segmented Highly-Branched Copolymers: 
Rationally Designed Macromolecules for Improved 
19F MRI 
5.1 Introduction 
Magnetic resonance imaging (MRI), which was developed in the 1970s,
1
 has advanced rapidly in 
recent decades. Due to the advantages of non-invasiveness, relatively high resolution, rich 
information content and lack of radiation burden,
2, 3
 MRI has become an indispensable diagnosis 
technique in both the clinic and in medical research. As a leading MRI modality, 
1
H MRI has been 
dominant in clinical scans because it can generate 3D anatomical images with high penetration 
depth especially for soft tissues.
4
 However, contrast agents are often required to enhance the 
imaging contrast through affecting the relaxation times of the protons in surrounding tissues. 
Emerging only four years later than 
1
H MRI,
5
 
19
F MRI has been recognised as a promising modality 
to complement 
1
H MRI. The most significant feature of 
19
F MRI is the physiological rarity of 
detectable 
19
F in the body, which minimises confounding background signal during imaging.
6, 7
 
Therefore 
19
F MRI is more advantageous in quantification and tracking, such as measurement of the 
partial pressure of oxygen (pO2), cell labelling, cell tracking, etc.
8, 9
  
  
19
F MRI highly relies on the use of contrast agents (CAs), which introduce exogenous 
19
F to the 
body. A successful 
19
F MRI CA should fulfil the following two basic criteria: (1) a single and 
narrow 
19
F resonance for maximum sensitivity and reduced chemical shift imaging artefacts;
10, 11
 (2) 
a short spin-lattice (T1) relaxation time for reduced scan time and long spin-spin (T2) relaxation time 
for increased image intensity in the case of the spin-echo pulse sequence.
10
 In recent years, 
polymer-based CAs have attracted increasing attention for 
19
F MRI owing to the diverse 
functionalities and architectures possible with polymers.
12, 13
 A variety of partly-fluorinated 
polymeric CAs have been reported, including linear polymers,
14-18
 star polymers,
19, 20
 dendritic 
polymers,
21-24
 hyperbranched polymers (HBPs),
25-29
 polymer nanogels,
30-32
 etc. Among them, HBPs 
have been considered to be excellent candidates for 
19
F MRI, in particular the HBPs synthesised via 
reversible addition-fragmentation chain transfer (RAFT) polymerisation.
25, 26, 29
 Specifically, these 
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novel HBPs that consist of fluoro monomer and PEG-based monomer possess quite a number of 
prominent properties. First, a high 
19
F payload (up to 20 mol% fluoro monomer) can be achieved 
while the water solubility is still maintained. Second, the strong tendency of 
19
F aggregation in 
aqueous solution can be prevented by positioning 
19
F segments within a 3D hyperbranched 
structure, leading to high 
19
F mobility and strong signal intensity. Third, the abundant 
functionalities (alkyne and trithiocarbonate groups) can be utilised for conjugation reactions to 
attach targeting/drug molecules as well as other imaging moieties. Therefore, RAFT synthesised 
HBPs represent a straightforward approach for the design of 
19
F MRI CAs. 
  Generally, the RAFT synthesis of HBPs requires the use of bifunctional monomers (or 
crosslinkers).
33
 Under optimised experimental conditions, well-defined HBPs with reasonably 
narrow molar mass dispersity can be obtained.
34-37
 Nevertheless, the structure of the resultant HBPs 
can be influenced by a number of factors related to the crosslinker (e.g., crosslinker type, 
crosslinker/CTA ratio, crosslinker concentration), and sometimes unwanted macroscopic gelation 
occurs.
38-40
 Other than using crosslinkers, self-condensing vinyl polymerisation (SCVP), which 
utilises initiator monomers (inimers), is another method for the synthesis of HBPs by free radical 
polymerisation.
41
 When the inimer is copolymerised with other conventional vinyl monomers, the 
degree of branching (DB) is dependent on the comonomer/inimer ratio (γ) and monomer 
conversion. In the past decade, RAFT-mediated SCVP (RAFT SCVP) has been developed for the 
controlled synthesis of HBPs with a myriad of branched architectures and functionalities.
42-53
 It is 
also worth noting that RAFT SCVP is a robust strategy for the design of segmented branched 
polymers, which are composed of linear polymer chains and thus possess unique properties due to 
chain entanglement.
54
 Benefitting from the RAFT technique,
55
 the HBPs synthesised by RAFT 
SCVP have controllable topologies, multifunctional groups and relatively narrow molar mass 
dispersity. For example, by using a polymerisable trithiocarbonate chain transfer agent (CTA), Gao 
and co-workers synthesised segmented hyperbranched polymers (SHBPs) of poly(glycidyl 
methacrylate), which beared highly-dense and hetero-functional groups and served as a versatile 
platform for a collection of standard click chemistries.
50
 Zhao and co-workers explored RAFT 
SCVP for the synthesis of hyperbranched and star polymers via one or two steps.
46
 Methyl 
methacrylate (MMA), styrene (St), methyl acrylate (MA) and tert-butyl acrylate (tBA) were 
selected to copolymerise with a polymerisable CTA (S-(4-vinyl)benzyl S‟-propyltrithiocarbonate). 
The DB and branch length of HBPs were tuneable, and the arm length of star polymers was 
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controllable, confirming that RAFT SCVP is a robust approach to synthesise hyperbranched and 
star polymers with desired segmental and arm composition. 
  Although a number of HBP-based CAs have been developed for 
19
F MRI, more detailed 
investigations are needed to understand how imaging properties are regulated by the hyperbranched 
molecular structure. However, it would be challenging to examine HBPs synthesised by using 
crosslinker as a model because of the complexity of this approach. As a comparable analogue, 
partly-fluorinated SHBPs synthesised by RAFT SCVP offer a simpler model for a systematic study 
due to the facile control over polymer structure as well as chain tacticity. To date such polymers 
have not been reported for application in 
19
F MRI. In this work we report the synthesis of water-
soluble and partly-fluorinated SHBPs via RAFT SCVP using a polymerisable trithiocarbonate 
CTA. By taking advantage of RAFT SCVP, SHBPs with different degree of branching and 
sequence distribution are prepared. A robust methodology is thus established for the design of 
SHBPs with targeted branched structure and composition. Both acrylate and methacrylate 
comonomers are used to examine the effect of flexibility of statistical copolymer chains in water. 
One particular aim is to determine how the hyperbranched structure, sequence distribution and 
composition affect the 
19
F NMR properties. This understanding will allow the synthesis of partly-
fluorinated SHBPs with tailored structure and properties for selective and tuneable 
19
F MRI. 
5.2 Experimental Section 
5.2.1 Materials 
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. Poly(ethylene glycol) 
methyl ether methacrylate (PEGMA, MW = 475), poly(ethylene glycol) methyl ether acrylate 
(PEGA, MW = 480), 2,2,2-trifluoroethyl methacrylate (TFEMA), 2,2,2-trifluoroethyl methacrylate 
(TFEA), and 2-hydroxyethyl methacrylate (HEMA) were passed through basic alumina columns to 
remove inhibitors prior to use. The initiator, 2,2‟-azobis(2-methylpropionitrile) (AIBN), was 
recrystallised from ethanol twice before use. 4-(Dimethylamino)pyridine (DMAP) and N,N‟-
dicyclohexylcarbodiimide (DCC, purchased from Alfa Aesar) were used as received. The 
trithiocarbonate RAFT agent, 4-cyano-4-(dodecylsulfanylthiocarbonyl)sulfanyl pentanoic acid was 
synthesised and purified according to a previously reported method.
56
 Milli-Q water with a 
resistivity of 18.4 MΩ cm-1 was used for the relevant experiments. Tetrahydrofuran (THF) and 
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dichloromethane (DCM) were obtained from a solvent purification system (MB-SPS-800-Auto, 
Mbraun) and used directly. All other solvent were of analytical grade. 
5.2.2 Synthesis 
5.2.2.1 Synthesis of the Polymerisable CTA, (S)-2-(Methacryloyloxy)ethyl 4-cyano-4-
(((propylthio)carbonothioyl)thio)pentanoate (MECP) 
4-Cyano-4-(dodecylsulfanylthiocarbonyl)sulfanyl pentanoic acid (8.07 g, 0.02 mol), HEMA (5.21 
g, 0.04 mol) and DMAP (0.489 g, 0.004 mol) were dissolved in 200 mL of DCM in a 500 mL round 
bottom flask immersed in an ice bath. DCC (5.25 g, 0.04 mol) in 50 mL DCM was added dropwise 
to the above solution. The resulted mixture was stirred at 0 
o
C for 1 h and then at room temperature 
for 24 h. After reaction, the mixture was filtered to remove the insoluble dicyclohexylurea by-
product. The filtrate was washed with 1 M HCl solution (200 mL × 3) and saturated NaHCO3 
aqueous solution (200 mL × 3), and then dried over anhydrous MgSO4 overnight in a freezer. After 
that the solution was filtered again and concentrated by rotary evaporation. The crude product was 
purified by flash column chromatography (Silica gel, 230-400 mesh) using petroleum spirit (40-
60)/ethyl acetate mixture (gradient from 9/1 to 7/3) as eluent. After removal of the solvents, a red 
oil was obtained and stored in a freezer away from light. Yield: 7.15 g, 69%. 
1
H NMR (500 MHz, 
CDCl3, ppm): 6.13 and 5.6 (s, 2H, CH2(CH3)C), 4.36 (m, 4H, COOCH2CH2), 3.32 (t, 2H, 
CH2CH2S), 2.36-2.56 (m, 4H, CH2CH2COO), 1.95 (s, 3H, CH2C(CH3)COO), 1.87 (s, 3H, 
SCH3C(CN)CH2), 1.69 (m, 2H, CH2CH2S), 1.26-1.40 (m, 18H, CH3(CH2)9CH2CH2S), 0.88 (t, 3H, 
CH3(CH2)9CH2CH2S). 
13
C NMR (125 MHz, CDCl3, ppm): 217.22, 176.61, 167.43, 136.22, 126.54, 
119.30, 63.08, 62.54, 46.67, 37.43, 34.16, 32.26, 30.02, 29.96, 29.89, 29.76, 29.68, 29.41, 29.28, 
28.02, 25.22, 23.03, 18.63.  
5.2.2.2 Synthesis of Segmented Highly Branched Polymers via RAFT SCVP 
A typical polymerisation is described as follows. PEGMA (1.43 g, 3 mmol), TFEMA (0.336 g, 2 
mmol), MECP (51.6 mg, 0.1 mmol) and AIBN (3.28 mg, 0.02 mmol) were dissolved in 1 mL of 
1,4-dioxane in a 10 mL tube placed with a magnetic stir bar. PEGMA/TFEMA/MECP/AIBN = 
30/20/1/0.2, and the comonomer/MECP ratio (γ) = 50. Then the tube was sealed with a rubber 
septum and purged with argon for 15 min, followed by immersing in a 70 
o
C oil bath for 24 h. The 
polymerisation was then quenched by immersing the flask in an ice bath and exposing to air. The 
conversions of PEGMA, TFEMA and MECP were found to be all above 97% according to 
1
H 
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NMR. The crude solution was diluted with THF and precipitated in cold hexane three times. A 
yellowish viscous oil was collected after drying at 35 
o
C in vacuum for 24 h. Yield: 1.46 g, 80%.  
  Following this procedure, a series of SHBPs was synthesised under the same conditions by 
varying the comonomer type and comonomer/MECP ratio. The polymer characteristics are listed in 
Table 5-1. 
5.2.2.3 Synthesis of Linear Statistical Copolymer Poly(TFEA-co-PEGA) 
PEGA (1.44 g, 3 mmol), TFEA (0.308 g, 2 mmol), 4-cyano-4-
(dodecylsulfanylthiocarbonyl)sulfanyl pentanoic acid (40.4 mg, 0.1 mmol) and AIBN (3.28 mg, 
0.02 mmol) were dissolved in 1 mL of 1,4-dioxane in a 10 mL tube placed with a magnetic stir bar. 
After purging with argon for 15 min, the tube was placed in a 70 
o
C oil bath for 24 h. The 
polymerisation was then quenched by immersing the flask in an ice bath and exposing to air. The 
crude sample was diluted with THF and precipitated in cold hexane three times. The collected 
sample was dried at 35 
o
C in vacuum for 24 h. A yellowish viscous oil was obtained. Yield: 1.1 g, 
62%. 
 
5.2.3 Characterisation 
Gel Permeation Chromatography (GPC)  
Molecular weights and molecular weight distributions were determined by GPC using a Waters 
Alliance 2690 Separations Module equipped with Waters 2414 Refractive Index (RI) Detector, 
Waters 2489 UV/Visible Detector, Waters 717 Plus Autosampler and Waters 1515 Isocratic HPLC 
Pump. Samples were dissolved in THF and passed through 0.45 µm filters before each 
measurement. THF was used as the mobile phase at a flow rate of 1 mL min
-1
. The system was 
calibrated using polystyrene (PS) standards, to which the number average molecular weight (Mn) 
and weight average molecular weight (Mw) were referenced. For measuring absolute molecular 
weights, a multi angle laser light scattering (MALLS) detector (DAWN 8+, Wyatt) was attached to 
the GPC, and the polymer solutions were eluted at a flow rate of 1 mg mL
-1
 in THF. The refractive 
index increment (dn/dc) was determined by using ATAGO Pocket Refractometer at room 
temperature. Briefly, polymer/THF solutions were prepared with concentrations from 10 to 300 mg 
mL
-1
, then the refractive index of each solution was measured 5 times to get an average value. 
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Refractive index as a function of polymer concentration was plotted, and the slope was calculated as 
the dn/dc for each sample. It was found that the dn/dc for all samples was approximately 0.04 ml g
-1
 
in THF at 25 
o
C. 
1
H and 
13
C Nuclear Magnetic Resonance (NMR)  
1
H NMR and 
13
C NMR were performed on Bruker Avance 500 MHz and 700 MHz spectrometer at 
25 
o
C using an internal lock (CDCl3 or D2O) and referenced to the residual non-deuterated solvent 
(CHCl3 or H2O). 
1
H-
13
C heteronuclear multiple-bond correlation (
1
H-
13
C HMBC) and 
1
H-
13
C 
heteronuclear single quantum coherence (
1
H-
13
C HSQC) spectra were recorded on a Bruker Avance 
700 MHz using CDCl3 as solvent at 25 
o
C. 
Dynamic Light Scattering (DLS)  
DLS measurements were carried out on a Nanoseries Zetasizer (Malvern, UK) at 25 
o
C. Polymers 
were dissolved in PBS at a concentration of 1 mg mL
-1
 and passed through 0.45 µm filters to 
remove dust particles prior to each measurement. Each hydrodynamic diameter was the average 
value of 5 measurements. To minimise the possible influence of large aggregates, number-averaged 
diameters are reported.  
UV-Vis Spectroscopy  
UV-Vis spectra were recorded on a Cary 4000 UV-Vis spectrophotometer. Samples were dissolved 
in acetonitrile at given concentrations at 25 
o
C. 
Differential Scanning Calorimetry (DSC) 
DSC analyses were carried out on a Mettler Toledo DSC1 Star System calorimeter. Samples (5~9 
mg) were heated from 25 to 150 
o
C at a heating/cooling rate of 10 
o
C min
-1
 in nitrogen atmosphere. 
The glass transition temperature was determined from the midpoint of the change in capacity in the 
second heating cycle (-100 to 150 
o
C). 
19
F Nuclear Magnetic Resonance (
19
F NMR)  
All 
19
F NMR spectra were acquired at 659 MHz on a Bruker Avance 700 spectrometer. The 
samples were prepared by dissolving the polymers in PBS/D2O (90/10, v/v) at a concentration of 20 
mg mL
-1
. All measurements were performed at 25 
o
C. A 90
o
 pulse of 15.1 µs was used in all 
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measurements, the relaxation delay was 2 s and the acquisition time was 0.18 s. Data were collected 
using a spectrum width of 46 kHz, 16k data points and 64 scans. 
  
19
F spin-spin relaxation times (T2) were measured using the Carr-Purcell-Meiboom-Gill (CPMG) 
pulse sequence at 25 
o
C. The samples were dissolved in PBS/D2O (90/10, v/v) at a concentration of 
20 mg mL
-1
. The relaxation delay was 2.3 s and the acquisition time was 0.18 s. For each 
measurement, the echo times were from 2 to 770 ms and 15 points were collected, which could be 
described by exponential functions for the calculation of T2. For the samples that have broad and 
unsymmetrical 
19
F peaks, the T2s were calculated by SigmaPlot software using nonlinear regression 
function (exponential decay, double, 4 parameters). For some samples, three T2 measurements were 
conducted, and the standard errors were found to be negligible (< 1%). 
  
19
F spin-lattice (T1) relaxation times were measured using the standard inversion-recovery pulse 
sequence. The relaxation delay was 2.5 s and the acquisition time was 0.18 s. For each 
measurement, the recovery times were from 2 ms to 3 s and 15 points were acquired.  
19
F Magnetic Resonance Imaging (
19
F MRI) 
Images of phantoms containing the polymer solutions were acquired on a Bruker BioSpec 94/30 
USR 9.4 T small animal MRI scanner. SHBPs solutions (100 mg mL
-1
 in pure water) were loaded 
in 30 × 8 mm clear glass vials, which were placed in a 
1
H/
19
F dual resonator 40 mm volume coil. 
1
H 
were acquired for localisation of the samples using a RARE sequence with an echo train length of 8 
(TE = 28 ms, TR = 2 s, FOV = 40 × 40 × 1 mm, Matrix = 96 × 96 × 1). 
19
F images were acquired in 
the same stereotactic space as the 
1
H image using fast low-angle shot (FLASH) and rapid 
acquisition with relaxation enhancement (RARE) sequence with an echo train length of 8. The 
detailed experimental parameters are given as follows. 
  19
F FLASH: TE = 3.72 ms, TR = 30 ms, Flip Angle = 20 degrees, NEX = 1024, FOV = 40 × 40 
mm, MAT = 96 × 96, Measurement time = 47 minutes. 
  19
F RARE-8: Rare Factor = 8, TE = 10 ms, Effective TE = 40 ms, TR = 1 s, NEX = 512, FOV = 40 
× 40 mm, MAT = 96 × 96, Measurement time = 1 h and 46 minutes. 
  19
F RARE-32: Rare Factor = 32, TE = 10 ms, Effective TE = 160 ms, TR = 1 s, NEX = 512, FOV 
= 40 × 40 mm, MAT = 96 × 96, Measurement time = 52 minutes. 
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5.3 Results and Discussion 
5.3.1 Polymerisation Mechanism and Molecular Design 
The aim of this work is to study the use of RAFT SCVP for the synthesis of segmented highly 
branched polymers (SHBPs) that are partly-fluorinated and water-soluble for 
19
F MRI applications. 
A polymerisable RAFT agent, (S)-2-(methacryloyloxy)ethyl 4-cyano-4-
(((propylthio)carbonothioyl)thio)pentanoate (MECP), was synthesised by the standard DCC/DMAP 
esterification between 4-cyano-4-(dodecylsulfanylthiocarbonyl)sulfanyl pentanoic acid and HEMA. 
As shown in Figure 5-1, MECP is a typical AB*-type inimer for SCVP, in which B* is a 
trithiocarbonate function for the RAFT polymerisation of the vinyl group A and other comonomers. 
Therefore, MECP can be exploited for controlled polymerisation via the RAFT process as well as 
the simultaneous formation of branching points through the A groups. 
 
Figure 5-1 Chemical structure of the polymerisable CTA. 
  As illustrated in Scheme 5-1, the polymerisation process follows the typical reaction mechanism of 
a SCVP.
54
 In the scheme the lower case letter, b and M refer to the reacted monomers. Upon 
initiation through the decomposition of AIBN, A-b-M* is generated through the chain transfer of 
propagating radicals of comonomers M at a rate constant of KBM, while A-b-A*-B* is formed by 
the chain transfer of propagating radicals of inimer A-B* at a rate constant of KBA. Then A-b-M* 
can undergo two possible reactions through the addition of either inimer or comonomers at rate 
constants of KMA and KMM, respectively. Meanwhile, through similar monomer additions, A-b-A*-
B* can be reacted with inimer and comonomers in six routes at its two activated sites A* and B*, 
resulting in the formation of the six depicted structures at rate constants of KAA, KAM, KBA, and 
KBM. As the polymerisation proceeds, highly branched macromolecules composed of linear chains 
are gradually produced via these reactions. According to the nature of the RAFT process, the 
equilibrium between the active propagating radicals and dormant thiocarbonylthio compound is 
very fast. Hence the chain growth progresses in a controlled fashion, yielding polymer segments 
with narrow molar mass distribution as well as the formation of branching structures. 
57
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Scheme 5-1 Reaction mechanism for RAFT SCVP. A: vinyl group of MECP. B: trithiocarbonate 
function of MECP. M: comonomers TFE(M)A and PEG(M)A. Lowercase letters „a‟ and „b‟ stand 
for reacted A and B, respectively. Asterisks represent activated sites for the addition of monomers 
and inimer.  
  The detailed synthetic route is described in Scheme 5-2. 2,2,2-Trifluoroethyl methacrylate 
(TFEMA) and 2,2,2-trifluoroethyl acrylate (TFEA) were selected as fluoro monomers, while 
poly(ethylene glycol) methyl ether methacrylate (PEGMA) and poly(ethylene glycol) methyl ether 
acrylate (PEGA) were chosen as PEG-based oligomers. Through RAFT SCVP using a 
polymerisable trithiocarbonate CTA (MECP), segmented highly branched p(TFE(M)A-co-
PEG(M)A) were prepared. According to the mechanism, each SHBP macromolecule contains an 
unreacted vinyl group and numerous trithiocarbonate end-groups. As described above, these SHBPs 
are intended for 
19
F MRI as CAs. A number of previous publications have pointed out that high 
19
F 
segmental mobility is of importance for achieving long spin-spin relaxation (T2) times, which are 
preferred for 
19
F MRI.
15, 17
 To achieve high 
19
F mobility in water, the 
19
F segments should be 
hydrated and separated from each other to avoid association. One strategy is to design statistical 
copolymers composed of units of fluoro monomers and hydrophilic PEG-based oligomers such as 
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PEGMA and PEGA. Consequently, two issues are to be addressed. First, the choice of monomers 
needs to be examined. As reported before,
14, 15
 tapered or block copolymers could cause 
19
F 
aggregation in water. In addition, the type of monomer (acrylates or methacrylates) can affect the 
segmental motion. Thus certain monomers with close reactivity ratios are required for the synthesis 
of statistical copolymers that have highly flexible polymer backbones. Second, the 
19
F content 
should be maximised. A high 
19
F payload is preferred for reducing scan time as well as improving 
image quality, but may lead to aggregation of 
19
F-containing units (short T2) and decreased water 
solubility. Hence the relationship of 
19
F payload and 
19
F mobility needs to be investigated. 
Following these findings, the next goal is to understand the influence of branched structure on the 
19
F NMR properties before 
19
F MRI evaluation. 
 
Scheme 5-2 Illustration of the synthesis of SHBPs via RAFT SCVP. Lowercase letters „a‟ and „b‟ 
stand for reacted A and B, respectively. „A‟ refers to unreacted vinyl groups in MECP, and „B*‟ 
denotes to trithiocarbonate groups that have not engaged in the RAFT process.  
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5.3.2 Synthesis of SHBPs via RAFT SCVP 
The RAFT SCVP of TFEMA and PEGMA using MECP as CTA was carried out in 1,4-dioxane at 
70 
o
C. The influence of reaction time was first studied by GPC and 
1
H NMR. As shown in Figure 5-
2, from 2 to 48 h, the GPC traces measured by RI detector evolved toward higher molecular weight 
with increasing monomer conversions evidenced by 
1
H NMR. Meanwhile, owing to the RAFT 
process, the molar mass dispersity (Đw, Mw/Mn) remained relatively low at 1.25~1.81. In addition, 
the monomer conversion reached ~90% after 6 h with MW of ~10
4
 g mol
-1
, indicating a rapid 
polymerisation rate. A shoulder peak appeared after 6 h with MW of ~ 10
5
 g mol
-1
, suggesting the 
formation of highly branched macromolecules via the polymerisation of vinyl groups of MECP. 
Nevertheless, the conversion of MECP could not be identified precisely by 
1
H NMR because its 
characteristic peaks were significantly overlapped with those of PEGMA units. According to the 
GPC results, the RAFT SCVP exhibited hybrid chain-growth/step-growth behaviour that could be 
described by two steps.
54
 In the first step (0-6 h), due to the much higher concentration of TFEMA 
and PEGMA compared with MECP, RAFT-mediated chain growth proceeded with rapidly 
increasing monomer conversions, yielding lightly branched polymers (macroinimers) with narrow 
molar mass distribution. In the second step (6-48 h), after the consumption of most comonomers, 
the macroinimers started to react with each other through the A group sites, resulting in highly 
branched polymers with dramatically increased MW as evidenced by the bimodal GPC curves. In 
fact, these two processes occur simultaneously, but each step dominates at different stages.
54
 
Similar results were also reported by others.
44, 45
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Figure 5-2 GPC traces of the samples withdrawn at different time intervals during a RAFT SCVP. 
Inset gives the monomer conversions determined by 
1
H NMR. Polymerisation conditions: 
[PEGMA]/[TFEMA]/[MECP]/[AIBN] = 40/10/1/0.2, [monomer] = 1 M, 70 
o
C. 
  The effect of monomer concentration was investigated next. As displayed in Figure 5-3 (A), single 
GPC peaks with low MW and narrow Đw were observed for the polymerisation performed at low 
monomer concentration (0.25 and 0.5 M). When the monomer concentration was above 1 M, 
bimodal GPC curves were obtained with a peak becoming more pronounced at MW of ~ 10
5
 g mol
-
1
, suggested that highly branched macromolecules were only produced at relatively high monomer 
concentrations instead of dilute conditions. We thus assume that a high monomer concentration 
increased the probability of condensation of macroinimers, facilitating the formation of polymers 
with highly branched structures. It was also found that an increase of the ratio 
[comonomer]/[MECP] (γ) resulted in polymers with higher MW mainly due to the longer chain 
length between two branching points (Figure 5-3 (B)). 
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Figure 5-3 GPC traces of RAFT SCVP at different monomer concentrations (A) and 
[comonomer]/[MECP] ratios. Condition for (A): [PEGMA]/[TFEMA]/[MECP]/[AIBN] = 
40/10/1/0.2, 70 
o
C, 24 h. Condition for (B): [PEGMA]/[TFEMA] = 4/1, [MECP]/[AIBN] = 5/1, 
[monomer] = 5 M, 70 
o
C, 24 h. 
  Based on these results, a series of SHBPs were synthesised via RAFT SCVP using a monomer 
concentration of 5 M. For an in-depth study, both methacrylates and acrylates were chosen to vary 
the polymer compositions. In addition, different [comonomer]/[MECP] ratios were selected for the 
synthesis of SHBPs with various degree of branching. The details of the SHBPs are summarised in 
Table 5-1. 
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Table 5-1 Molecular characteristics of the SHBPs synthesised by RAFT SCVP.  
Sample PEG(M)A:TFE(M)A:CTA
a
 Mn
 a
 Mn 
(kDa)
b
 
ĐM
b
 DB
c
 RB
c
 NCTA
d
 
SHBP-1 52:7:1 (PEGMA+TFEMA) 26400 1440 2.2 0.033 30 55 
SHBP-2 47:12:1 (PEGMA+TFEMA) 24900 690 3.6 0.033 30 28 
SHBP-3 35:17:1 (PEGMA+TFEMA) 20000 1030 2.3 0.037 27 51 
SHBP-4 30:22:1 (PEGMA+TFEMA) 18400 820 2.6 0.037 27 45 
SHBP-5 25:26:1 (PEGMA+TFEMA) 16800 510 3.8 0.038 26 30 
SHBP-6 16:26:1 (PEGMA+TFEMA) 12500 440 3.6 0.045 22 35 
SHBP-7 45:13:1 (PEGMA+TFEA) 23900 1030 2.5 0.033 30 43 
SHBP-8 48:15:1 (PEGA+TFEMA) 26100 430 1.8 0.036 28 16 
SHBP-9 39:12:1 (PEGA+TFEA) 20600 370 1.6 0.038 26 18 
SHBP-10 37:17:1 (PEGA+TFEA) 20400 230 2.1 0.036 28 11 
SHBP-11 34:22:1 (PEGA+TFEA) 19700 210 2.0 0.034 29 11 
SHBP-12 24:35:1 (PEGA+TFEA) 16900 130 2.0 0.033 30 8 
SHBP-13 4:3:1 (PEGA+TFEA) 2900 140 1.7 0.219 5 49 
SHBP-14 7:5:1 (PEGA+TFEA) 4600 160 1.2 0.142 7 35 
SHBP-15 14:11:1 (PEGA+TFEA) 8900 270 1.2 0.074 14 31 
LP-11 39:23:1 (PEGA+TFEA) 22700 13
e
 1.43
e
 0 - 1 
a
 Degree of polymerisation (DP) was determined by 
1
H NMR. Mn (
1
H NMR) of a single polymer 
chain was calculated by using the equation Mn = MWPEG(M)A × DPPEG(M)A + MWTFE(M)A × DPTFE(M)A 
+ MWMECP, assuming the polymerisations completely followed the RAFT process. 
b
 Absolute MW 
and ĐM were measured by GPC MALLS. 
c
 Degree of branching (DB) was calculated by the 
equation introduced in the main text. Repeating unit per branch (RB) = 1/DB. 
d
 Number of 
trithiocarbonate functionality per SHBP (NCTA) = Mn (GPC MALLS)/Mn (
1
H NMR). 
e
 Measured by 
GPC RI detector. All the SHBPs were synthesised in 1,4-dioxane at 70 
o
C for 24 h with [monomer] 
= 5 M and [MECP]/[AIBN] = 5/1. 
  One benefit of SCVP is that the degree of branching (DB) of the resultant HBPs can be predicted 
at given [comonomer]/[MECP] ratio and monomer conversion. In our study, the DBs of SBHPs can 
be calculated by the following equations.
54
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(5-1) 
 
(5-2) 
  In Equations 5-1 and 5-2, γ and  refer to [comonomer]/[MECP] ratio and monomer conversion, 
respectively. Because nearly full monomer conversion was achieved, Equation 5-1 can be 
simplified to Equation 5-2. Accordingly, the degree of branching was calculated to be between 
0.033 and 0.219 (Table 5-1). It should be stressed that the degree of branching is solely dependent 
on γ at fixed monomer conversions (e.g. 100%). Hence it is feasible to obtain targeted DBs by 
simply using a stoichiometric [comonomer]/[MECP] ratio. This feature is especially advantageous 
for the synthesis of SHBPs with tailored compositions and degrees of branching.
54
 As reported by 
Sumerlin and Vogt, highly-branched poly(N-isopropylacrylamide) with different degrees of 
branching were prepared through RAFT SCVP by varying ratios of monomer to CTA.
48
 
5.3.3 Characterisation of Structure and End Functionality of SHBPs 
The chemical structure of the SHBPs was characterised by NMR spectroscopy. SHBP-4 was chosen 
as a typical sample for detailed NMR analysis. As displayed in Figure 5-4 (A), all the characteristic 
peaks of TFEMA, PEGMA were found and assigned. Specifically, the peaks at 4.3 and 4.0 ppm are 
from CH2 adjacent to the ester bonds of TFEMA and PEGMA units, respectively. The dominant 
peak at 4.5~4.7 ppm can be ascribed to the CH2CH2O repeating units of PEGMA segments. 
Noticeably, the peaks of MECP were also identified, confirming the retention of CTA functionality. 
The presence of peaks from vinyl bonds is in accord with the aforementioned RAFT SCVP 
mechanism that each SHBP retains an unreacted vinyl group of MECP. According to 
1
H NMR, the 
measured ratio of PEGMA/TFEMA/MECP in the SHBP-4 was calculated to be 30/22/1, which is 
very close to the feed ratio 30/20/1. Therefore the Mn for a single polymer chain was calculated to 
be 18400 g mol
-1
 using the equation Mn = MWPEGMA × DPPEGMA + MWTFEMA × DPTFEMA + 
MWMECP. In addition, 
13
C NMR (Figure 5-4 (B)) verified the chemical structure with all the 
relevant carbon peaks being observed, such as at 221.8 ppm (trithiocarbonate groups), 175.3~177.4 
ppm (carbonyl groups), 126.0 and 107.9 ppm (vinyl groups), 128.2 (CN groups), 121.0~125.7 ppm 
(CF3 groups), etc. Both 
1
H and 
13
C NMR confirmed the successful incorporation of TFEMA, 
PEGMA and MECP units into the SHBPs via RAFT SCVP. 
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Figure 5-4 NMR spectra of SHBP-4 in CDCl3. (A) 
1
H NMR spectrum, inset is the expanded area of 
5.4~6.4 ppm. (B) 
13
C NMR spectrum, insets are expanded areas of 221.5~222 ppm and 120~130 
ppm.  
  To get more detailed information, SHBP-4 was characterised by 
1
H-
13
C 2D NMR. 
1
H-
13
C HSQC 
can be used to confirm the direct attachment of 
1
H atoms to 
13
C atoms through displaying 
correlations between resonances of 
1
H and 
13
C nuclei with one-bond C-H couplings (
1
JCH). In 
Figure 5-5 (A) the characteristic protonated carbons are labelled with numbers, and they can be 
assigned to the related cross-peaks. For example, the cross-peak 4 (δH = 4.3 ppm, δC = 60.9 ppm) is 
from the correlation of resonances of CH2 connected to the ester bond in TFEMA units, while 
cross-peak 5 (δH = 4.0 ppm, δC = 64.3 ppm) is from CH2 next to the ester bond in PEGMA units. It 
is worth mentioning that the CH2 adjacent to trithiocarbonate was also evidenced by two cross-
peaks (red circle; see Appendix D Figure A5.1 for the enlarged spectrum). Thee spectrum also 
confirms retention of trithiocarbonate functionalities in the SHBPs crucial for either further 
bioconjugation or chain extension. To be more specific, cross-peak 1 (δH = 3.2 ppm, δC = 37.1 ppm) 
is from the CH2 next to the reacted trithiocarbonate groups that engaged in the RAFT process, while 
cross-peak 1‟ (δH = 3.3 ppm, δC = 37.2 ppm) can be attributed to the neighbouring CH2 of unreacted 
trithiocarbonate groups that did not participate in the RAFT process. Hence, the coexistence of both 
reacted and unreacted RAFT species in the highly branched structure, a typical characteristic of 
RAFT SCVP, was elucidated by the 
1
H-
13
C HSQC spectrum. In addition, the correlations of CH2 in 
vinyl groups can also be confirmed by several cross-peaks (see Appendix D Figure A5.2), 
indicating different chemical environments of double bonds existing in the complicated highly 
branched structure.  
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  To further study the structure, SHBP-4 was also analysed by 
1
H-
13
C HMBC experiments, which 
can provide information about long distance connectivity between 
1
H and 
13
C atoms in particular 
the three-bond scalar coupling (
3
JCH) as well as occasional observation of 
2
JCH and 
4
JCH. As shown 
in Figure 5-5 (B), the correlations of major characteristic 
1
H-
13
C pairs were detected and labelled 
accordingly. The cross-peaks highlighted by a red circle are related to the correlations of 
1
H atoms 
in CH2 and 
13
C atoms in the neighbouring trithiocarbonate groups, providing further proof for the 
trithiocarbonate functionality in SHBP macromolecules.  
 
Figure 5-5 
1
H-
13
C HSQC spectrum (A) and 
1
H-
13
C HMBC spectrum (B) of SHBP-4 in CDCl3. The 
red circles highlight the correlations that are related to trithiocarbonate group and its neighbouring 
CH2.   
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  In addition to NMR analysis, the presence of trithiocarbonate was also confirmed by UV-Vis 
spectroscopy and the UV detector of GPC at wavelength of ~306 nm (see Appendix D Figure 
A5.3).  
5.3.4 Characterisation of Chain Sequence Distribution 
As stated in the Introduction, one design priority for 
19
F MRI polymeric CAs is to achieve a single 
19
F NMR resonance with strong signal intensity. Therefore the choice of monomers should be 
carefully considered as it directly determines the 
19
F NMR properties of the resulting polymers. In 
this study, hydrophobic TFEA and TFEMA were selected as fluoro monomers to provide the 
19
F 
NMR signal. Both of these monomers have moderate 
19
F contents that can possibly generate strong 
19
F signal while avoiding association of the fluorinated segments in water. In addition, both 
monomers have only one 
19
F chemical structure (CF3) and so is expected to produce a single 
19
F 
NMR resonance. PEG-based hydrophilic oligomers, PEGA and PEGMA, were copolymerised with 
TFE(M)A to obtain water-soluble polymers. SHBPs consisting of a range of compositions were 
synthesised, including TFEA/PEGA, TFEA/PEGMA, TFEMA/PEGA and TFEMA/PEGMA pairs 
(see Table 5-1 for details). 
1
H NMR was used for the investigation of the chain composition and 
sequence. In Figure 5-6 
1
H NMR spectra of SHBP-2, 7, 8 and 9 having relatively close 
TFE(M)A/PEG(M)A ratios are compared particularly within the chemical shift of 4~5 ppm to 
highlight several differences. For the sample contained TFEA and PEGMA, two peaks „a‟ and „b‟ 
(in solid box) were observed from 4.25 to 4.60 ppm, which could be assigned to the resonances of 
protons in CH2 adjacent to ester bond in TFEA, as further evidenced by the 
1
H-
13
C HSQC spectrum 
(see Appendix D Figure A5.4). In addition, a shoulder peak c (in dash box) was also found in the 
peak (4.07 ppm) for CH2 next to ester bond in PEGMA. These results imply that both TFEA and 
PEGMA segments exist in different chemical environments. 
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Figure 5-6 
1
H NMR spectra of 4 selected SHBPs with expanded region between 4~5 ppm. All 
spectra were recorded using CDCl3 except that SHBP-7 was additionally characterised in D2O.  
  To get more details, SHBP-7 was also analysed in D2O using the diffusion NMR technique (1D 
double-stimulated echo experiment) that suppressed the water signal at 4.7 ppm. Compared with the 
spectrum in CDCl3, only one peak of CH2 in TFEA was found and it was shifted to 4.6 ppm, while 
a single peak due to the CH2 adjacent to the ester bond in PEGMA appeared at 4.1 ppm without the 
previous shoulder peak. The 
1
H NMR spectrum in D2O indicates that the peaks „b‟ and „c‟ could be 
attributed to the hydrophobic segments in the polymer. In our previous paper, the reactivity ratios of 
PEGMA and TFEA were determined to be 2.46 and 0.22, respectively, suggesting a tendency of 
forming gradient copolymers.
58
 Based on these observations, we propose that SHBP-7 was 
constructed of poly(TFEA-co-PEGMA) gradient copolymer chains, which had TFEA-rich 
sequences (hydrophobic) and PEGMA-rich sequences (hydrophilic). Therefore the gradient 
incorporation of TFEA and PEGMA results in different chemical environments of TFEA and 
PEGMA units, as reflected by the changes in the 
1
H NMR spectra. On the basis of the 
1
H NMR 
results, the water-insoluble TFEA segments in SHBP-7 account for 40% of TFEA units, judged by 
comparing the integration of peaks „b‟ and peak „a‟, indicating a considerable loss of effective 19F 
loading. This may have implications for 
19
F MRI performance. 
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  The 
1
H NMR spectrum of SHBP-8 (24 mol% of TFEMA and 76 mol% of PEGA) was quite 
similar to that of SHBP-7. This may be due to the large differences in reactivity ratios of TFEMA 
and PEGA. However, for SHBP-9 and 2, a single peak for CH2 was found for both TFEA and 
PEGMA, illustrating that near-ideal copolymers were prepared owing to the close reactivity ratios 
of TFEA/PEGA and TFEMA/PEGMA. We suggest that statistical copolymers (poly(TFEA-co-
PEGA) or poly(TFEMA-co-PEGMA) are more preferable than gradient copolymers (poly(TFEA-
co-PEGMA) or poly(TFEMA-co-PEGA) (see Figure 5-7) for 
19
F MRI because the latter would not 
only reduce the effective of 
19
F loading but also cause potential multiple peaks in the 
19
F NMR 
spectrum.  
 
 
Figure 5-7 Illustration of the structures of copolymers with different sequence distribution. 
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5.3.5 19F NMR Studies 
In order to evaluate their potential as 
19
F MRI CAs, the SHBPs were examined by 
19
F NMR. 
Samples were dissolved in PBS/D2O (90/10, v/v) at a concentration of 20 mg mL
-1
. The SHBPs 
could form nanoparticles with diameters of 4~8 nm in PBS by direct dissolution (see Table 5-2). It 
should be mentioned that all the SHBPs were water-soluble even with incorporation of fluorinated 
units up to 60 mol% due to the excellent hydrophilicity of the PEG-based oligomers. As can be seen 
in Figure 5-8 (A), all the 
19
F NMR spectra exhibited a single peak at -73.1~-72.6 ppm. The small 
triplet at -76.6 ppm could be ascribed to residual fluorinated compounds, including monomer. 
Clearly, the peaks become broader when the 
19
F content increases, indicating the decreasing signal 
intensity caused by the elevated chance of 
19
F association at higher 
19
F content. This can also be 
concluded from the relevant values of half width listed in Table 5-2. 
 
Figure 5-8 Stacked 
19
F NMR spectra of the SHBPs in PBS/D2O(90/10, v/v) at 20 mg mL
-1
 at 25 
o
C. 
(A) Samples consisted of P(TFEMA-co-PEGMA) copolymer chains. (B) Samples composed of 
P(TFEA-co-PEGA) copolymer chains. Note: the peak intensities have been normalised to the same 
value (1.0). 
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Table 5-2 Physical and 
19
F NMR properties of the SHBPs.  
a 
Hydrodynamic diameters were measured in PBS (1 mg mL
-1
) by DLS at 25 
o
C, and number-
averaged diameters are reported here. 
b
 
19
F payloads were calculated based on 
1
H NMR results. 
c
 
19
F 
NMR spectra and measurements of relaxation times were performed by 
19
F NMR at 659 MHz in 
PBS/D2O (90/10, v/v) at 25 
o
C. 
c
 Half width is the peak width at half height. 
  To study the effect of copolymer composition and sequence on the 
19
F NMR spectra, SHBP-2, 7, 8 
and 9 were selected for comparison as these samples have similar fluorine contents of 
approximately ~3.0 wt%. From Figure 5-9 (A) one can see that SHBP-9 has the highest 
19
F NMR 
signal intensity, while SHBP-7 has the lowest intensity. At a given fluorine concentration, the signal 
intensity is dependent on mobility of the fluorinated segments, which can be affected by the 
flexibility of the polymer chains. As reported in our previous study,
15
 the fluorinated units 
connected to acrylate backbones have higher local mobility compared to those in methacrylate 
backbones. Therefore acrylate monomers are favoured for achieving high 
19
F signal intensity. The 
ratios of peak integral to fluorine concentration were calculated based on 
19
F NMR spectra. In 
Sample Dh
a
 F% 
(wt%)
b
 
T2 
(ms)
c
 
T1 (ms)
c
 Half width 
(Hz)
c
 
Tg (
o
C) 
19
F MRI 
Intensity
d
 
SHBP-1 7.90±0.65 1.5 17.9 291.4 119.4 -65.8 1.33 
SHBP-2 7.52±1.1 2.8 11.3 288.0 161.7 -60.7 0.65 
SHBP-3 6.24±0.51 4.8 6.5 282.4 288.9 -59.3 0.07 
SHBP-4 7.42±0.79 6.8 4.7 282.4 310.8 -57.9 0.01 
SHBP-5 5.89±0.50 8.8 3.6 284.4 783.7 -53.3 0.0009 
SHBP-6 8.12±0.42 11.9 3.0 291.4 1115.8 -51.6 0.0001 
SHBP-7 6.45±0.22 3.1 44.0 308.5 200.6 -60.9 10.62 
SHBP-8 6.29±0.24 3.3 33.9 302.3 248.0 -62.1 8.59 
SHBP-9 6.31±0.36 3.3 87.1 345.4 223.9 -61.2 17.59 
SHBP-10 6.07±0.31 4.8 51.7 330.0 320.5 -59.3 18.69 
SHBP-11 5.62±0.08 6.4 35.3 317.7 373.4 -57.7 17.34 
SHBP-12 5.56±0.06 11.8 20.3 308.5 422.2 -48.7 13.61 
SHBP-13 5.12±0.02 5.9 17.6 307.4 349.7 ‒ 4.50 
SHBP-14 4.09±0.06 6.1 24.4 309.1 333.7 ‒ 9.88 
SHBP-15 4.52±0.21 6.7 33.1 318.1 355.6 ‒ 16.80 
LP-11 3.95±0.15 5.8 43.9 319.3 371.2 ‒ 19.72 
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Figure 5-9 (B), the samples consisting of acrylate monomers exhibit higher ratios of peak integral to 
fluorine concentration, indicating that they have higher 
19
F signal intensity at a given 
19
F 
concentration. It is noteworthy that SHBP-7 shows a considerably low intensity because it 
contained 40% of „19F NMR-invisible‟ 19F, as revealed by 1H NMR spectrum. In the normalised 
spectra (see Appendix D Figure A5.5), SHBP-7 displays an unsymmetrical peak, which was caused 
by multiple 
19
F chemical environments in the gradient copolymers. In contrast, the statistical 
copolymer chains in SHBP-2 and 9 resulted in relatively symmetrical peaks. This is in good 
agreement with the 
1
H NMR results shown in Figure 5-6.  
 
 
Figure 5-9 
19
F NMR results of four SHBPs. (A) Stacked 
19
F NMR spectra of SHBP-2, 7, 8 and 9. 
(B) The ratios of peak integral to fluorine concentration. Samples were dissolved in PBS/D2O(90/10, 
v/v) at 20 mg mL
-1
 at 25 
o
C. 
  Spin-lattice (T1) and spin-spin (T2) relaxation times, which are two important parameters for 
19
F 
MRI, were measured by 
19
F NMR. Generally, highly mobile fluorine nuclei experience reduced 
dipolar couplings which can result in narrow 
19
F peaks and long T2 relaxation times. As depicted in 
Figure 5-10, it is clear that samples composed of acrylates have much longer T2 relaxation times 
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than their methacrylate counterparts, providing further evidence that fluorine atoms in acrylate 
backbones are more mobile. In addition, the sample with TFEA/PEGMA (SHBP-7) units exhibit a 
slightly longer T2 than the polymer consisting of TFEMA/PEGA (SHBP-8). Considering the 
gradient in sequence of the chains in SHBP-7, we assume that the 
19
F NMR-detectable nuclei were 
mainly from its PEGMA-rich sequences, where the 
19
F units were loosely dispersed, affording 
comparably higher mobility and longer T2 relaxation times than SHBP-8. Furthermore, when the 
19
F 
content increases, T2 decreases dramatically. For example, the T2 of samples with TFEA/PEGA 
dropped by 76% when 
19
F content was increased from 3.3 wt% to 11.8 wt%. This tendency 
confirms that the 
19
F mobility is becoming restricted at higher 
19
F contents due to the significantly 
increasing association in an aqueous environment. Compared with T2, the T1 values stayed 
relatively short at ~300 ms, implying that the spectral density of motions in the range of 700 MHz 
was not much affected by the change in polymer conformation. Similar results were observed in 
previous reports.
19, 20
 
 
Figure 5-10 T2 relaxation times of the SHBPs. Samples were dissolved in PBS/D2O(90/10, v/v) at 
20 mg mL
-1
 at 25 
o
C. 
  The glass transition temperature (Tg) of the SHBPs is also a measure of the molecular mobility of 
the main chains, and can be related to the NMR properties. The Tg of the homopolymers PTFEA 
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and PTFEMA were reported to be 2 and 60 
o
C,
59, 60
 respectively, whereas the Tg of PPEGA and 
PPEGMA were in the range of -70 ~ -65 
o
C.
61-63
 As listed in Table 5-2, for the SHBPs consisting of 
TFEMA and PEGMA (from SHBP-1 to 6), Tg increases gradually with the molar fraction of 
TFEMA from -65.8 to -51.6 
o
C. The same trend was also noted for SHBPs composed of TFEA and 
PEGA (from SHBP-9 to 12), as evidenced by the stack of DSC curves (see Appendix D Figure 
A5.6). In addition, the Tg values were predicted by using the Fox equation based on the composition 
determined by 
1
H NMR. In Appendix D Figure A5.7, the experimental Tg values are generally in 
agreement with the curve fitted by Fox equation. The deviation is reasonable as the Fox equation 
inherently gives the assumed Tg values. It could be expected that the segmental flexibility was more 
restricted for samples with higher Tg, and it is not surprising that longer T2 relaxation times were 
observed for the samples with lower Tg values because of the enhanced averaging of the dipole-
dipole and chemical shift interactions.
15
 Therefore, PEG-based oligomers are ideal monomers for 
the copolymerisation with fluoro monomers to yield copolymers with low Tg and good water-
solubility.  
  As discussed before, the degree of branching (DB) of the SHBPs can be adjusted by varying the 
[comonomer]/[MECP] ratio. In this work, SHBPs with different DBs and close [TFEA]/[PEGA] 
ratios were synthesised for the study on the relationship between DB and relaxation times. A linear 
analogue of SHBP-11 (LP-11, DB = 0) was also prepared for comparison. As displayed in Figure 5-
11, a remarkable decrease of T2 from 43.9 to 17.6 ms was observed with an increase of DB, 
implying poor 
19
F mobility for samples with high degrees of branching. This result suggests that 
samples with high DBs are more compact, leading to the increased rigidity, restricted 
macromolecular motion and reduced segmental flexibility. The change in macromolecular 
compactness was also confirmed by GPC MALLS, which revealed that samples with higher DBs 
showed larger absolute MWs at the same retention time (see Appendix D Figure A5.8). However, 
the spin-lattice relaxation time T1 was relatively constant at ~310 ms, indicating the little effect of 
chain motion at a frequency of 700 Hz. 
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Figure 5-11 
19
F T1 and T2 relaxation times of SHBPs with different degrees of branching and 
similar 
19
F contents of ~ 3 wt%. DB from low to high: LP-11, SHBP-11, SHBP-13, SHBP-14, and 
SHBP-15. 
5.3.6 19F MRI Studies  
The ultimate aim of this work was to exploit the SHBPs as contrast agents for 
19
F MRI. Following 
19
F NMR characterisation, the imaging performance was evaluated by in vitro 
19
F MRI. For 
comparison, SHBP-2, 7, 8 and 9 were selected for imaging as they possess different compositions 
but similar 
19
F content (~3 wt%). Samples were dissolved in pure water at a concentration of 100 
mg mL
-1
, and the solutions were loaded in 30 × 8 mm clear glass vials, of which the cross-sections 
were shown in phantom images. The vials in the resonator were localised using the 
1
H RARE 
sequence, then the samples were imaged using 
19
F FLASH which is a T1-weighted gradient echo 
sequence with a short scan time.
64
 As depicted in Figure 5-12, all four samples were effectively 
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visualised using 
19
F FLASH (repetition time TR = 30 ms) within 47 min. The signal-to-noise ratios 
(SNRs) for the images are displayed in Figure 5-12 (bottom right). Since the samples have different 
spin-spin relaxation times, T2-weighted imaging was then conducted using the RARE spin-echo 
pulse sequence. As shown in Figure 5-12, using the RARE sequence with an echo time TE of 41 
ms, SHBP-7, 8 and 9 that have T2s above 30 ms were all well imaged, while SHBP-2 having a short 
T2 of 11.3 ms exhibited a poor SNR. Notably, SHBP-9 with the longest T2 showed the brightest 
image. When the TE was increased to 157 ms, only SHBP-9 could be imaged, while SHBP- 7 and 8 
were detected with fairly low SNRs. SHBP-2 was found to be hardly visualised owing to its very 
short T2, affording a dark field. The 
19
F MRI results demonstrate that the SHBPs can be selectively 
imaged by making use of the differences in T2 values and selection of the appropriate pulse 
sequences.  
 
Figure 5-12 
19
F MRI results for four selected SHBPs. Top: phantom images of the samples using 
different sequences. Note that 
1
H RARE was performed to localise the sample vials. Bottom left: 
concentrations and 
19
F NMR profiles of the samples. Bottom right: signal-to-noise ratios for the 
imaging experiments. 
  For 
19
F MRI using a spin-echo pulse sequence, the imaging intensity can be described as the 
following equation.
65
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(5-3) 
  In Equation (5-3), I is the imaging intensity, N(F) is a measure of the number of fluorine nuclei in 
the sensitive volume of the imaging coil, and TR and TE are the pulse sequence repetition time and 
echo delay times, respectively. According to this equation, high fluorine content, long T2 and short 
T1 are required for the design of efficient contrast agents. The 
19
F MRI intensity values were 
estimated using Equation (5-3) using the parameters for the RARE-8 pulse sequence (TE = 41 ms, 
TR = 1 s, sample concentration = 100 mg mL
-1
). As listed in Table 5-2, the calculated imaging 
intensity generally decreases with the T2 relaxation time. It is not surprising that the SHBPs 
consisting of P(TFEA-co-PEGA) exhibit considerably higher imaging intensities compared to those 
containing P(TFEMA-co-PEGMA). In addition, the calculated imaging intensity decreases with the 
increase of DB, providing further evidence that SHBPs with low DBs are preferred for 
19
F MRI. 
Besides, the fluorine content plays an important role in imaging intensity. Compared with SHBP-9 
(3.3 wt%), SHBP-10 (4.8 wt%) has a shorter T2 relaxation time but a slightly higher imaging 
intensity due to the increased fluorine content.  
  These results suggest that SHBPs consisting of P(TFEA-co-PEGA) with low DB are excellent 
candidates as 
19
F MRI contrast agents. 
5.4 Conclusions 
Segmented and highly-branched polymers were successfully synthesised by RAFT SCVP of 
TFE(M)A, PEG(M)A and a polymerisable trithiocarbonate CTA. By varying monomer type and 
[comonomer]/[MECP] ratio, SHBPs with desired compositions and degree of branching were 
prepared. The structure of the SHBPs was thoroughly characterised by a range of different 
analytical techniques. Statistical copolymers were obtained using TFEA/PEGA or 
TFEMA/PEGMA, while gradient copolymers were produced with monomers having largely 
different reactivity ratios. The 
19
F NMR properties were affected by both chain composition and 
monomer sequence. Higher 
19
F mobility (longer T2) was achieved in statistical copolymers 
consisting of acrylate units due to greater segmental flexibility. In addition, the 
19
F mobility was 
greatly restricted for the samples with higher 
19
F contents due to increased association of the 
fluorinated segments. A shortened T2 was also observed with an increase in degree of branching, 
which caused increased compactness, rigidity, and restricted segmental motion. For gradient 
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copolymers, the 
19
F signal intensity was significantly reduced by the loss of solubilised 
19
F units in 
the chains. The relationship between T2 and chain flexibility was also revealed by thermal analysis, 
and longer T2 relaxation times were observed for the samples with lower glass temperatures, Tg. The 
imaging performance of the SHBPs was confirmed by 
19
F MRI. All the samples could be well 
imaged by T1-weighted imaging, while they could be selectively visualised using a T2-weighted 
sequence using different echo times.  
  In summary, we have demonstrated therefore a robust concept for the controlled design of 
polymeric 
19
F MRI contrast agents. By tailoring the branched structure and composition, the 
imaging properties of the agents can be effectively controlled, enabling the realisation of selective 
and tuneable 
19
F MRI agents. Furthermore, this work provides useful guidance for the future design 
of polymeric CAs with high 
19
F content, long T2 and short T1 for effective 
19
F MRI  
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Chapter 6 Partly-Fluorinated Star Polymers with a 
POSS core for F-19 MRI 
6.1 Introduction 
Owing to the rapidly advancing field of nanotechnology, the emergence of nanomedicine, which 
refers to the technologies for the diagnosis, treatment and prevention of diseases using 
nanomaterials, has revolutionised the biomedical field with a new generation of medicines.
1, 2
 In 
recent years, theranostic nanomedicine that combines therapy and diagnosis has drawn considerable 
attention.
3, 4
 Being integrated with functions such as drug loading, targeted drug delivery and 
imaging, theranostic agents can be utilised not only for drug delivery and localising but also for 
biomedical imaging, greatly enhancing cancer diagnosis and treatment. A vast library of 
nanomaterials have been exploited as potential platforms for the development of theranostic 
nanomedicine, including liposomes, micelles, polymer nanoparticles, inorganic nanoparticles, 
hybrid nanoparticles, etc.
3, 5
 To impart multifunctionality to a nanoparticle-based system, the 
convergence of both organic and inorganic components are often required, resulting in hybrid 
theranostic nanoparticles.
6-8
  
  Polyhedral oligomeric silsesquioxanes (POSS) are a class of silsesquioxanes that have the general 
formula, (RSiO1.5)n.
9
 The chemical structure of the most studied and exploited POSS can be 
described as (RSiO1.5)8, in which one Si atom has three stable Si-O bonds and a Si-C bond for the 
attachment of diverse functionalities. Therefore, as a type of organic/inorganic hybrid nanomaterial, 
POSS has been utilised as an excellent platform for the design of nanomedicine owing to its 
symmetrical cage-like structure, small particle size (0.53~1.5 nm), biological stability, low 
cytotoxicity, high density of functional moieties and commercial availability.
9-12
 In the past decade, 
great effort has been devoted to the fabrication of POSS/polymer hybrid nanomaterials, which have 
a number of benefits as therapeutic and diagnostic agents. First, the cage-like structure of POSS has 
been proven to be advantageous for entrapping various drug/gene/dye molecules.
13-18
 Second, the 
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introduction of polymers can facilitate diverse architectures (micellar, star-like, hyperbranched and 
dendritic structures) and functionalities (fluorescence agents, targeting ligands, stimuli-responsive 
properties, etc).
19-24
 Third, due to the well-defined structure of POSS molecules, POSS/polymer 
hybrid nanomaterials can be readily designed to have controlled structure and composition with 
narrow polydispersity, which are essential for building up robust platforms.
10
 According to the 
(RSiO1.5)8 structure, POSS possesses eight potentially-functionalisable sites. Hence, they have been 
extensively employed as core materials for the synthesis of star polymers which are constructed of a 
central core and multiple arms.
25-28
 Star polymers have been recognised as an important class of 
polymers for the development of nanomedicine owing to their 3D globular architecture and 
multifunctional arms.
29
 Recently, the synthesis of star polymers with POSS cores via controlled 
radical polymerisation (CRP) has attracted increasing attention. A number of such star polymers 
have been prepared by atom transfer radical polymerisation (ATRP)
14, 25, 30-32
 and reversible 
addition-fragmentation chain transfer (RAFT) polymerisation.
33, 34
 However, there are still very few 
reports utilising the RAFT-mediated approach compared with ATRP, despite the versatility and 
robustness of RAFT technique for the synthesis of star polymers.
35-37
 As a typical example, Ye and 
co-workers explored the „grafting from‟ synthesis of star polymers with POSS cores using RAFT 
polymerisation.
34
 Azide-functionalised POSS was conjugated with an alkyne-terminated chain 
transfer agent (CTA) via click chemistry (copper (I)-catalysed [2+3] Huisgen cycloaddition), 
resulting in a macroCTA anchored with eight CTA moieties. Then the macroCTA was used for the 
RAFT polymerisation of methyl methacrylate (MMA), yielding star polymers with a POSS core 
and PMMA arms. Confirmation of the controlled nature of the RAFT polymerisation was achieved 
by etching the core with HF, after which the PMMA arms were found to have narrow molar mass 
dispersity (1.15) by gel permeation chromatography (GPC).
38
 While the POSS-initiated 
polymerisation exhibited controlled characteristics, it was noteworthy that bimodal GPC traces were 
observed for the star polymers, indicating that the formation of star polymers was accompanied by a 
parallel polymerisation of linear analogues. This distribution of products is typically observed for 
star polymers synthesised via the „R-group‟ approach.35 
  Magnetic resonance imaging (MRI) is an indispensable modern diagnostic technique. It features 
non-invasive and radiation-free imaging and can provide 3D anatomic images at high resolution.
39
 
Although 
1
H is the dominant nuclei studied in MRI, 
19
F MRI has also been considered as a 
promising MRI modality in the past few decades because 
19
F has comparable nuclear magnetic 
resonance (NMR) properties to 
1
H. More importantly, the lack of detectable 
19
F in the body can 
ensure minimal background signal, highlighting the quantitative capability of 
19
F MRI. Very 
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recently, the development of polymeric agents for 
19
F MRI has been an active research field. Owing 
to the abundant architectures and functionalities present in polymeric systems, a wide range of 
partly-fluorinated polymers have been developed as contrast agents (CAs) for 
19
F MRI, including 
linear polymers,
40-43
 star polymers,
44, 45
 hyperbranched polymers,
46-51
 dendrimers,
52-54
 etc. These 
studies have pointed out that successful 
19
F MRI CAs should possess high fluorine content as well 
as highly mobile 
19
F nuclei. In Chapter 3, core crosslinked (CCS) star polymers were evaluated to 
be excellent candidates as 
19
F MRI agents. The positioning of 
19
F in flexible and water-soluble arms 
resulted in improved 
19
F mobility in aqueous solution compared with those in a hyperbranched core. 
Inspired by this finding, we propose that star polymers with a POSS core and partly-fluorinated 
arms could be utilised as efficient 
19
F MRI CAs and potential drug carriers.  
  In this chapter, we aim to synthesise star polymers with a POSS core and partly-fluorinated arms. 
Octavinyl POSS with eight vinyl groups was selected as the starting material, and functionalised 
with eight hydroxyl groups via UV-induced thiol-ene reaction. Then a macroCTA with eight CTA 
moieties on the POSS core was prepared through the esterification between hydroxyl-functionalised 
POSS and a carboxyl-terminated CTA. The macroCTA was used for the RAFT polymerisation of a 
fluoro monomer and PEG-based oligomer, affording star polymers with a POSS core. Owing to the 
presence of highly-mobile 
19
F units and a POSS cage with the potential for loading with a drug 
molecule, it is expected that these star polymers have the potential to be theranostic agents for 
19
F 
MRI and drug delivery. 
6.2 Experimental Section 
6.2.1 Materials  
Octavinyl POSS was purchased from Hybrid Plastics. Poly(ethylene glycol) methyl ether acrylate 
(PEGA, MW = 480) and 2,2,2-trifluoroethyl methacrylate (TFEA) were purchased from Sigma-
Aldrich and passed through basic alumina columns to remove inhibitors prior to use. 2-
Mercaptoethanol and 2,2-dimethoxy-2-phenylacetophenone (DMPA) were obtained from Sigma-
Aldrich and used as received. 2,2‟-Azobis(2-methylpropionitrile) (AIBN), was recrystallised from 
ethanol twice before use. 1,1‟-Azobis(cyclohexanecarbonitrile) (VAZO-88) was purchased from 
Sigma-Aldrich and used as received. 4-(Dimethylamino)pyridine (DMAP) and N,N‟-
dicyclohexylcarbodiimide (DCC, purchased from Alfa Aesar) were used as received. The 
trithiocarbonate chain transfer agent, 4-cyano-4-(((phenethylthio)carbonothioyl)thio)pentanoic acid 
(denoted as „CTA‟) was synthesised and purified according to a previously reported method.55 
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Milli-Q water with a resistivity of 18.4 MΩ cm-1 was used for the relevant experiments. 
Tetrahydrofuran (THF) and dichloromethane (DCM) were obtained from a solvent purification 
system (MB-SPS-800-Auto, Mbraun) and used directly. All other solvent were of analytical grade. 
6.2.2 Synthesis 
6.2.2.1 Synthesis of Hydroxyl-functionalised POSS (POSS-(OH)8 
Octavinyl POSS (5 g, 7.9 mmol), 2-mercaptoethanol (7.41 g, 0.095 mol) and the photoinitiator 
DMAP (0.243 g, 0.95 mmol) were mixed in 50 mL of THF in a 100 mL flask. Then the flask was 
sealed with a silicon septum and covered with aluminium foil, followed by purging with argon for 
20 min. The flask was subsequently exposed to UV irradiation (SunRay 600 UV flood curing 
system, UVitron) for 40 min at a constant power of 0.61 mW cm
-2
. After cooling to room 
temperature, the crude solution was concentrated by rotary evaporation and purified by precipitating 
in diethyl ether three times. A pale powder was obtained after drying in vacuum at room 
temperature for 24 h. Yield: 6.8 g, 68%. 
1
H NMR (700 MHz, DMSO-d6, ppm): 4.72 (t, 
1
H, 
CH2OH), 3.51 (q, 2H, CH2OH), 2.55 (q, 4H, CH2SCH2), 0.97 (t, 2H, SiCH2CH2S). 
13
C NMR (125 
MHz, DMSO-d6, ppm): 61.72 (CH2OH), 34.58 (CH2CH2OH), 26.29 (SiCH2CH2S), 13.55 
(SiCH2CH2S). 
6.2.2.2 Synthesis of POSS-based macroCTA (POSS-(CTA)8) 
POSS-(OH)8 (1.15 g, 0.92 mmol), CTA (3.7 g, 11 mmol) and DMAP (0.28 g, 2.31 mmol) were 
dissolved in 75 mL of THF, which was then purged with argon for 20 min in an ice bath. DCC 
(4.76 g, 23.1 mmol) in 25 mL of THF was injected to the flask over 10 min under argon 
atmosphere. The reaction was stirred at 0 
o
C for 1 h and then room temperature for 24 h. After 
reaction, the crude solution was filtered to remove the insoluble dicyclohexylurea precipitates. The 
filtrate was concentrated by rotary evaporation and purified by precipitating in hexane three times. 
After drying under high vacuum, a scarlet viscous oil was obtained. Yield: 3.17 g, 90%. 
1
H NMR 
(700 MHz, CDCl3, ppm): at 7.23-7.31 (m, 5H, C6H5 from the phenyl group), 4.24 (t, 2H, 
SCH2CH2O), 3.57 (t, 2H, S(C=S)SCH2CH2), 2.98 (t, 2H, S(C=S)SCH2CH2), 2.77 (t, 2H, 
SCH2CH2O), 2.65 (SiCH2CH2S), 2.38-2.52 (m, 4H, CH2CH2COO), 1.88 (s, 3H, 
SCCH3(CN)(CH2)), 1.05 (t, 2H, SiCH2CH2S). 
13
C NMR (125 MHz, CDCl3, ppm): at 216.84 
(carbon of trithiocarbonate group), 171.54 (COOCH2), 139.46 (the substituted carbon of phenyl 
group), 129.00, 128.87, 127.16 (rest five carbons in phenyl group), 119.22 (CN), 63.77 (COOCH2), 
46.80 (C(CH3)(CN)(CH2)) 38.27 (PhCH2CH2S), 34.35 (PhCH2CH2S), 34.14 (CH2CH2COO), 30.47 
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(SCH2CH2OOC), 30.03 (CH2CH2COO), 26.45 (SiCH2CH2), 25.18 (CH3C(CN)(CH2)), 13.29 
(SiCH2CH2). 
6.2.2.3 Synthesis of Star Polymers 
In a typical experiment, POSS-(CTA)8 (96 mg, 0.025 mmol), TFEA (0.462 g, 3 mmol), PEGA 
(3.36 g, 7 mmol) and AIBN (6.56 mg, 0.04 mmol) were dissolved in 10 mL of 1,4-dioxane in a 50 
mL flask. Feed ratio: [TFEA]/[PEGA]/[CTA]/[AIBN] = 15/35/1/0.2. The flask was then sealed with 
a rubber septum and purged with argon for 15 min before immersing in a 70 
o
C oil bath for 2 h. 
According to 
1
H NMR, the conversions of TFEA and PEGA were 73% and 60%, respectively. 
After polymerisation, ~1 mL of the crude solution was collected for characterisation, and the 
remainder was diluted to 30 mL in water and dialysed against water for 2 days using dialysis tubing 
with molecular-weight-cut-off (MWCO) of 100 kDa (Spectrum Laboratories Inc.). After 
lyophilisation, a yellowish viscous oil was obtained. Yield: 0.56 g, 22%. This sample was denoted 
as SP-1. 
  Two additional samples were synthesised by varying the monomer to CTA ratios under the same 
conditions, and purified using the same procedure. For the sample SP-2 synthesised using a feed 
ratio of [TFEA]/[PEGA]/[CTA]/[AIBN] = 30/70/1/0.2, the conversions of TFEA and PEGA were 
68% and 55%, respectively. Yield: 0.97 g, 44%. For the sample SP-3 synthesised using a feed ratio 
of [TFEA]/[PEGA]/[CTA]/[AIBN] = 45/105/1/0.2, the conversions of TFEA and PEGA were 65% 
and 52%, respectively. Yield: 0.73 g, 35%. 
6.2.3 Characterisation 
Gel Permeation Chromatography (GPC)  
Molecular weights and molecular weight distributions were determined by GPC using a Waters 
Alliance 2690 Separations Module equipped with Waters 2414 Refractive Index (RI) Detector, 
Waters 2489 UV/Visible Detector, Waters 717 Plus Autosampler and Waters 1515 Isocratic HPLC 
Pump. Samples were dissolved in THF and passed through 0.45 µm filters before each 
measurement. THF was used as the mobile phase at a flow rate of 1 mL min
-1
. The system was 
calibrated using polystyrene (PS) standards, to which the number average molecular weight (Mn) 
and weight average molecular weight (Mw) were referenced.  
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Fourier Transform Infrared (FTIR) Spectroscopy 
FTIR spectra were recorded on a Nicolet 5700 FTIR spectrometer (Thermo Electron Corporation) 
equipped with a Nicolet Smart Orbit ATR accessory having a diamond internal reflection element. 
Spectra were collected in the range of 4500 ‒ 525 cm-1 with a scan number of 64 and resolution of 4 
cm
-1
. 
1
H and 
13
C Nuclear Magnetic Resonance (NMR)  
1
H NMR and 
13
C NMR were performed on a Bruker Avance 700 MHz spectrometer at 25 
o
C using 
an internal lock (CDCl3 or DMSO-d6) and referenced to the residual non-deuterated solvent. 
1
H-
1
H 
Correlation spectroscopy (COSY), 1H-13C heteronuclear multiple-bond correlation (1H-13C HMBC), 
1
H-
13
C heteronuclear single quantum coherence (
1
H-
13
C HSQC) and distortionless enhancement by 
polarisation transfer (DEPT) 
13
C NMR spectra were recorded on a Bruker Avance 700 MHz using 
CDCl3 as solvent at 25 
o
C. 
Dynamic Light Scattering (DLS)  
DLS measurements were carried out on a Nanoseries Zetasizer (Malvern, UK) at 25 
o
C. Star 
polymers were dissolved in PBS at a concentration of 1 mg mL
-1
 and passed through 0.45 µm filters 
to remove dust particles prior to each measurement. Each hydrodynamic diameter was the average 
value of 3 measurements. To minimise the possible influence of large aggregates, number-averaged 
diameters are reported.  
19
F Nuclear Magnetic Resonance (
19
F NMR)  
All 
19
F NMR spectra were acquired at 659 MHz on a Bruker Avance 700 MHz spectrometer. The 
samples were prepared by dissolving the polymers in PBS/D2O (90/10, v/v) at a concentration of 20 
mg mL
-1
. All measurements were performed at 25 
o
C. A 90
o
 pulse of 15.1 µs was used in all 
measurements, the relaxation delay was 2 s and the acquisition time was 0.18 s. Data were collected 
using a spectrum width of 46 kHz, 16k data points and 64 scans. 
  
19
F spin-spin relaxation times (T2) were measured using the Carr-Purcell-Meiboom-Gill (CPMG) 
pulse sequence at 25 
o
C. The samples were dissolved in PBS/D2O (90/10, v/v) at a concentration of 
20 mg mL
-1
. The relaxation delay was 2.3 s and the acquisition time was 0.18 s. For each 
measurement, the echo times were from 2 to 770 ms and 15 points were collected, which could be 
described by exponential functions for the calculation of T2. 
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19
F spin-lattice (T1) relaxation times were measured using the standard inversion-recovery pulse 
sequence. The relaxation delay was 2.5 s and the acquisition time was 0.18 s. For each 
measurement, the recovery times were from 2 ms to 3 s and 15 points were acquired.  
6.3 Results and Discussion 
6.3.1 Design Concept  
The aim of this work was to synthesise star polymers with a POSS core and partly-fluorinated and 
water-soluble arms for potential applications as theranostic agents. The synthetic route is described 
in Figure 6-1. Vinyl-functionalised POSS was first reacted with 2-mercaptoethanol via UV-induced 
thiol-ene reaction to introduce hydroxyl groups to the POSS. Then CTA-functionalised POSS, a 
macroCTA, was synthesised through the standard DCC/DMAP esterification between hydroxyl-
functionalised POSS and carboxyl-terminated CTA molecules. The macroCTA was utilised for the 
RAFT copolymerisation of 2,2,2-trifluoroethyl methacrylate (TFEA) and poly(ethylene glycol) 
methyl ether acrylate (PEGA), yielding star polymers with a POSS core and P(TFEA-co-PEGA) 
arms. As reported in Chapter 5, P(TFEA-co-PEGA) copolymers are excellent candidates as contrast 
agents for 
19
F MRI because of the high mobility of the fluorine units in the polymer chain even with 
high molar fractions of TFEA. Therefore the multifunctional star polymers can be used for MRI and 
drug delivery. To be more specific, the arms are expected to be 
19
F MRI visible, while the POSS 
core has the potential to load drug molecules.  
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Figure 6-1 Schematic illustration of the synthesis of hydroxyl-functionalised POSS (POSS-(OH)8), 
CTA-functionalised POSS (POSS-(CTA)8) and star polymers with a POSS core and P(TFEA-co-
PEGA) copolymer arms. 
6.3.2 Synthesis of POSS-(OH)8 and POSS-(CTA)8 
Octavinyl POSS was reacted with 2-mercaptoethanol in THF by UV-mediated thiol-ene chemistry. 
The conversion was monitored by 
1
H NMR, and the samples were characterised by 
1
H and 
13
C 
NMR. In Figure 6-2 (A), multiple peaks of vinyl protons were found at 6.0~6.2 ppm for octavinyl 
POSS, and these peaks disappeared after 40 minutes of UV radiation, indicating the high efficiency 
of UV-induced thiol-ene reaction. The absence of vinyl peaks was also revealed by the spectrum of 
POSS-(OH)8, implying that all the eight vinyl groups were functionalised (see enlarged 
1
H NMR 
spectra in Appendix E Figure A6.1). In addition, all the characteristic proton peaks of POSS-(OH)8 
can be assigned in the spectrum (Figure 6-2 (A)) and the integrals matched the chemical structure 
(see Appendix E Figure A6.1). The 
13
C NMR spectrum in Figure 6-2 (B) further confirmed the 
chemical structure of POSS-(OH)8 with all the carbons assigned. The chemical structure was also 
verified by the relevant correlations in 
1
H-
1
H COSY spectrum ((see Appendix E Figure A6.1)). 
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These combined NMR results indicate the efficient functionalisation of octavinyl POSS with 2-
mercaptoethanol by UV-induced thiol-ene reaction. 
 
Figure 6-2 
1
H NMR (A) and 
13
C NMR (B) spectra of octavinyl POSS and POSS-(OH)8 in DMSO-
d6 at 25 
o
C. 
  In the next step, the POSS-(OH)8 was further reacted with 4-cyano-4-
(((phenethylthio)carbonothioyl)thio)pentanoic acid, which is a trithiocarbonate chain transfer agent 
(CTA) for RAFT polymerisation. The esterification was carried out in THF in the presence of 
DMAP/DCC at room temperature for 24 h. The resultant product was characterised by NMR 
techniques. In Figure 6-3 (A), the disappearance of the peak of hydroxyl group proton at 4.72 ppm 
was monitored, suggesting the successful attachment of eight CTA moieties to a POSS core by 
esterification. Owing to the complexity of the structure, the assignment of the NMR peaks was 
assisted by DEPT 
13
C NMR and 2D NMR (
1
H-
1
H COSY and 
1
H-
13
C HSQC) spectra (see Appendix 
E Figure A6.2 and 6.3). As shown in Figure 6-3 (A), all the characteristic peaks were found and 
assigned in 
1
H NMR spectrum, including the peaks of POSS-(OH)8 and CTA units. For example, 
the multiple peaks at 7.23~7.31 ppm are attributed to the protons of the phenyl group, and the peak 
at 1.05 is ascribed to the CH2 adjacent to the Si atom. In addition, the integral ratios were calculated 
to be in accord with the illustrated chemical structure. In Figure 6-3 (B), the 
13
C NMR spectrum is 
in good agreement with the 
1
H NMR results with all the relevant peaks assigned, such as the peaks 
at 216.84 (trithiocarbonate carbon), 171.54 (carbonyl carbon), 119.22 (CN group) and 13.29 ppm 
(the carbon adjacent to Si). The NMR results confirmed the successful synthesis of POSS-(CTA)8 
macroCTA with the targeted chemical structure and high yield (90%). 
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Figure 6-3 
1
H NMR (A) and 
13
C NMR (B) spectra of POSS-(CTA)8 in CDCl3 at 25 
o
C.  
6.3.3 Synthesis of Star Polymers using POSS-(CTA)8 as a MacroCTA 
The POSS-(CTA)8 was used as a macroCTA for the RAFT copolymerisation of 2,2,2-trifluoroethyl 
methacrylate (TFEA) and poly(ethylene glycol) methyl ether acrylate (PEGA) monomers, resulting 
in star polymers with a POSS core and eight P(TFEA-co-PEGA) copolymer arms. As the CTA 
molecules were connected to the POSS core via the R-group, this synthetic route can be classified 
as an R-group approach for the synthesis of star polymer by RAFT polymerisation and a "grafting 
from" method for the surface functionalisation. The detailed mechanism is illustrated in Scheme 6-
1.
35, 38, 56
 A propagating radical (Pn•) is formed after initiation process, then it transfers to the 
macroCTA to form a new radical anchored on the POSS core and a linear polymer with 
thiocarbonylthio group. This step implies that the synthesis of star polymer by R-group approach is 
accompanied by the generation of linear polymers. The new radical reacts with monomers to 
produce a new propagating radical (Pn•) located on the POSS core, which can continue to react with 
either macroCTA or linear polymer with thiocarbonylthio group during the chain equilibration, 
forming the targeted star polymers with thiocarbonylthio functionalities. As the chain equilibration 
between propagating radicals and dormant compounds is very fast, the arms and linear polymers are 
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growing with identical compositions and narrow molar mass distributions, and the degree of 
radical-radical termination is minimised as well. Generally, the polymerisation can be terminated by 
radical-radical termination between linear chains. However, due to the presence of multiple radicals 
on a core, star-star and star-linear couplings are also possible terminations, broadening the molar 
mass distribution of the final product.  
 
Scheme 6-1 Mechanism for the synthesis of star polymers using R-group approach by RAFT 
polymerisation. 
  According to the mechanism of R-group approach, the final product contains the targeted star 
polymer as well as those unwanted by-products formed by star-star, star-linear and linear-linear 
terminations. The increase of star polymer yield can be achieved by minimising the termination 
reactions, including: (1) using low initiator concentration, (2) reducing arm number, (3) introducing 
a stable intermediate as a „radical storage reservoir, and (4) using monomers that have fast 
propagating rates.
35, 57
 In addition, high temperature may be beneficial for increasing star polymer 
yield because it can shorten the polymerisation time by accelerating the propagating rate of 
monomer at a low radical concentration.
35
 Moreover, stopping the reaction at low monomer 
conversion is another common option as this can minimise the termination reactions.
36
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  We first attempted to synthesise star polymers in 1,4-dioxane using AIBN as initiator at 70 
o
C. 
The polymerisation kinetics were studied by analysing the samples withdrawn at given time 
intervals using GPC and 
1
H NMR. In Figure 6-4 (A), both TFEA and PEGA were consumed at 
similar rates, indicating the formation of P(TFEA-co-PEGA) arms with azeotropic composition. 
The low monomer conversions (< 20%) in the first three hours could be attributed to a low initiator 
concentration (1/10 of CTA) and a possible inhibition time. As shown in Figure 6-4 (B), the 
ln([M0]/[M]) was almost linear with time from 2 to 7 h, indicating a reasonable „controlled‟ 
polymerisation by RAFT process. However, the deviation from linearity revealed that the radical 
concentration was not ideally constant due to radical-radical termination reactions.  
 
Figure 6-4 GPC traces of the samples withdrawn at different time intervals using AIBN as initiator. 
Condition: POSS-(CTA)8/TFEA/PEGA/AIBN = 1/200/200/0.8, [monomer] = 1 M in 1,4-dioxane, 
70 
o
C. The percentage of star polymer in the polymer mixture was estimated by the deconvolution 
of GPC curves. 
  In Figure 6-4 (C), the GPC curve evolves toward short retention (high molecular weight) with 
polymerisation time. Notably, the curves for 5 and 7 h display multiple peaks. To be more specific, 
the peaks at ~16.5 min can be ascribed to the linear polymers produced during the RAFT 
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polymerisation, as illustrated in Scheme 6-1. The narrow peaks at ~14.5 min are due to the presence 
of star polymers, while the broad peaks at 12~14 min can be presumably attributed to the polymers 
formed by star-star coupling. The star polymer yield was estimated to be 74% and 65% after 5 and 
7 h, respectively, by the deconvolution of GPC curves. As shown in Figure 6-4 (D), the molar mass 
distribution (ĐM) was narrow (< 1.5), confirming the relatively well-defined structure by RAFT 
polymerisation. It should be noted that the molecular weights measured by GPC were found to be 
underestimates. Compared to linear polymers, star polymers were more compact and had different 
hydrodynamic volumes. Therefore conventional GPC, which was referenced to linear polystyrene 
standards, generated underestimated results. We suggest that 
1
H NMR was suitable for the 
estimation of the absolute molecular of the star polymers due to the relatively well-defined structure 
(eight arms). 
  A parallel experiment was also carried out using 100% larger concentration of AIBN (1/5 of CTA) 
to study the effect of initiator concentration. As shown Figure A6.4 in Appendix E, the monomer 
conversions reached 69% and 58% after 2 h for TFEA and PEGA, respectively, indicating an 
accelerated polymerisation by increased radical concentration. Star polymers with a yield of 72% 
and ĐM of 1.55 were obtained. These results suggest that the increase of AIBN from 1/10 to 1/5 of 
CTA increased the polymerisation rate while it had little effect to the star polymer yield or molar 
mass distribution. 
  In an attempt to increase the star polymer yield, VAZO-88 was then selected as initiator for the 
synthesis of star polymers at 90 
o
C. VAZO-88 is a well-known radical initiator that has relatively 
high decomposition temperature.
58
 The half-life time of VAZO-88 at 90 
o
C was calculated to be 7.6 
h using activation energy decomposition Ea = 149.1 kJ mol
-1
 and Arrhenius pre-exponential factor 
A = 7.1 × 10
16
 s
-1
, while the half-life time of AIBN at 70 
o
C was calculated to be 5.0 h using 
activation energy decomposition Ea = 131.7 kJ mol
-1
 and Arrhenius pre-exponential factor A = 4.31 
× 10
15
 s
-1
.
58
 By using VAZO-88 at 90 
o
C, the polymerisation time is expected to be shortened due to 
the increased propagating rates of the monomers, although the radical concentration was reduced 
compared to the polymerisation using AIBN . Thus the star polymers could be synthesised at a low 
radical concentration, which can possibly minimise radical-radical terminations. The polymerisation 
kinetics were investigated by motoring the polymerisation progress using GPC and 
1
H NMR. In 
Figure 6-5 (A), unlike the use of AIBN at 70 
o
C, both TFEA and PEGA were consumed very 
rapidly, reaching monomer conversions at ~80% within 3 h and ~90% after 6 h. This result 
indicates that the increase of polymerisation temperature greatly increased the propagating rates of 
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monomers. In addition, the polymerisation exhibited pseudo-first-order kinetics (Figure 6-5 (B)), 
suggesting a well-controlled RAFT polymerisation. The formation of star polymers was evidenced 
by the GPC results shown in Figure 6-5 (C) and (D). The molecular weight increased with 
polymerisation time, and the GPC traces were multimodal. The peaks of star polymers were found 
to be at 14.6~15.3 min with narrow ĐM (< 1.6), while the generation of linear polymers was 
confirmed by the peaks at ~17 min. In addition, the star-star termination is observed by the peaks at 
12~14 min. However, compared to the polymerisation using AIBN at 70 
o
C, the star-star coupling 
here is much less significant. We thus propose that the star-star termination was suppressed owing 
to the reduced radical concentration by using VAZO-88 at 90 
o
C. 
 
Figure 6-5 GPC traces of the samples withdrawn at different time intervals using VAZO-88 as 
initiator. Condition: POSS-(CTA)8/TFEA/PEGA/VAZO-88 = 1/200/200/0.8, [monomer] = 1 M in 
1,4-dioxane, 90 
o
C. The percentage of star polymer in the polymer mixture was estimated by the 
deconvolution of GPC curves.  
  The synthesis of star polymers was also conducted using different ratios of monomer to CTA. In 
Figure 6-6, the molecular weight of star polymers were increased by increasing the 
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[monomer]/[CTA] ratio from 25/1 to 100/1. However, the yield of star polymers was reduced from 
91% to 61%. We suggest that the chain equilibrations between the active propagating radicals on 
the POSS core and dormant thiocarbonylthio functionalities in linear and star intermediates were 
hampered owing to the increased steric hindrance around the POSS core, leading to the decreased 
star polymer yield. The copolymer arms have brush-like structure because of PEGA units, and 
hence the chain equilibrations are likely to be more restricted by the shielding effect of polymer 
brushes as the polymerisation proceeds. As reported by Perrier and Zhao, the introduction of free 
CTA was significantly beneficial to the control of molecular weight and dispersity during the 
grafting of polymers onto silica particles using Z-group approach.
59
 Very recently, Müller and co-
workers reported in a similar manner that the active free radicals were entrapped in the synthesis of 
well-defined cylindrical polymer brushes, and that this could be overcome by addition of free CTA 
molecules to the polymerisation as shuttles to transport radicals.
60
  
 
Figure 6-6 GPC traces (left) and GPC details (right) of the samples synthesised using different 
[monomer]/[CTA] ratios. Condition: POSS-(CTA)8/TFEA/PEGA/AIBN = 1/100-400/100-400/1.6, 
[monomer] = 1 M in 1,4-dioxane, 70 
o
C, 2 h.  
  Three star polymers having different arm length were synthesised using different monomer to 
CTA ratios, and the molecular details are summarised in Table 6-1. Star polymers with narrow ĐM 
(~1.4) were obtained. The increase of monomer to CTA feed ratio resulted in the increase of degree 
of polymerisation (by 
1
H NMR) and Mn (by GPC). In addition, the molar fraction of TFEA (~33%) 
was consistent with the TFEA/PEGA feed ratio (3/7) for all the three samples, implying that the 
TFEA and PEGA were polymerised at close rates. Nanoparticles were formed with diameters 
between 8.63 and 10.13 nm and measured using DLS following direct dissolution of the star 
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polymers in pure water. The increase of hydrodynamic diameter was in agreement with the increase 
of arm length and molecular weight. 
Table 6-1 Characteristics of the three star polymers. 
Sample
a
 Composition
b
 
(TFEA:PEGA:CTA) 
Mn
b
 
(
1
H NMR) 
Mn
c
 
(GPC) 
Mw/Mn
c
 Dh (nm)
d
 
SP-1 25:52:1 234k 71k 1.44 8.63±0.34 
SP-2 34:69:1 311k 87k 1.39 9.17±0.19 
SP-3 54:107:1 481k 102k 1.39 10.13±0.34 
a
 Polymerisation condition: POSS-(CTA)8/TFEA/PEGA/AIBN = 1/120/280/1.6 for SP-1, POSS-
(CTA)8/TFEA/PEGA/AIBN = 1/240/560/1.6 for SP-2, POSS-(CTA)8/TFEA/PEGA/AIBN = 
1/360/840/1.6 for SP-3, [monomer] = 1 M in 1,4-dioxane, 70 
o
C, 2 h. 
b
 The degree of 
polymerisation was determined by 
1
H NMR. Mn (
1
H NMR) = (MWPEGA × DPPEGA + MWTFEA × 
DPTFEA) × 8+ MWmacroCTA. 
c
 Measured by GPC. 
d
 Hydrodynamic diameter (Dh) was analysed by 
DLS in pure water at 25 
o
C, and number-averaged diameters are reported.  
  The star polymers were purified by dialysing against water for two days using dialysis tubing with 
100 kDa molecular-weight-cut-off (MWCO). In Figure 6-7, the GPC curve for the purified sample 
indicates that most of the linear polymer impurities were removed by dialysis. In addition, the peak 
of the by-products formed by star-star coupling almost disappeared. Indeed, the dialysis using 
membrane with MWCO as large as 100 kDa removed polymers with a wide range of molecular 
weights, including linear polymers, targeted star polymers and by-products with higher molecular 
weights. This was revealed to some extent by the relatively low yield after dialysis (22% for SP-1, 
44% for SP-2 and 35% for SP-3). Star polymers SP-2 and SP-3 were also purified using the same 
procedure (see Appendix E Figure A6.5 for GPC curves). 
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Figure 6-7 GPC curves of SP-1 before and after dialysis using dialysis tubings with 100 kDa 
MWCO. 
  The POSS-based precursors and purified star polymers were characterised by ATR-FTIR 
spectroscopy, and the resultant spectra are displayed in Figure 6-8. For the original octavinyl POSS, 
the characteristic peaks can be found at ~3000 cm
-1
 (C-H stretching vibration), 1603 cm
-1
 (C=C 
stretching vibration) and 1097 cm
-1
 (Si-O-Si stretching vibration). In the spectrum of POSS-(OH)8, 
the hydroxyl functionalisation was confirmed by the peak at 3354 cm
-1
 (-OH stretching vibration) 
and absence of the C=C peak at 1603 cm
-1
. In the spectrum of POSS-(CTA)8, the peak at 3354 cm
-1
 
for -OH groups disappeared, indicating the complete esterification between POSS-(OH)8 and CTA. 
In addition, the attachment of CTA to POSS was also revealed by a number of characteristic peaks 
at 3000~3100 cm
-1
 (aromatic C-H stretching vibration), 2115~2230 cm
-1
 (C≡N stretching 
vibration), 1734 cm
-1
 (C=O stretching vibration), 1600~1640 cm
-1
 (aromatic ring stretching 
vibration), etc. In the spectra for the star polymers, the peaks assigned to the copolymer arms can be 
clearly seen, such as the peaks at ~2860 cm
-1
 (C-H stretching vibration), 1450 cm
-1
 (CH3 anti-
symmetric deformation), 1350 cm
-1
 (C-F stretching vibration) and 1100 cm
-1
 (C-O-C stretching 
vibration). Moreover, the peaks of POSS-(CTA)8 were also found in the spectra of star polymers. 
The FTIR spectra provided additional evidence for the successful functionalisation of octavinyl 
POSS and the synthesis of star polymers using a POSS-based macroCTA.  
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Figure 6-8 FTIR spectra of the POSS-based precursors and star polymers. 
  The macroCTA and purified star polymers were analysed by 
1
H NMR. In Figure 6-9, the peaks of 
TFEA and PEGA units can be found in the spectra of star polymers, such as peaks at 4.51 ppm 
(CH2 adjacent to CF3), 4.18 ppm (neighbouring CH2 of COO in PEGA), 3.38 ppm (CH3 end group 
of PEGA), 1.6~2.3 ppm (protons in polymer backbone), etc. In addition, the characteristic peaks of 
CTA moieties are also identified, including peaks at 7.24~7.32 ppm (protons in phenyl group), 2.99 
(CH2 connected to the phenyl group), 1.04 ppm (CH2 adjacent to Si), and those peaks highlighted 
by the blue circle. Moreover, the peaks at 4.51 (for TFEA) and 4.18 ppm (for PEGA) were 
relatively symmetric, implying a single chemical environment due to the even distribution of TFEA 
and PEGA in the statistical copolymers. This is because TFEA and PEGA have the possibly close 
reactivity ratios. In Chapter 5, we have reported that gradient copolymers were obtained on the 
polymerisation of TFEA and poly(ethylene glycol) methyl ether methacrylate (PEGMA), which 
possess largely different reactivity ratios, and multiple chemical environments of TFEA and 
PEGMA were detected by both 
1
H and 
19
F NMR. The existence of peaks attributed to the CTA end-
group confirmed the retention of CTA functionalities in the star polymers. Furthermore, the small 
single peak at 4.86 ppm could be assigned to the methine proton in TFEA back bone adjacent to the 
trithiocarbonate group, as evidenced by 
1
H-
13
C HSQC and HMBC spectra (see Appendix E Figure 
A6.6). Similar observation has also been reported in a recent paper.
51
 According to the integral ratio 
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of the peak at 4.86 to the peak at 4.51 ppm, the P(TFEA-co-PEGA)arms in which there are TFEA 
units directly connected to the trithiocarbonate account for 76% of the total arms, indicating the 
preference of TFEA units being positioned directly to trithiocarbonate during the copolymerisation.  
 
Figure 6-9 
1
H NMR spectra of the POSS-(CTA)8 and star polymers in CDCl3 at 25 
o
C. 
6.3.4 19F NMR Studies 
One aim of this study was to utilise the star polymers as contrast agents for 
19
F MRI. As discussed 
in Chapter 5, P(TFEA-co-PEGA) copolymers are advantageous for 
19
F MRI because of the evenly 
distributed fluorine units in the copolymers, resulting in a single and strong 
19
F signal even with 
high 
19
F content. The star polymers were dissolved in PBS/D2O (90/10, v/v) at 20 mg mL
-1
 and 
evaluated by 
19
F NMR at 25 
o
C. As shown in Figure 6-10, a strong and symmetric peak was 
observed at around -73.4 ppm for all three star polymers, suggesting an identical chemical 
environment of the fluorine units.  
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Figure 6-10 
19
F NMR spectra of the star polymers. 
  The 
19
F NMR properties of the star polymers are listed in Table 6-2. All the three star polymers 
possess a close fluorine atom content of ~5.0 wt%, indicating a close TFEA/PEGA ratio in the 
copolymers. The spin-spin (T2) and spin-lattice (T1) relaxation times were measured by 
19
F NMR at 
659 MHz using a Bruker Avance 700 MHz spectrometer. The T2 is determined by the strength of 
the dipolar coupling of the 
19
F nuclei with the surrounding fluorine and proton nuclei, and hence is 
sensitive to the chemical environment of the 
19
F nuclei and their relative mobility. The T2 relaxation 
time was increased slightly with the arm length, indicating that longer arms had higher segmental 
flexibility and fluorine mobility. Meanwhile, the T1 relaxation time showed minimal variation 
between samples, suggesting that the spectral density of the 
19
F motion in the range of 700 MHz 
was not significantly affected by the change in arm length. 
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Table 6-2 
19
F NMR properties of the star polymers. 
Sample 
19
F wt%
a
 T2 (ms)
b
 T1 (ms)
b
 Half width 
(Hz)
c
 
19
F MRI Intensity
d
 
SP-1 4.9 37.0 (37.7)
d
 328.6 (328.3)
e
 345 13.93 
SP-2 5.0 42.1 329.6 353 16.24 
SP-3 5.1 44.7 331.8 358 17.52 
a
 Fluorine content was determined by 
1
H NMR. 
b
 Spin-spin (T2) and spin-lattice (T1) relaxation 
times were measured by 
19
F NMR using Carr-Purcell-Meiboom-Gill (CPMG) and inversion-
recovery pulse sequences, respectively. 
c
 The peak width at half height was obtained from the 
19
F 
NMR spectra. 
d
 
19
F MRI Intensity was calculated using Equation (6-1). 
e
 The relaxation times in the 
brackets were measured for SP-1 before dialysis. 
  The relaxation times of SP-1 before dialysis (denoted as „crude SP-1‟) were also examined to 
study the influence of linear impurities on 
19
F NMR properties. As provided in the brackets in Table 
6-2, the T2 relaxation time of crude SP-1 was measured to be 37.7 ms, slightly higher than that of 
the dialysed sample, revealing higher average fluorine mobility. Since the percentage of by-
products formed by star-star coupling is negligible (~2 wt% by GPC), we suggest that the longer T2 
of crude SP-1 could be mainly attributed to the presence of linear polymers, which was likely to 
have higher fluorine mobility than their counterparts connected to a rigid POSS core. Such 
explanation can be supported by the results studied in Chapter 5, in which the linear analogue 
possessed a longer T2 than the highly-branched polymers having same composition and fluorine 
content. As expected, T1 was nearly constant, implying the little effect of polymer architecture on 
T1. 
  In Chapter 5, a segmented highly-branched polymer (SHBP-10) was synthesised and it was 
constructed of P(TFEA17-co-PEGA37) chains, which had the same components and a very close 
fluorine content (4.8%) to the arms of the star polymers in this work. The T2 and T1 of SHBP-10 
were measured under the same conditions and found to be 51.7 and 330.0 ms, respectively. This 
implies that the copolymers in a highly-branched structure with low degree of branching are more 
segmentally flexible than those anchored on the POSS core. We thus speculate that the fluorine 
units in the arms of star polymers are less mobile than those positioned in a highly-branched 
architecture owing to a possibly more confined environment around the core. In addition, the little 
Chapter 6 Partly-Fluorinated Star Polymers with a POSS core for F-19 MRI 
 
 
179 
 
effect of polymer architecture on T1 relaxation time was further proved by the very small variation 
of T1 values. 
  For 
19
F MRI using a spin-echo pulse sequence, the imaging intensity can be calculated using the 
following equation.
61
 
 
 
(6-1) 
  In Equation (6-1), I is the imaging intensity, N(F) is a measure of the number of fluorine nuclei in 
the sensitive volume of the imaging coil, and TR and TE are the pulse sequence repetition time and 
echo delay times, respectively. According to this equation, an efficient contrast agent for 
19
F MRI 
should possess high fluorine content, long T2 and short T1. The 
19
F MRI intensity values were 
estimated using Equation (6-1). The parameters used in Chapter 5 for the RARE-8 pulse sequence 
were adopted for the simulation, i.e, TE = 41 ms, TR = 1 s, sample concentration = 100 mg mL
-1
. 
The intensity values were calculated to be from 13.93 to 17.52, increasing with the fluorine content 
and T2. These intensity values are relatively close to that of SHBP-9 (17.6) in Chapter 5. As studied 
in Chapter 5, SHBP-9 was well imaged using several pulse sequences (FLASH, RARE-8 and 
RARE-32). For example, the signal-to-noise ratio (SNR) was calculated to be as high as 48.42 
using RARE-8 spin-echo pulse sequence with a scan time of 1 h and 46 minutes. Therefore we 
expect that the star polymers have the comparable imaging property as SHBP-9 because they have 
the similar copolymer chains as well as relatively close theoretical MRI intensities. The favourable 
19
F NMR properties of these star polymers are in agreement with the observations in Chapter 5, and 
thus further confirmed that P(TFEA-co-PEGA) copolymers are excellent materials for the 
fabrication of 
19
F MRI agents based on star and hyperbranched polymers owing to the highly 
mobile 
19
F nuclei and high fluorine content.  
6.4 Conclusions 
This chapter reports the synthesis of star polymers with a POSS core as potential theranostic agents. 
Octavinyl POSS was functionalised with hydroxyl groups by the UV-induced thiol-ene reaction. 
The macroCTA having eight CTA moieties on a POSS core was synthesised through the 
esterification between hydroxyl-functionalised POSS and carboxyl-terminated CTA. Star polymers 
consisting of eight partly-fluorinated copolymer arms and a POSS core were synthesised by the 
RAFT copolymerisation of fluoro monomer and PEG-based monomer using the POSS-based 
macroCTA. The synthesis of star polymers was accompanied by the formation of linear polymers 
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and polymers formed by star-star terminations, as was evidenced by the kinetics study. Star 
polymers with different arm length were synthesised by varying the feed ratio of monomer to CTA, 
and were purified by extensive dialysis in water. The evenly distributed fluorine units in the arms 
were observed by 
1
H NMR. Nanoparticles with diameters of 8~10 nm were formed by dissolving 
the star polymers in water, and the particle size increased with arm length. The single fluorine 
chemical environment was confirmed by a single peak in the 
19
F NMR spectra. The T2 relaxation 
time was increased with arm length. The T2s were shorter than those of linear (main impurities in 
this Chapter) and highly-branched (polymers in Chapter 5) analogues, indicating that the fluorine 
nuclei were less mobile in the arms of star polymers because of the possibly confined environment 
around the POSS core. The theoretical values of 
19
F MRI intensity were estimated, and confirmed 
that the star polymers showed potential for use as 
19
F MRI agents with high imaging intensity. 
  As stated in the Introduction, the POSS core has the potential to be exploited for encapsulating 
drug/gene/dye molecules. In addition, the trithiocarbonate could be utilised for conjugation 
reactions after aminolysis, as demonstrated previously.
51
 Therefore these multifunctional star 
polymers with a POSS core and partly-fluorinated arms are promising theranostic agents for cancer 
diagnosis and treatment.  
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Chapter 7  
Conclusions 
7.1 Overall Conclusions 
This thesis focuses on the design, synthesis and evaluation of multifunctional polymer nanoparticles 
as next-generation contrast agents for 
19
F MRI. The development of highly–efficient contrast agents 
is crucial for the maturing and popularisation of 
19
F MRI for biomedical diagnosis. In addition, a 
molecular level understanding is required for the design and applications of polymeric 
19
F MRI 
agents. Therefore this thesis aimed to develop multifunctional polymers with various architectures 
for 
19
F MRI-related applications and ultimately build a fundamental understanding of the 
relationship between molecular structure and imaging property. 
  The initial work was started by the design of star-like hyperbranched polymers as pH-responsive 
contrast agents for selective 
19
F MRI, as detailed in Chapter 2. The aim was to study how the 
19
F 
mobility could be tuned using a pH-responsive hyperbranched structure. Star-like hyperbranched 
polymers were synthesised using the arm-first approach by reversible addition-fragmentation chain 
transfer (RAFT) polymerisation. In those water-soluble molecules, the pH-responsive 
hyperbranched core consisted of TFEA and DMAEMA units, while the hydrophilic arms were 
composed of PPEGMA brush-like polymers. Nanoparticles were formed by dissolving the star-like 
polymers in aqueous solution, and the particle size was found to be highly dependent on the pH. 
The 
19
F signal intensity was dramatically decreased when the solution pH was above the pKa of 
DMAEMA. The spin-spin (T2) relaxation time was strongly related to both the 
19
F content and the 
change in particle conformation. A strong 
19
F signal and long T2 were only achieved under acidic 
conditions (pH < 6.5) owing to the enhanced mobility of the fluorinated segments. In contrast, the 
T2 relaxation time was significantly reduced above the pKa. The T1 relaxation time was not affected 
significantly by the change in solution pH. A strong dependence of imaging performance on pH was 
confirmed by in vitro 
19
F MRI, suggesting potential applications of these polymeric CAs for 
selective 
19
F MRI in the diagnosis of cancer tissue. 
  To study the effect of placement of 
19
F nuclei in the arms of star polymers, CCS polymers were 
synthesised by RAFT dispersion polymerisation and evaluated as 
19
F MRI agents, as reported in 
Chapter 3. The densely-crosslinked core contained disulfide bonds, and the partly-fluorinated arms 
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were comprised of PPEGMA-b-P(TFEMA-co-DMAEMA) block copolymers. The synthetic 
conditions were studied and optimised. Nanoparticles of the CCS polymers were formed in aqueous 
solution by direct dissolution, and the particle size was dependent on pH owing to the presence of 
the pH-responsive DMAEMA units. The biodegradability was confirmed by treatment with 
reducing agents. The 
19
F signal intensity and T2 relaxation time decreased with an increase of pH of 
the polymer solution. As revealed by in vitro 
19
F MRI, the CCS polymers could be imaged well at 
acidic pH while they had poor imaging performance above the pKa of DMAEMA, demonstrating 
that these CCS polymers are promising 
19
F MRI contrast agents for the selective imaging of tumour 
tissues. Compared to the star-like polymers described in Chapter 2, one of the CCS polymers (CCS-
1) had a close 
19
F content but could be imaged in greatly shortened time (from 9 h 6 min to 1 h 8 
min), suggesting that the mobility of the 
19
F nuclei in a star polymer architecture could be enhanced 
by placing the fluorine segments in the flexible arms rather than in a relatively confined crosslinked 
(or hyperbranched) structure. It should be stressed that CCS polymers contained TFEMA segments 
that have a higher glass transition temperature than TFEA units, and thus are less preferable for 
19
F 
imaging agents due to the restricted 
19
F motion and shortened T2 relaxation time. However, the 
imaging performance of CCS polymers was none-the-less improved compared with its counterparts 
consisting of TFEA units, implying that the polymer architecture played an important role in the 
imaging properties. 
  In Chapter 4, multifunctional hyperbranched polymers containing iodine and fluorine (HBIPFs) 
were designed for CT/
19
F MRI bimodal imaging. Hyperbranched polymers consisting of iodo-
monomer and PEGMA units were prepared by RAFT polymerisation, and then chain extended with 
TFEA and PEGMA. HBIPFs with different contents of iodine and fluorine were obtained by 
varying the monomer feed ratio. The HBIPFs could be degraded by treatment with reducing agents 
such as GSH and TCEP. Nanoparticles were formed with diameters between 10~15 nm by direct 
dissolution of the HBIPFs in water. The radio-opacity of these nanoparticles in aqueous solution 
was confirmed by in vitro CT experiments, while the solutions of the nanoparticles could be 
visualised by 
19
F MRI. These results suggest that hyperbranched polymer is a promising platform 
for the design of molecular imaging agents for CT/
19
F MRI bimodal imaging. 
  The effect of polymer architecture on imaging performance was evidenced by the study on star 
and hyperbranched polymers. An in-depth understanding on the molecular level was pursued in 
Chapter 5. Segmented and highly-branched polymers (SHBPs), which were synthesised by RAFT 
SCVP of TFE(M)A, PEG(M)A and a polymerisable CTA, were chosen as a model to systematically 
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study the effect of molecular structure on the imaging performance. SHBPs with desired 
compositions and degree of branching (DB) were prepared by varying monomer type and 
[comonomer]/[MECP] ratio. The structure of the SHBPs was thoroughly characterised by a range of 
different analytical techniques. Statistical copolymers with fluorine units evenly distributed were 
obtained using TFEA/PEGA or TFEMA/PEGMA, while gradient copolymers were produced using 
monomers having largely different reactivity ratios. The 
19
F NMR properties were affected by both 
chain composition and monomer sequence. Higher 
19
F mobility (longer T2) was achieved in 
statistical copolymers consisting of acrylate units due to greater segmental flexibility. In addition, 
the 
19
F mobility was greatly restricted for the samples with higher 
19
F contents due to the increased 
association of the fluorinated segments in aqueous solution. Moreover, a shortened T2 was observed 
with an increase in DB, which caused increased compactness, rigidity, and restricted segmental 
motion. The 
19
F signal intensity of the SHBPs consisting of gradient copolymers was significantly 
reduced by the loss of solubilised 
19
F units in the chains. The relationship between T2 and chain 
flexibility was also revealed by thermal analysis, and longer T2 relaxation times were observed for 
the samples with lower glass transition temperatures in the bulk. The imaging performance of the 
SHBPs was confirmed by 
19
F MRI. All the samples could be well imaged by T1-weighted imaging, 
while they could be selectively visualised using a T2-weighted sequence using different echo times. 
Therefore the imaging performance could be regulated by tailoring the branched structure and 
composition of the SHPBs, enabling the selective and tuneable 19F MRI. 
  Theranostic agents combined with 
19
F MRI function are advantageous for monitoring drug 
delivery and quantitative diagnosis due to the high sensitivity and high-resolution capabilities of 
19
F 
MRI. Chapter 6 explored the fabrication of POSS-based star polymers for potential 
19
F MRI and 
drug delivery. Star polymers consisting of eight partly-fluorinated copolymer arms and a POSS core 
were synthesised by the RAFT copolymerisation of TFEA and PEGA using a POSS-based 
macroCTA. The synthetic mechanism was revealed by kinetic study, and the existence of linear 
polymers and polymers formed by star-star terminations was evidenced as the characteristics of the 
R-group approach. Star polymers with different arm length were synthesised by varying the feed 
ratio of monomer to CTA, and were purified by extensive dialysis in water. The evenly distributed 
fluorine units in the arms were observed by 
1
H NMR. Nanoparticles with diameters of 8~10 nm 
were formed by dissolving the star polymers in water, and the particle size increased with arm 
length. A single fluorine chemical environment was confirmed by a single peak in the 
19
F NMR 
spectra, and it was noted that the T2 relaxation time was increased with increasing arm length. 
However, the T2s were shorter than those of linear and highly-branched (polymers in Chapter 5) 
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analogues, indicating that the fluorine nuclei were less mobile in the arms of star polymers because 
of the possibly more confined environment around the POSS core. Nevertheless, the fluorine 
mobility was higher than that of hyperbranched structures having high DBs. The theoretical values 
of 
19
F MRI intensity were estimated, confirming that the star polymers could be used for 
19
F MRI 
with potentially high imaging intensity. These multifunctional star polymers with drug 
encapsulating capability imparted by the POSS and the possibility of conjugation by the 
trithiocarbonate functionality are promising theranostic agents for 
19
F MRI-enabled cancer 
diagnosis and treatment.  
 
7.2 Comparison of the as-designed polymeric agents 
Partly-fluorinated polymers with various star and hyperbranched structures were synthesised in this 
thesis for 
19
F MRI-related applications. The molecular details and 
19
F NMR properties of the 
representative samples are listed in Table 7-1. 
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Table 7-1 Comparison of the partly-fluorinated polymers developed in this thesis. 
Polymer Type Representative 
Sample 
Polymer 
Chain
a
 
Mn 
(kDa)
b
 
ĐM
b
 
19
F 
wt%
c
 
T1 
(ms)
d
 
T2 
(ms)
d
 
Dh 
(nm)
e
 
19
F MRI 
Intensity
f
 
Application 
Star-like 
hyperbranched 
polymers 
Star-1 PPEGMA-b-
P(TFEA-co-
DMAEMA) 
225 1.6 1.4 420-
471
g
 
7-40
g
 10-25
h
 0.85 Selective  
19
F MRI 
Core corsslinked 
star polymers 
CCS-1 PPEGMA-b-
P(TFEMA-co-
DMAEMA) 
653 1.2 2.3 250-
472
g
 
1-39
g
 18.3-
23.7
g
 
1.43 Selective  
19
F MRI 
Hyperbranched 
polymers 
HBIPF-1 P(TFEA-co-
PEGMA) 
227 2.0 1.3 405 61 13.5 1.20 CT/
19
F MRI 
bimodal 
imaging 
Segmented 
highly-branched 
polymers 
SHBP-9 P(TFEA-co-
PEGA) 
370 1.6 3.3 345 87 6.3 3.86 Improved and 
tuneable 
19
F MRI 
Star polymers 
with a POSS core 
SP-1 P(TFEA-co-
PEGA) 
234
i
 1.4
i
 4.9 329 37 8.6 3.06 
19
F MRI and 
drug delivery 
 
a
 The copolymer chains in which the fluorine segments were distributed. 
b
 Absolute molecular weight and ĐM were measured by GPC MALLS or triple 
detection GPC. 
c
 Fluorine content was determined by 
1
H NMR. 
d
 T1 and T2 relaxation times were measured by 
19
F NMR in PBS/D2O(90/10, v/v) at 25 
o
C. 
e
 Hydrodynamic diameter was measured by DLS (1 mg mL
-1
 in PBS) at 25 
o
C, and number-averaged diameters were reported. 
f
 The intensity of 
19
F 
MRI using spin-echo pulse sequence (e.g., RARE-8) was simulated by using the Equation (2-1). Supposed parameters: TE = 41 ms, TR = 1 s, polymer 
concentration = 20 mg mL
-1
 in water. 
g
 T1 and T2 relaxation times and Dh were measured at different pH from 4 to 9. 
h
 Determined by cryo-TEM at pH 
6 and 9. 
i
 Mn was calculated by 
1
H NMR, and ĐM was measured by a GPC RI detector. 
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  In this thesis, the highest mobility of 
19
F nuclei was achieved by statistical copolymers P(TFEA-
co-PEGA) owing to the close reactivity ratios and resultant evenly distributed fluorinated units 
along the polymer chain. Polymers consisting of P(TFEA-co-PEGA) segments possessed high 
fluorine contents (up to 11.8%), a single and strong 
19
F signal resonance, long T2 relaxation times 
(up to 87 ms) and short T1 relaxation times (~350 ms), and hence they displayed significantly 
improved 
19
F MRI performance compared to their counterparts containing other polymer chains 
such as P(TFEA-co-DMAEMA), P(TFEMA-co-DMAEMA), P(TFEA-co-PEGMA), P(TFEMA-co-
PEGA) and P(TFEMA-co-PEGMA)).  
  The mobility of fluorine segments was decreased with an increase in degree of branching (DB) for 
the hyperbranched structure. In addition, the placement of 
19
F nuclei in a hyperbranched structure 
with a low DB is more advantageous for improving 
19
F mobility than positioning the 
19
F in the arms 
of star polymer. Moreover, the 
19
F nuclei were more mobile in in arms of the star polymer than in a 
hyperbranched structures having high degree of branching. Furthermore, the flexibility of the 
fluorinated segments in the arms of star polymers could be enhanced by increasing the arm length.  
  Therefore we conclude that low-DB hyperbranched polymers consisting of P(TFEA-co-PEGA) 
segments and star polymers having P(TFEA-co-PEGA) arms are promising candidates for 
19
F MRI-
related applications due to the excellent imaging performance as well as the architectural 
advantages.  
  In summary, multifunctional polymers with a range of architectures and compositions have been 
synthesised using the RAFT technique and evaluated as contrast agents for 
19
FMRI-related 
applications. The molecular level understanding gained in this thesis provides useful guidance for 
the future design of highly-efficient contrast agents for 
19
F MRI-based molecular imaging and 
therapy.  
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Appendix A, Supporting Information for Chapter 2 
 
 
Figure A2.1 
1
H NMR spectra of alkyne-CTA (A) and original CTA (A), and 
13
C NMR spectrum of 
alkyne-CTA. All spectra were recorded using CDCl3 at 25 
o
C. 
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Figure A2.2 GPC curves of the synthesis of PPEGMA using S-1-dodecyl-S'-(α,α'-dimethyl-α''-
acetic acid) trithiocarbonate as CTA. [PEGMA]:[CTA]:[AIBN] = 50:1:0.1, [PEGMA] = 1 M in 
toluene, 70 
o
C. 
 
 
Figure A2.3 GPC traces of Star-2 (A) and Star-3 (B) before and after dialysis. [Macro-
CTA]:[TFEA]:[DMAEMA]:[EGDMA]:[AIBN] = 1:8:24:8:0.2 and 1:16:16:8:0.2 for Star-2 and 
Star-3, respectively. Polymerised in THF at 70 
o
C for 24 h, [monomer] = 0.5 M. 
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Appendix B, Supporting Information for Chapter 3 
 
 
 
Figure A3.1 RAFT polymerisation of PEGMA using alkyne-CTA. (A) Pseudo-first-order kinetic 
plot of the polymerisation. (B) Dependence of number-average molecular weight (Mn, determined 
by GPC) and molar-mass dispersity (ĐM) on monomer conversion. (C) GPC traces during the 
polymerisation. 
Appendix B 
 
 
193 
 
 
Figure A3.2 GPC traces of the polymers related to the synthesis of CCS-2 and CCS-3. 
 
 
Figure A3.3 GPC traces during the degradation of CCS-1 using DTT in THF. [DTT] = 50 mM, 
[CCS-1] = 1.15 × 10
-3
 mM. Note that the sample solutions were exposed to air during the 
measurements. 
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Figure A3.4 Zeta potential of CCS-1 and CCS-2 at different pH in PBS (1 mg mL
-1
) at 25 
o
C. 
 
Calculation of arm number 
The arm number can be calculated according to the previously published methods. 
1, 2
 
  First, the weight fractional of arms in CCS polymer can be calculated using Equation (A3-1). 
 
 (A3-1) 
 
  In which WFarm is the weight fractional of arms in CCS polymer, marm is the mass of arms, Xarm is 
the conversion of arms that are incorporated into CCS polymer, mCL is the mass of crosslinker, and 
XCL is the conversion of crosslinker. We assume that the conversion of crosslinker is 100% because 
of the high polymerisation rate in a RAFT dispersion polymerisation.  
  Then the arm number can be obtained by Equation (A3-2). 
 
(A3-2) 
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  In which f is arm number, Mw(CCS) is weight-average molecular weight of CCS polymer and Mw(arm) 
is weight-average molecular weight of arms. 
  The details are listed in the following table. 
Table A3.1 Details for the calculation of arm numbers. 
Sample marm (g) Xarm mCL XCL Mw(CCS) Mw(arm)
a
 WFarm f 
CCS-1 2.16 0.74 0.58 1 764400 10500 0.734 53 
CCS-2 0.39 0.65 0.1 1 516300 11300 0.717 33 
CCS-3 0.53 0.6 0.139 1 785500 11700 0.713 49 
a
 Mn (
1
H NMR) was used for Mw(arm)  
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Appendix C, Supporting Information for Chapter 4 
 
 
Figure A4.1 
1
H and 
13
C NMR spectra of the iodo-monomer TIBMA in DMSO-d6 at 25 
o
C. 
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Figure A4.2 
1
H NMR (A), 
13
C NMR (B), 
1
H-
1
H-COSY (C), 
1
H-
13
C-HSQC (D) spectra of the 
RAFT agent PETTC in CDCl3 at 25 
o
C. 
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Appendix D, Supporting Information for Chapter 5 
 
 
Figure A5.1 Enlarged area of the 
1
H-
13
C HSQC spectrum of SHBP-4. The two cross-peaks for two 
different types of CH2 adjacent to the trithiocarbonate can be clearly distinguished. 
 
Figure A5.2 Enlarged area of the 
1
H-
13
C HSQC spectrum of SHBP-4. The relevant cross-peaks for 
the CH2 of the vinyl group are identified. 
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Figure A5.3 (A) UV-vis spectra of SHBP-4 and MECP showing the characteristic absorbance of 
trithiocarbonate compounds at 306 nm. (B) GPC trace given by UV detector monitoring the 
wavelength of 306 nm. 
 
Figure A5.4 Enlarged area of the 
1
H-
13
C HSQC spectrum of SHBP-7. The two highlighted cross-
peaks can be assigned to the CH2 adjacent to the ester bond in TFEA within different chemical 
environments. 
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Figure A5.5 Normalised 
19
F NMR spectra of SHBP-2, 7, 8 and 9. Samples were dissolved in 
PBS/D2O(90/10, v/v) at 20 mg mL
-1
 at 25 
o
C. 
 
Figure A5.6 Stacked DSC curves for the SHBPs. Samples (5~9 mg) were heated from 25 to 150 
o
C 
at a heating/cooling rate of 10 
o
C min
-1
 in nitrogen atmosphere. The glass transition temperature 
was determined from the midpoint of the change in capacity in the second heating cycle (-100 to 
150 
o
C). 
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Figure A5.7 Comparison of experimental and theoretical (calculated using the Fox Equation) Tg 
values of samples consisting of TFEMA and PEGMA units with different weight fractions of 
TFEMA. 
 
 
Figure A5.8 Absolute MW versus retention time measured by GPC MALLS in THF for the 
polymers with various degrees of branching (DB).  
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Appendix E, Supporting Information for Chapter 6 
 
 
Figure A6.1 (A) 
1
H NMR spectrum of POSS-(OH)8 with integrals displayed. (B) Comparison of 
the spectra of Octavinyl POSS and POSS-(OH)8 in the region where the peaks of vinyl protons are. 
(C) 
1
H-
1
H COSY NMR spectrum of POSS-(OH)8. All spectra were recorded in DMSO-d6 at 25 
o
C. 
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Figure A6.2 Normal and DEPT 
13
C NMR spectra of POSS-(CTA)8 in CDCl3 at 25 
o
C. 
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Figure A6.3 
1
H-
1
H COSY (A) and 
1
H-
13
C HSQC NMR spectra of POSS-(CTA)8 in CDCl3 at 25 
o
C. 
 
Figure A6.4 GPC trace of the sample synthesised using an increased AIBN concentration (1/5 of 
CTA). Condition: POSS-(CTA)8/TFEA/PEGA/AIBN = 1/200/200/1.6, [monomer] = 1 M in 1,4-
dioxane, 70 
o
C. The percentage of star polymer in the polymer mixture was estimated by the 
deconvolution of GPC curves. The conversions of TFEA and PEGA were 69% and 58%, 
respectively, as determined by 
1
H NMR.  
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Figure A6.5 GPC curves of SP-2 (A) and SP-3 (B) before and after purification using dialysis 
tubing of 100 kDa MWCO.  
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Figure A6.6 
1
H-
13
C HSQC (A) and HMBC (B) spectra of SP-1 in CDCl3 at 25 
o
C. 
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“When it is obvious that the goals cannot be reached, do not adjust the goals, adjust the action 
steps.” 
―Confucius 
 
 
 
 
